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ABSTRACT 
 
Delivering drugs to the brain for the treatment of brain diseases has been fraught with low bioavailability of 
drugs due to the Blood-Brain Barrier (BBB). The intranasal (IN) route of delivery has purportedly been 
given recognition as an alternative route of delivering drugs to the brain with improved bioavailability if the 
nose-to-brain option is considered. However, drugs administered through the nasal mucosa suffer some 
challenges such as mucocilliary clearance, enzymatic degradation, inability of a controllable drug release to 
give a precise dose, resulting in frequent dosing and absorption into the systemic circulation through the 
blood rich vessels in the mucosa, thus facing the BBB challenge. The aim of this study was to develop a 
novel Nano-co-Plex (NCP), a magnetic nano-carrier loaded with a therapeutic agent which is further 
incorporated into a nasal thermosensitive electro-responsive mucogel (TERM) for in situ gelling, for electro-
actuated release of the incorporated drug-loaded NCP in a controllable “on-off” pulsatile manner, which is 
achieved with the aid of an external electric stimulation (ES). The released drug-loaded NCP was then 
targeted to the brain via a direct nose-to-brain drug delivery pathway with the aid of an external magnetic 
field (MF) for rapid transportation. The ES was brought about by applying a 5V potential difference (PD) 
using electrodes on the nose and the external MF would then be applied by placing a magnetic headband 
on the head of the patient. In this research, the drug-loaded NCP was prepared by firstly synthesizing iron 
oxide nanoparticles (Magnetite) which were then coated with Polyplex; a polymeric complex fabricated 
employing polyvinyl alcohol (PVA), polyethyleneimine (PEI) and fIuorecein isothiocyanate (FITC). The 
coated magnetite was thereafter loaded with Carmustine (BCNU), an effective drug commonly used in 
brain tumor treatment, to formulate the BCNU-NCP. The TERM was prepared by blending a 
thermosensitive polymer, Pluronic F127 (F127) with mucoadhesive polymers, chitosan (CS) and 
hydroxypropyl methylcellulose (HPMC). Polyaniline (PANI) was included in the blend as the electo-active 
moiety of the formulation. Finally, the BCNU-NCP was incorporated into the gel to form a Nanogel-
Composite. A Box–Behnken design model was employed for the optimization of the Nanogel Composite. 
TERM, BCNU-NCP and Nanogel Composite were characterized employing Thermogravimetric analysis 
(TGA), Superconducting Quantum Interference Device (SQUID) magnetometry, Fourier Transform Infrared 
Spectroscopy (FTIR), Nuclear Magnetic Resonance (NMR), X-ray Diffractometry (XRD), Scanning Electron 
Microscopy (SEM), Cyclic Voltammetry (CV), Transmission Electron Microscopy (TEM), Rheological, 
Porositometry, Textural and Zetasize analyses. In vitro drug release, ex vivo permeation and in vivo studies 
were performed. The BCNU-NCP was found to be paramagnetic with a magnetization value of 61emu/g, 
possessing a mixture of spherical and hexagonal shaped core-shell nanoparticles of size 30-50nm with 
zeta potential of +32 ±2mV. The NCP displayed a high degree of crystallinity with 32% Polyplex coating. 
The loading capacity of NCP was 176.86µg BCNU/mg of the carrier and maximum release of 75.8% of the 
loaded BCNU was achieved after 24 hours. FTIR and NMR confirmed the conjugation of PVA and PEI of 
the Polyplex at a ratio of 1:4. Cytotoxicity of the BCNU-loaded Nano-co-Plex displayed superiority over the 
conventional BCNU towards human glioblastoma (HG) A170 cells. Cell studies revealed enhanced uptake 
and internalization of BCNU-NCP in HG A170 cells in the presence of an external MF. BCNU-NCP was 
found to be non-toxic to healthy brain cells. A thermally stable gel with desirable rheological and 
mucoadhesive properties was developed. The results revealed gelation temperature of 27.5±0.5°C with a 
porous morphology. Nanogel Composite possesses electroactive properties and shows response to ES 
and releases incorporated BCNU-NCP in an “on-off” pulsatile drug release profile upon application of a 5V 
PD. The in vitro release studies showed an average release of BCNU-NCP per release cycle to be 10.28%. 
Ex vivo permeation studies were performed using a freshly excised nasal tissue of the New Zealand white 
rabbit; the results showed that BCNU-NCP was able to permeate through the nasal tissue at a 6 times 
greater amount in the presence of a MF than in the absence of MF. BCNU concentration was found to be 
high in the brain and CSF of rabbit when the Nanogel Composite is intranasally administered compared to 
the IV injection of the conventional BCNU. Furthermore, application of the MF was found to increase the 
concentration of BCNU in the brain and CSF of the rabbit. The result of Field Emission Electron Probe 
Micro Analyzer (FE EPMA) was further used to confirm the presence of NCP in the rabbit brain tissue. 
Histopathological results indicated mild lesions in the nasal mucosa of the rabbit after IN administration of 
Nanogel Composite. The results of the in vitro, ex vivo and the in vivo proved that the Nanogel Composite 
is superior in delivering BCNU into the brain than the conventional drug delivery system for the treatment of 
brain tumor as it was able to release the therapeutic agent in a controllable manner. The MF applied aided 
drug to be targeted and rapidly transported to the brain via a direct nose-to-brain pathway thereby 
circumventing the BBB and increasing bioavailability of drug in the brain. This vehicle may also be used to 
deliver other similar therapeutic agents into the brain for the treatment of various brain diseases.  
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CHAPTER 1 
INTRODUCTION 
 
1.1. BACKGROUND TO THIS STUDY 
Delivery of drugs to the brain has been fraught with issues of low bioavailability. 
This is due to the impervious nature of the Blood-Brain-Barrier (BBB). The BBB 
consists of an endothelial membrane separating the systemic circulation and 
central interstitial fluid (Pardridge, 1999). The vasculature serving the Central 
Nervous System (CNS) has capillaries with tight junctions preventing permeation 
of drugs. The BBB also comprises a double layered structure called the arachnoid 
membrane, which acts as a barrier between the blood and Cerebrospinal Fluid 
(CSF) (Vyas et al., 2005a). These characteristics of the BBB restrict the movement 
of molecules from the general circulation to the brain and spinal cord (Lerner et al., 
2004). The BBB usually restricts the passage of hydrophilic substances from the 
blood to the brain but allows certain lipophilic substances to pass through to the 
brain (Sharma et al., 2015). The development of therapies to treat brain diseases 
has long been frustrated by the failure of systemically administered drugs to 
permeate the brain. The delivery mechanism through the BBB and the 
physicochemical properties of the molecule of the drug are factors that must be 
considered when designing drug delivery systems for brain targeting. 
 
The systemic delivery of drugs through the oral, intravenous and the transdermal 
routes requires drug to pass through the blood circulation in order to reach the 
brain, and it is fraught with the challenge of passing through the BBB. The delivery 
of drugs using intranasal delivery has been explored by a number of investigators 
as it is purportedly a more reliable method for drug delivery to the brain than the 
systemic administration (Serralheiro et al., 2015; Mistry et al., 2015; Nasr, 2015; 
Serralheiro et al., 2014). This is due to its ability to bypass the BBB and directly 
propel the drugs through the olfactory lobe to the brain which enhances their 
bioavailability. Many therapeutic agents such as peptides and proteins which are 
poorly absorbed orally and extensively metabolized in the gastrointestinal tract 
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(GIT) and the liver have been found to be ideally delivered through the nasal route. 
Advantages of intranasal delivery over other routes of delivery include; 1) non-
invasiveness, 2) affords direct delivery of drug to brain by circumventing theBBB, 
3) targeted delivery to the brain is possible, 4) rapid delivery, low toxicity and side 
effects, 5) by-passes first-pass metabolism, and 6) provides a larger surface area 
for drug delivery. 
 
Comparative studies of the nasal route and other routes of administration such as 
intravenous, oral and transdermal have been explored (Lalatsa et al., 2014; Kumar 
et al., 2008a; Westin et al., 2005). It was observed that the nasal route was more 
efficient in delivering a wide range of therapeutic compounds including peptides 
and proteins in the presence of permeation enhancers resulting in higher 
bioavailability (Costantino et al., 2007; Türker et al., 2004). The drug uptake into 
the brain from the nasal mucosa mainly occurs via two different pathways. One is 
the systemic pathway by which some of the drugs administered into the nasal 
cavity are absorbed into the systemic circulation via the blood-rich vessels and 
capillaries of the nasal mucosa. The other is the olfactory pathway by which the 
drug travels from the nasal cavity directly to CSF and brain tissue (Mistry et al., 
2009; Seju et al., 2011; Shah et al., 2015; Vyas et al., 2005b).  
 
Almost all research in intranasal drug delivery have employed the mechanism of 
passive diffusion that relies mainly on a combination of proper drug instillation 
deep in the nasal cavity, gravity, and the properties of the neuro-epithelium to gain 
access to the CNS. However, a substantial quantity of drugs goes through the 
systemic pathway thereby reducing the quantity via the olfactory pathway (Kumar 
et al., 2008a). Such phenomenon is a limitation in the intranasal delivery of drugs 
directly to the brain as this reduces the bioavailability of the drugs delivered to the 
brain. Furthermore, there has been no controlled way in which the therapeutics get 
delivered to the brain when they are introduced into the nasal cavity. Furthermore, 
drugs meant for direct nose-to-brain delivery should have a protective embodiment 
that can entrap/encapsulate the therapeutic substances whilst in the nasal cavity. 
There is therefore a need for the drugs to be protected whilst in the nasal cavity 
and be delivered into the brain in a controlled manner in conjuction with a „driving 
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force‟ that can propel the drugs directly to the brain after being released in the 
nasal mucosa.  
 
The use of electroactive polymers as a protective embodiment as well as in 
release of therapeutics when external electric stimulus is applied may be very 
useful. The use of magnetic nanoparticles in fabricating the drug delivery systems, 
which on application of magnetic field may act as a „driving force‟, has the potential 
of guiding and propelling the drugs to the brain via the olfactory pathway and 
therefore bypassing the systemic pathway. This will improve the bioavailability of 
drugs in the CNS. It is envisaged that the application of an external electric and 
magnetic fields may cause controlled release and uptake of drugs through the 
olfactory pathway thereby circumventing the BBB thus enhancing the delivery and 
subsequent distribution of drug within the brain.  
 
Learner and coworkers (2004) investigated a method to increase intranasal 
delivery and drug distribution within the brain using iontophoresis, to actively drive 
drug movement across an electric field to the brain. In their method, electrodes 
containing a drug reservoir were applied to the nasal neuro-epithelium of the rabbit 
with a return electrode placed at the back of the rabbit‟s head. Upon the 
application of a relatively small sustained current, charged drug molecules were 
driven from the nasal cavity into the brain. This method actually allows the 
passage of more drugs to the brain compared to other methods. However, the 
method is cumbersome and invasive since electrodes have to be inserted deep 
into the nasal cavity and patience non-compliance is envisaged. Therefore, a drug 
delivery device administered via the intranasal route which applies electric and 
magnetic fields, and is not cumbersome and invasive, for targeted brain delivery is 
paramount for the management of CNS diseases in order to enhance the 
bioavailability of drug in the brain. Hence this study was undertaken to explore the 
use of electro-active polymers to formulate an electro-responsive gel and 
containing drug-loaded magnetic nanoparticles which in the presence of an 
external electric stimulus, control the release of drug and the presence of external 
magnetic field enhances rapid transportation of the drug-loaded nanoparticles to 
the brain and CNS via the olfactory pathway.  
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1.2. RATIONALE AND MOTIVATION FOR THIS STUDY 
This study proposed to develop an electro-magneto-responsive polymeric drug 
delivery system by exploring the use electro-active polymers which are polymers 
that respond to external electric stimulations. These polymers include polyaniline 
(PANI), polypyrrole (PPy), ethylene vinyl acetate (EVA), polyethylene, polylactic 
acid (PLA), polyglycolic acid (PGA), polylactic-co-glycolic acid (PLGA), and 
polythiophene which could be employed in preparing a drug delivery system for 
direct delivery of therapeutics to the brain through the nasal mucosa. A number of 
these polymers were explored in designing the intranasal drug delivery system 
described herein. The applications of these polymers are mostly in the production 
of artificial muscles. On application of an electric field these polymers are able to 
swell and/or contract. Such physicochemical changes are converted into 
mechanical work in a muscle actuator. This concept was employed in designing a 
drug delivery system that can deliver therapeutic drugs directly to the brain 
through the nasal cavity. 
 
Magnetic nanoparticles were fabricated by employing substances and compounds 
which possess the capacity to respond to a magnetic field. Such substances 
include iron and gadolinium compounds. These compounds were employed to 
develop the magnetic nanoparticles using techniques such as co-precipitation in 
an alkaline medium. The magnetic nanoparticles were coated with biodegradable 
and biocompatible polymers such as polyvinyl alcohol (PVA), poly ethylene glycol 
(PEG), polyethyleneimine (PEI) and loaded with the therapeutic agents. Due to the 
magnetic property of the nanoparticles, it is anticipated that the nanoparticles 
would move in the direction of the magnetic field which would be positioned on the 
patient‟s head in the form of a headband for a nose-to-brain delivery. The target 
size of the nanoparticles was less than 200nm. The driving force which is the 
magnetic field would create a „pulling‟ effect on the nanoparticles attracting them 
towards the brain. By so doing it was envisaged that the nanoparticles would 
bypass the systemic pathway for uptake of drugs into the brain through the 
olfactory pathway thereby circumventing the BBB since most of the nanoparticles 
would migrate rapidly to the brain through the olfactory pathway. When the 
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nanoparticles reach the brain, the drug would be released by dissolution and 
diffusion into the cells thereby evading the BBB. 
 
The magnetic nanoparticles would be subsequently incorporated into a gel. The 
gel was fabricated employing thermosensitive and mucoadhesive polymers in 
addition to the electroactive polymers, this was to enable the gel to be liquid at 
room temperature and then gel at physiological temperature for ease of 
administration. This gel would possess mucoadhesive capabilities in order to 
provide a long residence time in the nasal mucosa. In developing the electro-
responsive gel, the electroactive polymer would be incorporated or blended 
homogenously with the other polymers such as chitosan and hydroxypropyl 
methylcellulose using techniques such as polymer blending, copolymerization or 
crosslinking to generate an inter-penetrating network that would erode degrade or 
dissociate in the presence of an electric field. When the gel erodes, degrades or 
dissociates, the drug-loaded nanoparticles embedded within the gel would be 
released and in the presence of external magnetic field, the drug-loaded 
nanoparticles would migrate rapidly to the brain through the olfactory pathway with 
the aid of external magnetic field.  
 
The gel was employed to control the release of the drug-loaded nanoparticles for 
24 hours as well as confine the drug-loaded nanoparticles in the nasal region to 
prevent premature clearance into the tracheal region as the patient breathes. The 
gel should be thermosensitive, and thermoreversible, possessed mucoadhesion 
capability and responded to an applied external electric field. The use of self-
adhesive patch electrodes and a magnetic headband were employed to create an 
electric and magnetic field respectively. The electric field was required to 
dissociate or degrade the gel and transport the drug-loaded nanoparticles through 
the olfactory pathway to the brain. The self-adhesive patched electrode would be 
placed on the nose of the patient to generate an electric field creating an electric 
stimulus that dissociated or degraded the polymeric gel to release the drug-loaded 
nanoparticles. The magnetic headband would be able to generate magnetic fields 
thereby attracting the nanoparticles towards the brain for a nose-to-brain drug 
delivery. On reaching the brain, the nanoparticles were anticipated to circumvent 
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the BBB and then release the drugs in the brain cells. Figure 1.1 shows a 
schematic of the design. The nanoparticles were labelled with fluorescent markers 
such as fluorescein isothiocyanate (FITC) to aid imaging of the transport and bio-
distribution of the nanoparticles.  
 
This drug delivery system may find applications in CNS diseases such as 
Alzheimer‟s and Parkinson‟s disease, schizophrenia, stroke, epilepsy, AIDS 
dementia Complex and brain tumor wherein drugs such as Galantamine, 
Levodopa, Clozapine, Alteplase, Clopidogrel, Zidovudine and Carmustine may be 
suitably incorporated into the nanoparticles. It is envisaged that the proposed drug 
delivery system, by circumventing BBB, will improve the bioavailability of CNS 
drugs thereby enhancing the pharmacological management of CNS diseases 
using an intranasal drug delivery system. 
 
 
Figure 1.1: Schematic conceptualization of design criteria for release of drugs 
using an external electric stimulation and a magnetic field 
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1.3. AIM AND OBJECTIVES 
The aim of this study was to design an intranasal drug delivery system that 
encompasses drug loaded magnetic nanoparticles which are incorporated into a 
thermosensitive electro-responsive mucoadhesive gel for controlled and targeted 
“nose-to-brain” delivery of therapeutic agents via the olfactory pathway with the aid 
of an external electric and magnetic fields for enhanced delivery. Figure 1 provides 
a schematic conceptualization of the design criteria for drug release using an 
electric and magnetic fields as examples of applied stimuli. In order to achieve this 
aim, the following objectives were fulfilled: 
 
1. To undertake preliminary studies on the electro-active, mucoadhesive and 
thermosensitive polymers including modification of these polymers using 
techniques such as blending, copolymerization and crosslinking to assess their 
suitability for the development of a responsive gel. 
 
2. To characterize the selected polymers employed in the formulation of the gel, 
using various techniques such as, Fourier Transform Infrared Spectroscopy 
(FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis 
(TGA) and Scanning Electron Microscopy (SEM). 
 
3. To fabricate stimuli-responsive polymeric nanostructures such as magnetic 
responsive nanoparticles via precipitation, chemical crosslinking, solvent 
evaporation/emulsification. The nanostructures were labelled using fluorescent 
markers such as fluorescein isothiocyanate (FITC), to aid imaging and detection of 
the bio-distribution of the nanostructures. 
 
4. To incorporate a drug model such as carmustine, galantamine, levodopa, 
clozapine, alteplase, clopidogrel or zidovudine in the nanostructures for the 
treatment of brain tumors, Alzheimer‟s diseases (AD), Parkinson‟s, Schizophrenia, 
Stroke, epilepsy or AIDS dementia Complex, respectively. 
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5. To evaluate the physicochemical and electro-active properties of the nanogel 
using rheological and textural profiling analyses, as well as cyclic voltammetry in 
order to further characterize the nanogel. 
 
6. To evaluate the physicochemical properties of the nanostructures using 
zetasize and zeta potential analyses, surface morphological characterization, drug 
loading/entrapment efficiency and conductivity analysis. 
 
7. To assess in vitro drug release from the nanogel in the presence of various 
stimuli such as electric field and determine the optimum parameter required for the 
release and transport of nanostructures from the gel into the brain with the aid of 
an external magnetic field. 
 
8. To undertake in vivo studies using New Zealand White rabbits to assess the 
performance of the novel intranasal drug delivery system, and evaluate the 
influence of an electric and magnetic stimuli. 
 
1.4. NOVELTY OF THIS WORK 
The following points highlight the novelty of this research. 
 
1. Design and formulation of novel nanoparticles employing polyvinyl alcohol 
(PVA), polyethyleneimine (PEI) and fluorescein isothiocyanate (FITC) referred to 
as Polyplex. 
 
2. Coating of iron oxide nanoparticles with the Polyplex to form a Nano-co-Plex 
with the capability of significant drug loading and release. The drug-loaded Nano-
co-Plex possesses the ability to respond to magnetic field. 
 
3. Formulation of a thermosensitive electro-responsive mucogel (TERM) as an in 
situ intranasal drug delivery system that is liquid at room temperature and can 
form a gel at physiological temperature. The gel has the ability to control the 
release of therapeutic agents incorporated in it upon the application of external 
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electrical stimulus. The released therapeutic agents have the potential to be 
attracted to the brain via the olfactory pathway with the aid of an external magnetic 
stimulus. The electrical stimulus is in form of a self-adhesive electrode and the 
magnetic stimulus is in form of a magnetic headband. 
 
4. The use of electrical stimulation on the nose in form of patched electrode to 
actuate controlled release of drug from the nasal mucosa. 
 
5. The use of a magnet in form of a magnetic headband to enhance rapid 
migration of the drug-loaded nanoparticles to the brain after being released in the 
nasal cavity via the olfactory pathway. 
   
1.5. OVERVIEW OF THIS THESIS 
Chapter 1 provides an introduction and background of the study, delineating the 
challenges experienced with delivering drug to the brain due to BBB. The use of 
intranasal drug delivery as alternative to systemic delivery was enumerated. The 
rationale and motivation for this research as well as the aim and objectives are 
outlined in this chapter. 
 
Chapter 2 provides a literature review, focusing on intranasal delivery of drugs for 
nose-to-brain delivery employing the olfactory route for the management of brain 
diseases. Techniques employed to fabricate and evaluate the intranasal drug 
delivery was enumerated. 
 
Chapter 3 provides a description of the synthesis of Nano-co-Plex by exploring 
the use of magnetic iron oxide nanoparticles and coated with Polyplex which was 
sythesized from PVA, PEI and FITC conjugate, loaded with carmustine (BCNU), 
an effective brain tumor chemotherapeutic agent. Detailed characterization of the 
Nano-co-Plex was carried out. In vitro drug release and cell studies were 
undertaken to determine the cytotoxicity and cellular uptake, as well as 
internalization of the drug-loaded Nano-co-Plex, in the absence and presence of a 
magnetic field. 
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Chapter 4 provides a description of formulating a thermosensitive electro-
responsive mucogel (TERM) as a potential controlled intranasal drug delivery 
system, possessing mucoadhesive properties, which responds to an external 
electric field in releasing therapeutic agents. The carmustine-loaded Nano-co-Plex 
was incorporated into the gel to formulate the Nanogel Composite. A Design of 
Experiment (DoE) was extensively evaluated using a Box-Behnken Experimental 
Design (BBED). The BBED desirability function was employed to generate an 
optimized Nanogel Composite. Furthermore, this chapter deals with the 
physicochemical and physicomechanical characterization of the optimized 
Nanogel Composite. Chemical structure evaluation was undertaken using FTIR, 
XRD and NMR analyses.  DSC and TGA were used to evaluate the thermal 
behaviour of the Nanogel Composite. SEM and porositometry analyses were 
undertaken to assess the surface morphology. Rheological evaluation was used to 
assess the viscoelastic properties and the gelation temperature of the Nanogel 
Composite. Cyclic voltammetry and conductivity analyses were employed to 
observe the electro-activity of the formulation. Texture profiling was undertaken to 
evaluate the mucoadhesive strength of the Nanogel Composite. In vitro studies 
were undertaken on the Nanogel Composite using an electrical stimulation to 
assess the release characteristics of the formulation.  
 
Chapter 5 provides the ex vivo evaluation of Nanogel Composite using an excised 
nasal epithelial tissue of New Zealand White rabbit. The ex vivo permeation 
studies were conducted to ensure the viability of the application of an electric 
stimulation on Nanogel Composite to release BCNU-loaded Nano-co-Plex. 
Furthermore, the effect of a magnetic field on the transportation of the BCNU-
loaded Nano-co-Plex across the nasal epithelial tissue of rabbit was evaluated. 
This study represents a prototype investigation prior to in vivo studies. 
  
Chapter 6 details the in vivo performance of the optimized Nanogel Composite in 
comparison to the conventional drug available on the market. In vivo studies were 
carried out using New Zealand White rabbits. The effect of electric stimulation on 
the release behaviour of the nanoparticles and the effect of magnetic field on the 
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transport of the nanoparticles to the brain via the olfactory pathway were 
evaluated.  
 
Chapter 7 provides recommendations and future outlook of the study. A 
hypothesis based on “Proteo-Alkaloid” conjugation of Lactoferrin (Lf) and 
Galantamine (Gal) via the self-assembly functionality of Lf was postulated. The 
hypothesis explored the combination of these two compounds as one dosage 
form, taking into consideration their iron and free radical scavenging abilities. A 
dual neuroprotection and neurotherapeutic interventional approach was 
postulated. 
 
1.6. CONCLUDING REMARKS 
The novel thermosensitive electro-responsive mucogel containing drug-loaded 
magnetic nanoparticles can be considered as an alternative therapy for 
circumventing the BBB. The novel development has the potential to increase 
bioavailability of drugs to the brain via a direct nose-to-brain delivery.  It is 
therefore envisaged that this system is a promising technology for non-invasive 
treatment of brain diseases and disorders. 
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 CHAPTER 2 
A REVIEW OF NOSE-TO-BRAIN NEUROTHERAPEUTIC INTERVENTIONS 
 
2.1. INTRODUCTION 
Delivery of drugs to the brain has been fraught with issues of low bioavailability 
(Krol, 2012). The central nervous system (CNS) which is made up of the brain and 
the spinal cord do not have adequate access to the blood compartment due to the 
Blood-Brain Barrier (BBB) and other barriers. CNS disorders have been recorded 
as the number one source of disability and account for more extended care and 
hospitalizations than the combination of most other diseases (Misra et al., 2003). 
For instance, over 36 million people in the world today have CNS related diseases 
and disorders, the numbers will continue to rise to about 66 million by 2030, and 
projected to be around 115 million by 2050 (Liu et al., 2013). Treating CNS 
disorders and ailments in general which include Alzheimer‟s disease, Parkinson‟s, 
Schizophrenia, Stroke, epilepsy, AIDS dementia Complex, brain tumor and 
Huntington disease is extremely challenging due to the presence of various 
obstacles that restrict passage of drug across the BBB for onward delivery to the 
brain (Radhika et al., 2011).  
 
The BBB which is both physiologically and anatomically a biological natural 
occurrence with no single scientific theory to explain all the events happening 
therein (Roth and Barlow, 1961) according to Roth and Barlow five decades ago, 
the challenges are still on even as of today. Researchers are therefore searching 
for the best methods to develop drug delivery systems and techniques to transfer 
pharmaceutical substances to the brain and CNS for the management of 
neurodegenerative disorders and delivery of drugs to the brain and the CNS in 
general having in mind the BBB obstacle. Lipophilic substances with molecular 
weight less than 600 Da are known to permeate the BBB, which implies that the 
more lipophilic the drug molecules the better the permeability of the drug, the use 
of prodrug will be an excellent approach in increasing the permeability, the prodrug 
on getting to the brain will be converted to the parent drug (Illum, 2000). Several 
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attempts and strategies such as disturbing the BBB (Alves, 2014), carrier 
mediated drug delivery osmotic BBB disruptions (Aryal et al., 2014), biochemical 
BBB disruption (Griep et al., 2013), drug manipulations including prodrugs, 
receptor-mediated drug delivery, chemical drug delivery, vector-mediated drug 
delivery (Lu et al., 2014), alternative routes such as intraventricular and intrathecal 
route, olfactory pathway, other techniques include injections, catheters, and 
pumps technique, implant of device directly to the brain, biodegradable polymer 
wafers, microspheres and nanoparticles techniques, have been explored (Misra et 
al., 2003). The use of intranasal route has been explored by various researchers 
and has been established to be a promising route of transferring therapeutic 
substances directly to the brain by employing the olfactory pathway through the 
nasal mucosa in order to bypass the BBB and its associated problems. 
 
2.2. BIOLOGICAL BARRIERS AS AN IMPEDIMENT TO CNS DRUG 
DELIVERY 
There are biological barriers limiting the delivery of drugs to the CNS thereby 
contributing to the difficulties in treating CNS diseases and disorder.  Due to these 
biological barriers, transcranial drug delivery has been used to overcome these 
barriers. This approach entails three types of delivery systems which are; intra-
cerebroventricular injection, convection enhanced diffusion and intracerebral 
implantation. These methods however require an invasive approach through into 
the brain. Implantation of transcranial catheters has been confirmed to be 
connected to numerous complications and is known to be temporary (Bleier et al., 
2013). These barriers are enumerated below. 
 
2.2.1. Blood-Brain Barrier 
Knowledge about the BBB might assist researchers in designing better drugs or 
approaches in fabricating systems for delivering therapeutic agents to the brain. 
The BBB is a special membranous barrier that distinguishes the CNS from the 
systemic circulation (Begley, 1996; Misra et al., 2003; Schlosshauer and Steuer, 
2002). The BBB is naturally designed to protect the brain from foreign organisms 
and deleterious chemicals in the blood, but allows the supply of necessary 
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nutrients to the brain for the well-being of the brain to maintain and regulate the 
microenvironment for accurate neuronal signaling (Abbott et al., 2010) and other 
functions. The protection of the Brain and the CNS is sorted by the barrier function 
of the brain capillary endothelial and the choroid epithelial cells. The blood 
capillaries of the brain are anatomically different from that of other tissues and 
organs. The blood capillaries consist of special cells known as endothelial cells; 
these cells are sealed with tight junctions with their membrane separating the 
systemic circulation and the central extracellular fluid of the brain. The vasculature 
serving the CNS also has capillaries with tight junctions. The arachnoid membrane 
which is a doubled layered structure covers the brain and constitutes a barrier 
between the blood and the CSF (Shawahna et al., 2013; Kuhnline Sloan et al., 
2012; Nag et al., 2011; Kaur et al., 2008; Vyas et al., 2005a). Therefore, BBB is 
primarily a prominent obstruction in drug delivery to the brain.  
 
2.2.2. Blood-Cerebrospinal Fluid Barrier 
The Blood Cerebrospinal Fluid Barrier (BCSFB) (Lam et al., 2012) is another 
barrier that exists, it inhibits the passage of drugs to the CNS during systemic 
administration (Chalbot et al., 2010; Yasuda et al., 2013). BCSFB is resides in the 
epithelium of the choroids plexus (Johanson et al., 2011), the arrangement of 
which limits the passage of therapeutic molecules into the CSF. The choroid 
plexus and the arachnoid membranes play a major role at the barriers between the 
blood and CSF (Chalbot et al., 2010; Misra et al., 2003). It is clear that the 
endothelium of the cerebral  blood  vessels  and the  epithelium  of  the  choroid  
plexus prevent  the penetration  of  large solutes  directly  into the  brain  and  
CSF. 
 
2.2.3. Blood-Tumor Barrier  
Blood Tumor Barrier (BTB) is a barrier formation at the local site of the tumor cells 
that do not permit drugs from reaching brain tumors in therapeutic quantity to 
exterminate the tumor cells. A range of barriers that are physiologically oriented 
are found in solid tumors and they prevent drug delivery via the cardiovascular 
system. Solid tumor consists of neoplastic cells, drug delivery to these cells is 
hindered because uneven distribution of microvasculature throughout the tumor 
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interstitial resulting into drug delivery inconsistency (Misra et al., 2003). Apart from 
dealing with the BBB, there is also the problem of BTB. Many innovative methods 
have been used to improve drug delivery to the tumor cells, of which has been 
reviewed by Groothuis (2000).  
 
2.3. NASAL ANATOMY AS AN AID TO CNS DRUG DELIVERY 
It is pertinent to understand the anatomy of the nasal cavity when discussing the 
intranasal administration, absorption and transporting of drugs to the brain and 
CNS. Figure 2.1 shows the Lateral wall of the nasal cavity. The nasal cavity is 
located within the skull; it spans from the base of the skull to the roof of the mouth. 
It is a midline structure that is divided into two equal haves by the nasal septum. 
Each half which consists of the roof and the floor as well as medial and lateral 
walls (formed by the bone and cartilage skeleton of the skull) begins from the 
nostril at the anterior part and ends up at the nasopharynx at the posterior part 
where the two airways confluence (Hinchcliffe and Illum, 1999). The nasal cavity 
roof consists of frontal and nasal bones anteriorly, in the middle is the cribriform 
plate of ethmoid bone, ala of the vomer and the sphenoidal process of the palatine 
bone posteriorly (James Zinreich et al., 1990). The floor is composed of the bones 
of the hard palate which are the palatine process of maxilla anteriorly and 
horizontal plate of palatine bone posteriorly. The middle wall is made up of the 
nasal septum which passes from the roof to the floor of the nasal cavity (Peter, 
2003). 
 
The nasal cavity consists of paranasal sinuses which are frontal sinuses, ethmoid 
sinuses, maxilla sinuses and sphenoid sinuses, they are air-filled spaces 
surrounding the nasal cavity and are lined with mucosa membrane with small 
openings into the nasal cavity (Napier, 2013). The nomenclatures and locations of 
these sinuses are derived from the bones in which they lie, which are the frontal, 
ethmoid, maxilla and sphenoid respectively. Both the frontal and maxilla sinuses 
open into the nasal cavity through the semilunar hiatus (El-Gendy and Alsafy, 
2010; Langille et al., 2012; Thiagarajan, 2013),  sphenoid sinuses open into the 
speno ethmoid recess (Weiglein et al., 1992) and ethmoid sinuses which consist of 
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the anterior, middle and posterior parts open into the nasal cavity by the 
infundiblum, ethmoidal bulla and the superior meatus respectively (Napier, 2013; 
Shanmugam et al., 2011). The nasal cavity communicates through the lateral 
nasal wall with the maxillary and frontal sinuses and more posteriorly with the 
sphenoid sinuses. The septum provides support for the nasal structures and 
regulates nasal passage while the middle concha warms up and humidifies the 
inspired air (Aktas et al., 2003). 
 
The nasal cavity which has a total volume and surface area of approximately 20ml 
and 150 cm2 respectively (Chaturvedi et al., 2011) is splited into three areas which 
are (1) the vestibular section which  is the most anterior part of the nasal cavity 
and surrounded by the nose cartilages  with epithelium lining same as that of 
the skin. The anterior area is between 10–20 cm2.  (2) The respiratory section with 
area of approximately 130 cm2, is the main area of the nasal cavity, this is the part 
where the absorption of therapeutic compounds into the systemic circulation takes 
place. The respiratory section is made up of the respiratory epithelium which 
consists of ciliated and non-ciliated columnar cells, mucous secreting goblet cells 
and the basal cells.  Many of the epithelial cells are covered on their apical surface 
with microvilli. The ciliated cells protrude out of the surface with few micrometers 
and can make synchronized movement that can push the mucus layer on the 
surface of the respiratory epithelium towards the nasopharynx, this is a useful 
action that is responsible for the mucociliary clearance mechanisms which 
eliminate foreign and undesired substances from the nasal mucosa into the GIT 
via the nasopharynx. (3) The olfactory section which occupies 10–20 cm2 in the 
roof of the nasal cavity (Hinchcliffe and Illum, 1999). Figure 2.1 shows the 
anatomy of the nose. 
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Figure 2.1: Lateral wall of the nasal cavity, and cross-sections through the internal 
ostium, the middle of the nasal cavity, and the choanae. Hatched area in the upper 
figure, olfactory region. NV, nasal vestibule, IT, inferior turbinate and orifice of the 
nasolacrimal duct; MT, middle turbinate and orifices of frontal sinus, anterior 
ethmoidal sinuses and maxillary sinus; ST, superior turbinate and orifices of 
posterior ethmoidal sinuses. Source (Mygind and Dahl, 1998). 
 
Intranasal drug delivery has fascinated the interest of researchers based on the 
fact that the nasal mucosa has been established as a substitute route for the 
delivery of high molecular weight therapeutic substances including protein and 
peptides that are liable to either acidic or enzymatic degradation as well as first 
pass hepatic metabolism when administered orally. It has also been explored as a 
promising route for the administration of vaccines (Singh et al., 2012), and a viable 
route for the delivery of biopharmaceuticals (Tong-un et al., 2010). The initial use 
of nasal delivery was largely confined to topical applications, example of such 
applications include nasal steroids for treatment of nasal allergies, also 
phenylephrine and oxymetazoline for the treatment of nasal decongestion. These 
drugs operate locally at the site of administration and does not require passing 
through the systemic pathway (Maggio and Pillion, 2013). Intranasal route 
provides a non-invasive and alternative method of delivering therapeutic 
compounds with ease of administration of those drugs that are restricted by the 
BBB to the brain and CNS than the systemic administration which is associated 
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with various side effects (Hanson and Frey, 2008). The nose-to-brain drug delivery 
is possible because of the position of the trigeminal as well as the olfactory nerves 
which connect the brain to the nasal cavity. Drugs can be transported directly from 
the nasal mucosa to the brain through the olfactory region which is strategically 
located in between the nasal cavity and the CNS region allowing drugs to bypass 
the BBB and BCSFB. The penetration of drugs to the brain however depends on 
several factors such as properties of nasal formulations, types of nasal device, 
dosing, drug amount and deposition, mechanism of transport, mucocilliary 
clearance and other local site barriers. 
 
There are several advantages of intranasal drug delivery over the systemic 
delivery of drugs some of which are listed in Table 2.1. The advantages and the 
limitation of intranasal drug administration are shown in Table 2.1. It is obvious 
that the advantages overweigh the limitations thereby making intranasal 
administration of drugs a better method of drug administration especially to the 
brain and CNS than the oral, intravenous, transdermal administration and of 
course implantations. The delivery systems and devices are considerable factors 
in intranasal drug delivery because of the physiology and structure of the nose. 
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Table 2.1: Advantages and Limitation of Intranasal Drug Administration. 
 Advantages Limitations 
1 The surface area of the nasal 
mucosa is large for dose 
administration (Misra et al., 2003) 
Amount of administered drugs is 
limited to 25-200 μl. (Afifi et al., 
2005) 
 
2 Rapid absorption of drug is 
possible due to rich blood 
capillaries and vessels in the 
nasal mucosa (Andrews et al., 
2009; Soane et al., 1999) 
 
Adversely affected by 
pathological conditions (Alam et 
al., 2010; Misra et al., 2003) 
3 Possibility of Rapid onset action 
of delivery (Li et al., 2002; Vyas et 
al., 2005a)  
 
Drug permeability may be 
affected due to  the ciliary 
movement (Andrews et al., 2009) 
4 Ease of administration, 
noninvasive (Andrews et al., 
2009; Mistri et al., 2012)  
Drug permeability is limited due 
to enzymatic inhibition (Ozsoy et 
al., 2009) 
5 Bypasses BBB (Singh et al., 
2012) 
Drug with nasal irritation may not 
be acceptable through this route 
(Alam et al., 2010) 
 
6 Evade the gastrointestinal tract 
and first pass metabolism (Soane 
et al., 1999; Vyas et al., 2005)  
 
 
 
7 Improved bioavailability (Dhuria et 
al., 2009; Vyas et al., 2005a) 
 
8 Possibility of direct absorption into 
systemic circulation and CNS 
(Ozsoy et al., 2009) 
 
 
9 Lower dose amount to reduction 
of side effects (Alam et al., 2010; 
Vyas et al., 2005) 
 
 
10 Improved convenience and 
compliance  
 
11 Self-administration of drugs (Alam 
et al., 2010) 
 
 
12 It avoids the use of sterile 
procedure (Alam et al., 2010) 
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2.3.1. The Olfactory Pathway as an Opportunity for CNS Drug Delivery 
The Olfactory region is located at the roof of the nasal cavity just below the 
cribiform plate of the ethmoid bone and crosses a bit down the septum and lateral 
wall. Its position is strategic as one end interacts with the nasal cavity and the 
other end with the CSF. It is therefore the only area of the CNS that has external 
link to the outside surroundings. Olfactory neurons directly penetrate through the 
cribiform plate into the olfactory epithelium of the nasal cavity (Padowski and 
Pollack, 2010). The olfactory epithelium is formed by the olfactory receptor 
neurons which are arranged at intervals among the other sustaining cells and the 
basal cells. The olfactory system is responsible for perceiving smell.  Variety and 
numerous odorant molecules can be perceived by mammals and humans through 
their sense of smell which is mediated by the olfactory system. 
 
The olfactory system has the ability to detect different kinds of odors by applying 
information theory measurements to olfactory bulb activity images (Fonollosa et 
al., 2012). Humans can sense approximately between 10 000 to 100 000 
substances as having a distinct odor (Buck, 2005). The olfactory bulb is a structure 
found at the bottom of the brains of human and it is being protected and cradled by 
the cribiform plate which also separates it from the nasal cavity. It is the site that 
processes information about odors, which is the principal purpose of the olfactory 
(Buck and Axel, 1991). Figure 2.2 shows the schematic illustrations of the various 
types of cell in the olfactory region. Receptor cells which are the neurones are 
situated among columnar sustentacular cells. The axons of the receptor cells 
emerge from the epithelium in bundles enclosed by ensheathing glial cells. 
Spherical globose basal cells and flattened horizontal basal cells lie on the basal 
lamina. The Bowman‟s gland opens on to the surface via their intraepithelial ducts. 
At the surface are cilia of the receptor cells and microvilli of the supporting cells.  
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Figure 2.2: Illustrations of the various types of cells in the olfactory region. 
Reproduced from (Mistry et al., 2009). 
 
2.3.2. Proposed Pathways of Therapeutic Agents Introduced into the Nasal 
Cavity 
When therapeutic compound is intranasally administered, it is liable to follow 
different routes as depicted in Figure 2.3. The drug may find its way into the 
systemic pathway via the blood vessels and capillaries in the nasal mucosal. The 
probability of the drug going into the blood is very high considering the fact that the 
nasal cavity is very rich in blood supply. This is one of the reasons intranasal 
administrations of drugs is preferred for the drugs that have a high risk of being 
significantly degraded in the gastrointestinal tract or those that are highly 
metabolized through the first pass effect of the liver. An example of this is 
highlighted in the oral administration of Olanzapine (Kumar et al., 2008) where 40 
percent of the drug was metabolized in GIT and liver prior to reaching the systemic 
circulation.  The drug may also find its way into the olfactory system and ultimately 
reach the CNS. The trigeminal nerve which controls the facial sensation has been 
established to transport drugs to CNS and brain in particular. In the nasal cavity, 
the drugs that could not make it to the blood, olfactory and the trigeminal pathway 
may be degraded through the action of the enzymes in the nasal cavity or be 
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eliminated via mucocilliary clearance (Preetha et al., 2013). Drugs that find their 
way into the systemic circulation may be delivered to the body tissues and organs 
or be eliminated from the blood by normal clearance mechanism. Drugs may also 
be distributed from the CNS to brain or migrate from the brain to the CNS. Drugs 
in the CNS and brain may also be eliminated by clearance into the blood. 
 
 
Figure 2.3: Possible transport pathways of a compound introduced into the nasal 
cavity. Adapted from (Graff and Pollack, 2005; Illum, 2004, 2003, 2000). 
 
2.3.3. Mechanism of Direct Nasal Mucosa to Brain Delivery via the Olfactory 
Pathway 
The mechanism of direct nasal mucosa to brain drug delivery has not been firmly 
established but it has been evidenced by the work of various researchers that 
intranasal delivery of therapeutic agents is delivered to the brain along the 
olfactory and trigeminal pathway. For example, Renner et al. (2012) intranasally 
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administered fluorescently labeled insulin into mice; the insulin migrated deep into 
the anterior area of the olfactory region moving across from the nasal mucosa 
epithelium to the cribriform plate to gain access to the olfactory bulb. Higher 
quantities of insulin were found in the in the olfactory nerve layer up to the 
glomerular layer. Similarly, insulin labeled with nanogold was delivered intranasally 
to mice, insulin was also found in the olfactory nerve layer of the mice and 
intracellular nanogold was detected in the nucleus of the cells of the olfactory bulb 
(Renner et al., 2012). Various researches have been conducted to demonstrate 
that molecules can be transported from the nasal mucosa by widely dispersing 
these molecules throughout the olfactory region, carrying them across to the 
olfactory bulb and subsequently reaching the brain. 
 
Dhuria et al. (2010) described the mechanism involved in the transporting drug 
molecules to the brain and CNS. They reported that drugs interact with the nasal 
mucosa comprising nasal epithelium and the drug molecules are distributed by 
both olfactory and trigeminal nerves where the nerve endings send chemosensory 
information to the brain. Drugs may be transported to the brain through 
perivascular spaces which is located in the lamina propria or through intracellular 
and extracellular pathways. On reaching the lamina propria, drugs may pass into 
the openings formed by unsheathing cells neighboring the olfactory nerves, and 
then penetrate the olfactory bulb including the CSF. From the CSF, drugs can 
diffuse and blend with interstitial fluid of the brain via bulk flow mechanisms. Drugs 
that pass through the perivascular channels may also exit through the same 
channels; this is an important process by which substances get eliminated from 
the CNS to the external environment. The mechanism may also involve the 
passage of the drug into the primary neurons found in the olfactory epithelium and 
then penetrate to the olfactory bulb via intracellular axonal transport. Axonal 
transport occurs when the drugs penetrate the neurons by endocytosis for onward 
movement to the CNS with subsequent possible circulation of the drug into inner 
brain tissues (Illum, 2004).  
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2.4. EVIDENCE OF NOSE-TO-BRAIN DRUG DELIVERY 
Nose-to-brain delivery of drugs and neurologic substances such as insulin and 
other growth factors along the olfactory neural pathway to treat neurological 
disorders was first proposed and patented in 1989 by W. H Frey II (2010). Recent 
developments in intranasal drug delivery have shown intranasal administration of 
drugs as a harmless and suitable route for delivering drugs to the brain and CNS 
generally for the treatment of neurodegenerative ailments, for the special reason 
of the existence of the BBB which does not allow the passage of most therapeutic 
agents to the brain and CNS. Lipophilic compounds penetrate quickly and 
effectively across the nasal membranes into the systemic circulation through the 
transcellular pathway which shows the same plasma profile to that of intravenous 
injection in terms of absorption with bioavalaibility of drugs up to a 100%. Because 
of this quick action, lipophilic compounds seldom pass through the olfactory 
pathway in the nasal cavity. However hydrophilic compounds and larger 
compounds have serious difficulty in passing across the nasal membrane into the 
blood circulation for systemic delivery, even if they do cross, they are still faced 
with the issue of BBB for brain delivery. It has been established that the 
bioavailability of less lipophilic molecules and large molecules is about 1-10% 
(Illum, 2004). The olfactory pathway is therefore an inevitable route for the delivery 
of these compounds to the brain and CNS via the nasal cavity. Several therapeutic 
agents have been successfully delivered to the CNS using the intranasal route of 
administration.  
 
2.4.1. Delivery of RNA, Enzymes, Insulin and Protein 
Enzymes, proteins and insulin have been successfully delivered to the brain 
through the nasal mucosa. Trigeminal nerve has been known to also contribute to 
the movement of drugs to the brain. Renner et al. (2012a) examined delivery of 
fluorescently labeled Small interfering Ribonucleic acid (siRNA) from the nasal 
mucosa to the olfactory bulbs via the olfactory pathway. Their result showed that 
after thirty minutes of intranasal administration, fluorescently labeled siRNA was 
detected in the olfactory epithelia, lamina propria as well as the olfactory bulbs 
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along the olfactory pathway and was dispersed throughout the olfactory region as 
depicted in Figure 2.4. 
 
Recently, α-l-iduronidase (IDUA) action was detected widely in the brains of IDUA-
deficient mice after concentrated laronidase administration via the nasal mucosa 
and it was also detected after intranasal treatment with an adeno-associated virus 
(AAV) vector expressing human IDUA. This was demonstrated by Wolf et al. in the 
course of providing the first evidence of lysosomal enzyme passing the BBB when 
administered via the nasal route (Wolf et al., 2012). Brain-derived neurotrophic 
factor, ciliary neurotrophic factor, and neurotrophin-4/5 can promote neuronal 
survival in event of injury to the CNS. Delivery of these substances is difficult 
because of their large molecular weights which prevent them from crossing the 
BBB. These proteins have been successfully delivered intranasally and high 
concentrations of the proteins were detected in the brain 25 minutes after nasal 
administration (Alcalá-Barraza et al., 2010). Delivery of insulin employing the 
olfactory nerve pathway was carried out by Renner et al., the aim of their study 
was to deliver insulin directly to the olfactory bulbs through the olfactory nerve 
pathway employing the intranasal route of administration (Renner et al., 2012a). 
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Figure 2.4: Showing fluorescently labeled siRNA distribution in the olfactory bulb 
of rat. Scale= 30µm: ONB=olfactory nerve bundle, OM=olfactory mucosa, 
CP=cribiform plate, ONL=olfactory nerve layer, GL=glomerular layer. Adapted 
from (Renner et al., 2012b). 
 
2.4.2. Delivery of Drug-Loaded Nanoparticles 
Liu et al. (2013) modified poly(ethyleneglycol)-poly (ε-caprolactone) nanoparticles 
by conjugating the nanoparticles with Lactoferrin to obtain Lactoferrin-conjugated 
PEG-PCL nanoparticle (Lf-NP) using a maleimide-thiol reaction for delivering of 
neuroprotective drugs to treat Alzheimer‟s Disease (AD) employing intranasal 
route for direct nasal mucosa to CNS delivery. In their experiment, the Lf-NP was 
labeled with Cy5.5 a fluorecein probe for real time imaging and biodistribution in 
mice. Three hours after intranasal administration, they observed a very strong 
fluorescent signal of Cy5.5-labeled Lf-NP in the brain of the mice as shown in 
Figure 2.5. They used NAP (NAPVSIPQ), an 8-amino acid neuropeptide fragment 
as model drug. The outcome when their system was evaluated in AD mice 
intranasally showed an enhancement delivery of the neuroprotective drug in the 
brain.  
 
Chitosan nanoparticles have demonstrated the potential for enhancing the brain 
uptake of venlafaxine hydrochloride a drug for the management of depression via 
29 
 
nasal route. Venlafaxine side effects such as increased blood pressure, tiredness, 
pain, tachyarrhythmia, dizziness, sexual dysfunction observed when administered 
via oral or intravenous make its intranasal delivery to brain and CNS a promising 
and preferred method (Haque et al., 2012). 
 
 
Figure 2.5: Distribution and retention of Cy5.5-Lf in the brain following 
intranasal administration. Adapted from (Liu et al., 2013). 
 
Rivastigmine (Fazil et al., 2012) and thymoquinone (S. Alam et al., 2012) loaded 
Chitosan nanoparticles have been produced by ionic gelation method to increase 
the uptake of drug to the brain and to enhance the bioavailability of the drug in 
CNS following administration through the nasal route. Shadab et al. 
(2012) investigated the potential use of Chitosan nanoparticles for the purpose of 
delivering therapeutic agents to the brain intranasally. This was achieved by 
preparing bromocriptine (BRC) loaded Chitosan nanoparticles using ionic gelation 
of Chitosan with tripolyphosphate anions with mean size of 161nm. Figure 2.6 
shows the SEM image of the nanoparticle revealing the morphology of the 
optimized BRC loaded nanoparticles. Optimized technetium labeled BRC was 
employed in investigating the biodistribution of the BRC in the brain and blood of 
the mice after intranasal and intravenous administration. At 30 minutes following 
administration, the brain/blood ratio of BRC loaded chitosan nanoparticles 
administered intranasally was found to be higher than that of intravenous 
administration. These results indicate a direct nasal mucosa to brain transport 
bypassing the BBB. Al-Ghananeem et al. (2010) have used Chitosan 
nanoparticles to delivered Didanosine an HIV reverse transcriptase inhibitor to the 
brain via the nasal mucosa. The didanosine-loaded Chitosan nanoparticles were 
made by ionotropic gelation of Chitosan with tripolyphosphonate anions. They 
compared the intranasal delivery to intravenous delivery. Their findings highlighted 
that the concentration of therapeutics in the olfactory bulb, CSF and brain were 
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considerably higher after intranasal administration than those after intravenous 
administration of didanosine aqueous solution. 
 
 
Figure 2.6: SEM image showing surface morphology of optimized bromocriptine 
loaded Chitosan nanoparticles. Adapted from (Shadab et al., 2012). 
 
Thermo-sensitive gels with lorazepam microspheres using Chitosan and pluronics 
were prepared and characterized for nasal delivery to the brain by Jose et al 
(2013).  In vitro drug release and permeation studies of their investigation showed 
that the gel formulation is capable of sustaining a 24-hour drug release. This may 
provide controlled release advantage and improved bioavailability for nasal drug 
delivery. 
 
Nose-to-brain delivery system in combination with cell-penetrating peptide (CPP) 
modified nano-micelles comprising polyethylene glycol–polycaprolactone (PEG–
PCL) copolymers conjugated with the CPP, Tat (MPEG–PCL–Tat) (Kanazawa et 
al., 2013) has been synthesized to deliver siNRA to the brain following intranasal 
administration. Alexa-dextran (Anionic dextran labeled with Alexa Fluor 568) as a 
model siRNA was complexed with Tat to obtain MPEG–PCL–Tat/Alexa-dextran 
nano complex. Sprague–Dawley male rats were employed for in vivo study, 100µL 
was administered intravenously and 80µL intranasally to the rats, the result of 
intranasal administration was compared with intravenous administration as 
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depicted in Figure 2.7 revealed the presence of Alexa-dextran in those rats that 
were dosed intranasally and none in those that were dosed intravenously. The 
results confirm intervention of nose-to-brain of therapeutic agents to the brain for 
managing neurogenerative diseases. 
 
 
Figure 2.7: Dynamics of MPEG–PCL–Tat complex in brain tissue following 
intranasal and intravenous administration (Kanazawa et al., 2013). 
 
2.4.3. Microemulsion Formulations 
Thakkar et al. (2013) prepared and characterized mirtazapine microemulsion for 
intranasal delivery, to determine its brain drug delivery using pharmacokinetic 
studies, and assess its performance pharmacodynamically for the antidepressant 
activity. Their investigation demonstrated a rapid movement and higher 
concentration of mirtazapine into the brain with intranasal administration compare 
to oral administration, which may be helpful for the treatment of depression. 
Acharya et al. (2013) prepared and evaluated intranasal oil in water microemulsion 
of carbamazepine to improve its solubility and enhance the brain uptake. 
Intranasal microemulsion of carbamazepine was prepared by water titration 
method using oleic acid as oil, Tween 80 as surfactant and Transcutol® as co-
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surfactant. Their experiment resulted in higher brain/plasma ratio with nasal 
microemulsion in comparison to ratio obtained after intraperitoneal injection of 
carbamazepine solution. Porecha et al. (2009) prepared and characterized 
microemulsions/mucoadhesive microemulsions of Diazepam, Lorazepam and 
Alprazolam, evaluated their pharmacodynamic behavior by carrying out 
comparative sleep induction studies in male albino rats to appraise their role in 
effectual management of insomnia patients, intranasal administration of these 
drugs was compared with oral administration, They observed faster onset sleep 
after intranasal administration compare to oral. The result of their investigation 
also showed that the mucoadhesive microemulsions of the formulation following 
intranasal administration indicated rapid and higher drug transport to the rat brain 
and thereby induced quick sleep and prolonged sleep. 
 
Kumar et al. (2008a) have prepared nanoemulsions which contain risperidone to 
achieve brain uptake of drug through the nasal mucosa; they compared a 
risperidone nanoemulsion and risperidone mucoadhesive nanoemulsion via 
intranasal and intravenous administration. Their results showed that intranasally 
administered mucoadhesive nanoemulsion was a more efficient and exhibit better 
brain targeting of risperidone, which is an indication of how important 
mucoadhesion is in nasal drug delivery. They also prepared nanoemulsions and 
olanzapine mucoadhesive nanoemulsions employing water titration method, these 
formulations were intranasally and intravenously administered to rats. It was 
observed that the biodistribution of olanzapine in the brain and blood of rats 
(brain/blood uptake ratios) after intranasal and intravenous administrations of 
olanzapine formulations at 30 minutes were 0.88 and 0.04 respectively (Kumar et 
al., 2008b). This result proved that intranasal administration enhances 
bioavailability of drugs compare to intravenous administration. Zhang et al. (2004) 
while investigating ways of enhancing the solubility of nimodipine and its brain 
absorption in microemulsion, their result showed absorption of nimopidine in the 
olfactory bulb to be enhanced three-fold after intranasal administration, compared 
with intravenous injection. 
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Dalpiaz et al. (2014) have used solid lipid microparticles (SLMs) as a carrier 
system for the nasal administration of antiretroviral drug zidovudine (AZT) with 
ursodeoxycholic acid (UDCA) (UDCA−AZT) prodrug for direct nose to brain 
targeting, Figure 2.8 shows the micrographs of unloaded (A) and UDCA–AZT 
loaded (B) SLMs based on tristearin. They employed hot emulsion technique using 
tristearin and stearic acid as lipidic carrier. Their study showed that in the 
presence of chitosan, there is six-fold bioavailability of prodrug in the CSF, and up 
to 1.5 μg/mL of prodrug within 150 min after nasal administration, which is an 
evidence of direct nose- to-brain delivery pathway. 
 
 
Figure 2.8: Environmental scanning electron microscopy (ESEM) micrographs of 
unloaded (A) and UDCA–AZT loaded (B) SLMs based on tristearin (Dalpiaz et al., 
2014). 
 
2.4.4. Liposomes as Delivery Vehicles 
Galanthamine hydrobromide (GH) which is an effective therapeutic agent that is 
widely used in Alzheimer‟s disease management has been delivered into the rat 
brain successfully through the intranasal route of administration employing flexible 
liposomes as the delivery vehicle (W. Li et al., 2012). Salama et al. (2012) 
prepared phospolipid based colloidal nanocubic vesicles by integrating non-ionic 
copolymers, poloxamer 188 or 407, in the lipid bilayer. Their aim was to 
encapsulate olanzapine in the matrix.  Their investigation resulted in development 
of nanocubic vesicles and enhancement of the delivery of olanzapine to the brain 
with bioavailability up to 37.9% and brain targeting efficiency of100% after 
intranasal administration. Liposomes have been employed in delivering 
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rivastigmine to the brain tissue through intranasal administration. Liposomes as 
delivery vehicle significantly improved the exposure and resulted in higher 
concentration of the therapeutic agent in the brain (Mutlu et al., 2011; Arumugam 
et al., 2008). 
 
Alam et al (2014) prepared nanostructured lipid carrier (NLC) to confirm and 
assess the improvement of duloxetine (DLX) loaded NLC in the brain folowing 
intranasal administration, they employed Gamma imaging technique to study the 
localization of DLX, their result revealed about 8 fold of DLX concentration in the 
brain in comparison to being administered intravenously. Li Weize et al. (2012) 
delivered GH successfully into the rat brain through the olfactory pathway while 
investigating the intranasal administration effects of GH loaded flexible 
liposomes on the effectiveness of acetylcholinesterase inhibition. Figure 2.9 shows 
the TEM image of the GH loaded liposomes. They discovered a quick action of 
movement of GH into the brain with the flexible liposomes following intranasal 
administration. Their investigation therefore indicates that the intranasal 
administration of GH loaded liposomes may be a promising technology to be 
explored in future for the treatment of AD.  
 
Eskandari et al. (2011) have developed nasal nanostructured lipid carriers of 
valproic acid for direct nasal mucosa to brain delivery. Their aim was to lower the 
dosage, provide prolonged action of the drug and evaluate its efficacy against 
generalized tonic-clonic seizures in rats, their study established that administration 
of vaproic acid nanostructure via the nasal route is an appropriate method in 
maintaining vaproic acid effect with a higher brain uptake using much lower dose 
compare to systemic adminstration. Migliore et al. (2010) evaluated the efficiency 
of cationic liposomes for the delivery of proteins to the brain by employing the 
nasal route of administration. They loaded the liposomes with ovalbumin and a 
50μg was intranasally administered to rat, it was observed that after 6 hours, 
ovalbumin was widely distributed throughout the brain of the rat. Solid lipid 
nanoparticles (SLNs) have been developed and optimized as intranasal drug 
delivery system for ondansetron (Joshi et al., 2012) and risperidone (Patel et al., 
2011). The method employed for preparing the SLNs was solvent diffusion-solvent 
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evaporation method. Significant quantities of therapeutic agents were rapidly 
delivered to the CNS and brain after intranasal administration of the drug-loaded 
solid lipid nanoparticles that were formulated. 
 
 
Figure 2.9: TEM image of GH loaded flexible liposomes adapted from (W. Li et al., 
2012) 
 
Polymeric micelles have been developed for intranasal drug delivery. Chiappetta 
et al. (2013) prepared poly(ethylene oxide)–poly(propylene oxide) polymeric 
micelles for intranasal administration which was loaded with high payloads of 
efavirenz an antiretroviral drug for treating HIV dementia. Poloxamer F127, and 
mixed polymeric micelles containing 75% of T904 and 25% of F127 was employed 
with an attempt to determine the effect on size of the micelles as well as the drug 
payload. They compared intranasal administration of their formulation with 
intravenous administration; the result of their investigation shows four times 
bioavailability enhancement in the CNS for intranasal administration compared to 
intravenous which is as a result of direct migration of the nanomicelles to the 
olfactory region for onward delivery to the CNS. The size of the micelles ranged 
from 13.5nm to 247.3nm when the efavirenz was fully encapsulated. 
 
2.4.5. Direct Drug Application into the Nasal Cavity 
Direct drug application without any protective vessel has been demonstrated by 
various researchers for example, Deferoxamine (DFO) has been delivered using 
the noninvasive intranasal method of administration. Hanson et al. (2009) reported 
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that employing intranasal route to administer DFO resulted in higher brain uptake 
of DFO compare to intravenous administration, it also amount to reduction in 
systemic absorption, and subsequently resulted in prevention and treatment of 
stroke damage after middle cerebral artery occlusion in rats. Fine et al. determined 
whether intranasal administration of DFO would minimize loss of memory in the 
P301L mouse and how the treatment might affect AD neuropathology, their finding 
was that intranasal administration with DFO reduced both inﬂammation and 
oxidation which are the two phenomena associated with Alzhiemer‟s Disease 
(Fine et al., 2012).  
 
Application of recombinant tissue plasminogen activator (tPA) to ischemic stroke 
has been carried out by Liu et al. (2012) using direct nose-to-brain approach 
because of the BBB issues and the associated side effect of the systemic 
pathway. Their study examined the therapeutic benefit of tPA when it is 
intranasally administered for direct CNS targeting for the treatment of stroke in rat 
model. Their result shows tPA content of 307 mg/ml at 30 min in the brain 
compare to 7 mg/ml measured 2 h after intravenous injection of tPA 
(10 mg/kg), signifying intranasal administration to be an effective method of 
delivering high molecular weight drugs for brain and spinal cord targeting (Liu et 
al., 2012) 
 
Cocaine was intranasally and intravenously administered to male Sprague-Dawley 
rats by Chow et al (1999). The result of both routes of administration indicated 
similarity in concentration of cocaine in the brain. The concentration of cocaine in 
the olfactory lobe was investigated after 1 min of dosing and small fraction of the 
dose was found delivered in the olfactory bulb via the olfactory pathway, much of 
the cocaine have been trapped by the blood rich nasal mucosa for onward 
systemic delivery to the brain and CNS. 
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2.5. CONVENTIONAL NASAL DRUG DELIVERY DOSAGE FORMS 
2.5.1. Nasal Drops 
The purpose of using nasal drops is to instill the drugs inside the surface of the 
nasal cavity. Nasal Drops are the simplest and most convenient systems that have 
been developed for intranasal drug delivery. Aukema et al. have used nasal drops 
to deliver steroids into the middle meatus for the treatment of polyposis and 
chronic rhinosinusitis with fluticasone propionate (Aukema et al., 2005). Daley-
Yates and Baker in their experiment tried to measure the bioavailability of 
Flutticasone Propionate administered as a nasal drops and  also compare it to 
being administered as a nasal gel, it was observed that the formulation has low 
systemic bioavailability which is much lower than when administered as nasal gel 
(Daley-Yates and Baker, 2001). Nasal drops have been however reported to 
deposit human serum albumin in the nostrils better than nasal sprays (Patel, 
2013). Nasal drops do not have dose precision which is an obvious shortcoming of 
the system. In addition liquid formulations are more easily emptied to the 
nasopharynx thereby showing quick clearance from nasal mucosa which is an 
impediment to sustained drug release (Alsarra et al., 2010). 
 
2.5.2. Nasal Sprays 
Nasal sprays function by the action of hand operated metered dose pumps and 
actuators to infuse a fine vapor into the nostril, they can therefore deliver exact 
dose from 25-200ul an advantage over nasal drop. Several nasal sprays have 
been developed over the years for drug delivery. Some of which are highlighted in 
Table 2.2. Chesnut III et al used Salmon calcitonin nasal spray at a dose of 200 IU 
daily to drastically reduce the threat of new vertebral fractures in postmenopausal 
women with osteoporosis (Chesnut III et al., 2000). Fluticasone nasal spray has 
been used to reduce the occurrence of pediatric obstructive apneas and 
hypopneas (Brouillette et al., 2001). Others include: Nicotine nasal spray for 
tobacco withdrawal (Blondal et al., 1999; Hjalmarson et al., 1994; Stapleton and 
Sutherland, 2011; Sutherland et al., 1992). Nicotine nasal spray for analgesic 
purposes (Yagoubian et al., 2011).  
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Table 2.2: Review of recent development in nasal sprays for delivery of 
therapeutic agents. 
Therapeutic Agents Functions References 
Nicotine 
 
Tobacco withdrawal 
 
(Blondal et al., 1999; 
Hjalmarson et al., 1994; 
Stapleton and 
Sutherland, 2011; 
Sutherland et al., 1992) 
 
Salmon Calcitonin 
 
Reduces new vertebral 
fractures in 
postmenopausal women 
with osteoporosis and in 
the treatment of 
Refractory Mania 
 
(Chesnut III et al., 2000; 
Lee et al., 2011; Vik et 
al., 2013) 
 
Fluticasone 
 
reduces the occurence 
of pediatric obstructive 
apneas and hypopneas  
 
(Brouillette et al., 2001) 
 
Fentanyl pectin 
 
Pain relief in the 
treatment of cancer 
 
(Radbruch et al., 2012; 
Taylor et al., 2010) 
Oxytocin 
 
Treatment of Autistic or 
Asperger's Disorder 
 
(Guastella et al., 2010) 
Mometasone Furoate Treatment of nasal 
polyps in children 
(Chur et al., 2013) 
 
 
 
 
2.5.3. Nasal Gels 
Gelation occurs usually through polymers crosslinking by forming covalent bond 
known as chemical crosslinking or by non-covalent bonding and van der Waals 
forces known as physical crosslinking (Piechowiak et al., 2012). Gel formulations 
increase the contact time with the nasal mucosa and also increases efficiently the 
residence time of the therapeutic substances in the nasal mucosa. These 
advantages are dependent however on the type of polymers used. Other 
advantages include reduction of taste impact, reduction of leakages of the 
formulation from the anterior part and mucosa target for better absorption 
(Chaturvedi et al., 2011). Table 2.3 shows some of the recent development of 
nasal gel in delivering therapeutic agents through the nasal mucosa. 
 
39 
 
Table 2.3: Review of recent development in nasal gel for delivery of therapeutic 
agents 
Therapeutic 
Agents 
Functions Polymers Used References 
Midazolam 
Hydrochloride 
Treatment of 
epilepticus 
Pluronic F127 (Basu and 
Bandyopadhya
y, 2010) 
 
Ondansetron 
Hydrochloride 
Management 
of nausea  
and vomiting 
that is 
associated with 
cancer 
chemotherapy 
 
Pluronic F127 and 
hydroxypropylcellulose 
(Bhalerao et 
al., 2009) 
 
Chlorphenirami
ne maleate 
Antihistaminic 
drug 
Sodium Carboxymethyl 
cellulose and 
Hydroxypropyl 
methylcellulose 
 
(Soliman et al., 
2010) 
Ropinirole Dopamine D2 
agonist  
chitosan and hydroxyl 
propyl methyl cellulose 
(Khan et al., 
2010) 
 
Sumatriptan Treament of 
migrane and 
severe 
headache 
 
Carbopol 934P and 
Pluronic F127 
(Majithiya et 
al., 2006) 
Lorazepam Treatment of 
status 
epileptics 
 
Pluronic F127 and 
Chitosan 
(Jose et al., 
2013) 
Curcumin Anti-
inﬂammatory, 
antioxidant, 
anti-tumoural 
and 
antimicrobial 
 
polyethylene glycol 400 
and Pluronic F127 
(Chen et al., 
2013) 
Venlafaxine Treatment of 
chronic 
depression 
 
Methyl cellulose and 
Pluronic F127 
(Pund et al., 
2013) 
Vinpocetine Prevention of 
Azheimer‟s 
disease, 
ischemic stroke 
Hydroxypropylmethylcellul
ose, methyl cellulose and 
Carboxymethyl Cellulose 
(Badie, 2012) 
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2.5.4. Nasal Powders 
The instability of therapeutic agents may inform the development of this delivery 
system, where solution and suspension dosage form may not be adequate to 
sustain the drug. Preservative is not required in the formulation and there is 
possibility of administration of larger doses of therapeutic agents. The suitability of 
powder for delivery of both peptide and non-peptide drugs has been established 
(Chaturvedi et al., 2011; Joshi and Misra, 2001). For nasal powder formulation to 
be efficient, factors such as aerodynamic properties, particle size, degree of 
irritancy of the formulation as well as the solubility of the therapeutic compounds 
must be considered. Nasal powder do not have metered dosage and causes nasal 
mucosa irritancy on application, these are however some of its disadvantages 
(Akhtar, 2012). Table 2.4 shows Review of some recent development in nasal 
powder for delivery of therapeutic agents. 
 
Table 2.4: Review of recent development in nasal powder for delivery of 
therapeutic agents. 
Therapeutic Agents Functions References 
Anthrax vaccine Prevention of Anthrax (Wang et al., 2012) 
 
Norwalk virus-like 
particles (NV VLP) 
Antigen 
Prevention of norovirus 
infections 
(Velasquez et al., 2011) 
Tacrine hydrochloride Treatment of Alzheimer‟s 
disease 
(Saladini et al., 2013) 
 
Desmopressin Treatment of nocturnal 
enuresis 
 
(Fransén et al., 2009) 
Sumatriptan  Treatment of migraine (Djupesland and 
Dočekal, 2010)  
 
Zolmitriptan Treatment of migraine (Gavini et al., 2013) 
 
2.6. THE USE OF SPECIALIZED INTRANASAL DRUG DELIVERY SYSTEMS 
In the bid to find solution to the problem of BBB, specialized intranasal drug 
delivery systems have been developed by researchers to overcome the issue of 
bioavailability of therapeutic agents to the brain.  
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2.6.1.  Liposomes 
There are flexible and conventional liposomes which are differ by their high elastic 
fluid membranes that permit a number of molecules to pass across via the cellular 
membranes. (Elsayed et al., 2006; W. Li et al., 2012). Liposomes have several 
attractive features as pulmonary drug delivery systems particularly with respect to 
the controlled delivery. One of the alleged advantages of liposomes as a drug 
carrier is in their ability to effectively encapsulate small and large molecules 
(Alsarra et al., 2008; Tan et al., 2010) and alter auspiciously the pharmacokinetic 
profile of the encapsulated substance thereby providing selective and sustained  
pharmacological effects at the site of administration (Joshi and Misra, 2001). The 
control release profile of the encapsulated therapeutic agent in liposomes is 
difficult to manage, this may however be a major disadvantage of this system 
(Hearnden et al., 2012). Table 2.5 shows recent development in nasal liposomes 
drug delivery. 
 
Table 2.5: Review of recent development in nasal liposomes for delivery of 
therapeutic agents. 
Therapeutic Agents Functions References 
Ovalbumin Chelating agent (Migliore et al., 2010) 
 
hepatitis B surface 
antigen (HBsAG) 
 
Vaccine (Tiwari et al., 2011) 
Galanthamine 
hydrobromide 
Treatment of Alzheimer‟s 
disease 
 
(W. Li et al., 2012) 
Olanzapine Treatment of 
schizophrenia 
 
(Salama et al., 2012) 
Rivastigmine Treatment of Alzheimer‟s (Arumugam et al., 2008; 
Mutlu et al., 2011) 
 
Duloxetine Treatment of depression (M. I. Alam et al., 2012) 
 
 
2.6.2. Microspheres 
Microspheres are small spherical particles which are made up of macromolecular 
compounds of sizes of micrometer range usually from 1 to 1000 µm. Microspheres 
are matrix systems that are manufactured from basically natural and synthetic 
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polymers, drugs can then be incorporated into the matrix system by dispersion 
throughout the polymeric matrix. Microspheres have the ability to protect the drug 
from enzymatic degradation and are capable of prolonging the drug effect by 
sustained drug release. Table 2.6 shows some recent works done on 
microspheres as drug delivery system for nasal administration. 
 
Table 2.6: Review of recent development in microspheres for nasal delivery of 
therapeutic agents. 
Therapeutic 
Agents 
Functions Polymers Used References 
Rokitamycin Antibiotics Chitosan (Gavini et al., 
2011) 
 
Rizatriptan 
Benzoate 
Treatment of 
migraines 
Abelmoschus 
esculentus polysaccharide 
(Sharma et al., 
2013) 
 
Amlodipine 
Besylate 
Treatment of 
hypertension 
Polyvinyl Alcohol (Swamy and 
Abbas, 2012) 
 
Ondansetron 
Hydrochloride 
Treatment of 
nausea and 
vomiting 
Pectin (Mahajan et 
al., 2012) 
 
 
Lorazepam Treatment of 
status 
epileptics 
 
Pluronics PF-127 and PF-
68 
(Jose et al., 
2012) 
Valsartan Treatment of 
hypertension 
hydroxypropyl 
methylcellulose 
(Pardeshi et 
al., 2012) 
 
 
2.6.3.  Nanoparticles 
Nanotechnology is a very recent area of interest by researchers. Nanoparticles are 
colloidal solid particles with very small size in the nanometer range, usually from 
1nm to 1000nm in diameter. Nanoparticulate drug delivery system through the 
systemic pathway possesses distinct advantages for delivery of drugs to the brain. 
However, the bioavailability of the therapeutics in the brain is still not satisfied (Hu 
et al., 2009; Lu et al., 2005; Xia et al., 2012). Intranasal drug delivery of 
nanoparticles absorb via the olfactory pathway will be a promising way of getting 
43 
 
drugs to the brain and CNS in general. Table 2.7 shows a summary of recent 
development in nanoparticles for intranasal delivery of therapeutic agents. 
2.6.4. Microemulsions 
Microemulsions are made up of oil phase, aqueous phase, surfactant and co-
surfactant. Due to their lipophilic nature and their small size, microemulsion has 
been explored to be a good intranasal delivery system which efficiently improves 
drug absorption in the nasal mucosa. Microemulsion has advantage of being easy 
to produce compare to other delivery systems, because its production is mainly by 
mixing and stirring with magnetic stirrer or sonicator or by titration (Patel et al., 
2013) and requires simple instruments and laboratory equipments. Microemulsion 
has been discovered to be a novel approach to improve water solubility of poor 
water soluble drugs and subsequently increase bioavailability (Mahajan and Rasal, 
2013). Table 2.8 shows some of the recent work done using microemulsion as 
intranasal drug delivery system. 
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Table 2.7: Summary of recent development in nanoparticles for intranasal delivery 
of therapeutic agents. 
Therapeutic 
Agents 
Functions Polymers Used References 
Insulin Treatment of 
Alzheimer‟s 
disease 
 Glycopolymers. poly(3-
acrylamidophenylboronic 
acid-ran-N-maleated 
glucosamine)  
(Cheng et al., 
2012; X. Zhang 
et al., 2012; 
Zheng et al., 
2013) 
 
NAPVSIPQ 
(Neuropeptide) 
Treatment of 
Alzheimer‟s 
Poly (ethylene glycol)-co-
poly(ε-caprolactone) 
(Liu et al., 2013) 
 
Meloxicam Treatment of 
rheumatoid arthritis 
(Anti inflammatory 
drug) 
 
Polyvinylpyrrolidone (Kürti et al., 
2013) 
Losartan 
Potassium 
Treatment of 
Hypertension 
Poly (lactic-co-glycolic 
acid) PLGA 
(Verma et al., 
2013) 
 
Venlafaxine 
 
Treatment of 
depression 
 Chitosan (Haque et al., 
2012) 
 
Rivastigmine Treatment of 
Alzheimer‟s 
Disease 
 
Chitosan (Fazil et al., 
2012) 
Bromocriptine 
 
Treatment of 
Parkinson‟s 
disease 
 
Chitosan (Shadab et al., 
2012) 
 Thymoquinone Treatment of 
inflammatory 
disorder and cancer 
 
Chitosan (S. Alam et al., 
2012) 
Hepatitis B 
virus surface 
antigen 
(HBsAg) 
 
Vaccine N,N,N-Trimethyl chitosan 
 
(Subbiah et al., 
2012) 
plasmid DNA Vaccine chitosan–sodium 
deoxycholate 
(Cadete et al., 
2012) 
 
Clostridium 
botulinum type-
A neurotoxin 
 
Vaccine Pullulan (Nochi et al., 
2010) 
Ovalbumin (as 
model antigen) 
Vaccine N-trimethyl chitosan (Bal et al., 2012) 
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Table 2.8: Summary of recent development in microemulsion for intranasal 
delivery of therapeutic agents. 
Therapeutic Agents Functions References 
Nimodipine Treatment for 
cerebrovascular spasm, 
stroke and migraine 
 
(Zhang et al., 2004) 
 Mirtazapine Treatment of depression (Thakkar et al., 2013) 
 
Carbamazepine Treatment of epilepsy (Acharya et al., 2013) 
Olanzapine Treatment of 
schizophrenia 
 
(Patel et al., 2013)  
Diazepam Treatment of anxiety 
disorders, alcohol 
withdrawal symptoms or 
muscle spasm 
(Porecha et al., 2009) 
 
 
2.6.5.  Nanoemulsions 
 Nanoemulsions are thermodynamically stable and are stabilized by surfactants 
(Shafiq et al., 2007). They can be produced by simple emulsification method such 
as titration and by mixing oil, water, surfactant and co-surfactant together (Shafiq-
un-Nabi et al., 2007). They are important vehicles for delivery of hydrophobic 
compounds, which make them an important intranasal drug delivery system. Due 
to their characteristic size and properties, which includes kinetic stability, they are 
very effective in encapsulating the drugs and successfully direct them towards the 
desired targets (Thiagarajan, 2011). They do not have toxic effect on human and 
animal cells due to their non-toxicity and non-irritancy (Aboofazeli, 2010) which are 
excellent properties that make them suitable for therapeutic purposes and good 
candidates for intranasal delivery system. Table 2.9 shows some of the 
therapeutic agents that have been recently designed for delivery via intranasal 
nanoemulsion. 
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Table 2.9: Review of recent development in nanoemulsion for nasal delivery of 
therapeutic agents. 
Therapeutic Agents Functions References 
 Risperidone Treatment of psychotic 
disorders 
(Kumar et al., 2009, 
2008a) 
 
Olanzapine Treatment of 
schizophrenia 
 
(Kumar et al., 2008) 
Safranal  Treatment of convulsive 
disorders 
 
(Jain et al., 2012) 
Rizatriptan benzoate Treatment of migrane (Bhanushali et al., 2009) 
 
 
2.6.6.  Iontophoretic Delivery 
Lerner and coworkers (2004) investigated a method to increase the bioavailability 
and distribution of drug in the brain by employing iontophoresis as an intranasal 
delivery system to force the passage of drug from the nasal mucosa across to the 
brain employing an electric field. In their experiment, they charged up electrodes 
with drug and then applied it directly deep into the nasal neuro-epithelium of the 
rabbit, they then position a return electrode at the back of the rabbit‟s head. When 
electric current is applied, the charged drug molecules were forcefully driven 
across the nasal mucosa into the brain via the olfactory pathway. This method 
actually permits delivery of more therapeutics to the CNS compared to other 
methods. However, the method is cumbersome and highly invasive since the 
electrode has to be inserted deep into the nasal cavity potentially damaging the 
nasal mucosa.  
 
2.7. CHALLENGES AND FUTURE TRENDS OF DIRECT NOSE-TO-BRAIN 
DELIVERY 
There are several challenges facing direct nose to brain delivery. It has been 
recorded that drugs arrive at the CNS and the brain following nasal delivery, but 
the quantity of drugs recorded to have reached the brain is limited also the 
evidence of preferential brain delivery documented is limited. The dimension of the 
nasal cavity may also limit the dosage per time; the capacity of reaching sufficient 
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bio-distribution has not been established by this route of administration. Current 
intranasal delivery systems available cannot exploit the merits of nasal drug 
delivery maximally due to large amount of the dose been deposited at the anterior 
segment of the nose and thereby reducing drastically the amount of drugs that will 
eventually reach the olfactory region resulting in low bioavailability. The drug 
remaining at the surface of the nasal cavity may cause irritation and foul taste 
which may result in patient compliance problem.  
 
Most nasal formulations are in form of liquid, powder or gel. Liquid formulation is 
limited by solubility, stability and dose volume. Powder and gel formulations may 
be faced with issues of stability, absorption across the mucosal epithelium cells, 
residence time and degradation. In general nasal drug delivery systems may face 
the problem of low bioavailability in the CNS and brain due to various factors. 
Enzymatic barriers which are amongst the limiting factors of drug absorption in the 
nasal epithelium are caused by the various enzymes such as carboxylesterases 
that subsist in considerable quantity in the nasal mucosa (Krishnamoorthy and 
Mitra, 1998). The presence of these enzymes may result in degradation of 
substances introduced into the nasal mucosa due to their metabolic actions and 
thereby stand as barrier for intranasal drug absorption into the olfactory epithelium. 
Enzyme inhibitors such as boroleucine and puromycin may be used to minimize 
enzymatic metabolism of protein and peptide drugs (Grassin-Delyle et al., 2012). 
Permeation through the nasal epithelium cells poses a challenge to intranasal drug 
delivery; drug administered via the nasal mucosa permeates by passive 
paracellular and active transcellular transport. Drug can also permeate by 
transport via intercellular tight junctions, transcytosis and carrier mediated 
transport (Arora et al., 2002). Low molecular weight and lipophilic drugs can 
permeate with ease across the nasal mucosa epithelium, but hydrophilic drugs 
and high molecular therapeutic agents such as peptide and protein have low 
permeability (Bahadur and Pathak, 2012) and therefore present challenges in 
intranasal delivery. The use of permeation enhancers and prodrugs has been 
employed to improve permeability in nasal drug delivery. 
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Mucociliary clearance is a vital defense mechanism of the respiratory system that 
protects the lung against noxious inhaled pathogens such as bacteria, allergens, 
virus, toxins and other undesirable substances (Fliegauf et al., 2013; 
Alagusundaram et al., 2010; Kanthakumar et al., 1994). When these substances 
reach the nasal mucosa, they adhere and dissolve in the mucus lining and are 
transported to the GIT through the nasopharynx for onward ejection into the GIT. 
This is the one of the fates of therapeutic agents introduced to the nasal cavity. 
The clearing mechanism reduces the transport of drugs to the CNS and brain 
through the olfactory pathway and also reduces the residence time of drugs in the 
nasal cavity. These factors contribute to limiting the bioavailability of therapeutics 
in the CNS. Mucocilliary clearance depends on the drug site deposition and 
deposition area also depend on parameters including mode of nasal 
administration, texture of the formulation, physicochemical properties of the drug 
and the velocity of the delivered particles [169]. The mucocilliary clearance 
problem can be overcome by using mucoadhesive polymers in formulating nasal 
drug delivery system. Alginate and Chitosan are good examples of mucoadhesive 
polymers that can be employed in formulation of nasal drugs. Chitosan has been 
used by various researchers (Fazil et al., 2012; Haque et al., 2012; Gavini et al., 
2011) to increase the mucoadhesion of formulation in order to increase the 
residence time of the therapeutic agent in the nasal cavity. Poor physicochemical 
properties of the drugs and formulations may be another issue that needs to be 
addressed to achieve successful intranasal drug delivery.  
 
The use of novel and specialized approaches such as nanoparticles, 
microspheres, liposomes mucoadhesive polymers to encapsulate and protect the 
drugs has been a way to enhance the bioavailability of drugs in the brain and 
CNS. Mechanisms of transport and absorption of drugs in the nasal epithelium is 
another issue to be considered, for example some of the solutes introduced to the 
nasal cavity follow the trigeminal route and major part of the solutes may be 
distributed to the orofacial tissues which may reduce bioavailability of drugs in the 
brain and the CNS as evidenced by the work of Johnson et al.  Trigeminally 
innervated structures were found to have up to 20-fold higher tissue 
concentrations of lidocaine than the brain and blood following intranasal 
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administration of lidocaine to rats (Johnson et al., 2010). In addition, the nasal 
vasculature is undeniably another limiting factor to direct nasal mucosa delivery to 
the CNS and brain to treat neurogenerative diseases as it clears applied 
therapeutic agents into the system circulation for possible systemic delivery or 
elimination. This may be overcome by ensuring rapid movement of therapeutic 
agents to the olfactory region for onward delivery to the brain via the olfactory 
pathway.  
 
Considering the mechanism involved in transporting the drug directly to the brain 
which depends on passive diffusion of the drugs to the olfactory epithelium before 
being transported to the brain, substantial part of the drugs may have found their 
way into the blood and then follow the systemic pathway thereby limiting the 
amount of drug that will follow the olfactory pathway for onward delivery to the 
CNS. This action ultimately reduces bioavailability to the brain and CNS.  A 
formidable strategy is therefore desirable which will not only enhance the 
bioavailability of the drugs in brain and CNS (by the drugs going through the 
olfactory pathway) but ultimately ensuring timely and sustainable delivery to the 
brain and CNS within the shortest possible time in order to prevent drugs passing 
through the systemic pathway. Researchers are thus challenged to find an 
improved and better method of getting the drugs into the brain via the nasal 
mucosa in order to increase bioavailability of drugs in the brain by transportation 
and absorption going through the olfactory pathway instead of the systemic 
pathway.  
 
2.8.  CONCLUDING REMARKS  
This chapter shows evidence of direct nasal mucosa to brain and CNS delivery, 
the importance of the intranasal route of administration and its great potential as a 
means of delivering therapeutic agents to the brain for the management of brain 
diseases that may not have been possible due to the BBB and other barriers. The 
nasal mucosa is very rich in blood vessels and capillaries for systemic delivery, the 
probability of the drugs administered intranasally getting absorbed into the 
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systemic pathway is very high, even though, only molecules permeable through 
BBB will eventually reach the brain.  
 
All the researches enumerated in this chapter have employed the mechanism of 
passive diffusion that relies mainly on instillation of drug deep in the nasal cavity, 
physicochemical properties of the nasal and neuro-epithelia as well as gravity to 
penetrate the brain and CNS via the olfactory pathway. However, substantial 
quantities of drugs still go through the systemic pathway thereby reducing the 
quantity via the olfactory pathway. This is a challenge in the intranasal delivery of 
drugs as this action reduces the bioavailability of the drugs in the brain. Application 
of a „driving force‟ that can propel the therapeutic agents directly to the brain after 
being administered through the nasal mucosa may be a promising way of 
increasing bioavailability and decrease the time drugs reach the CNS and brain for 
the treatment of neurogenerative diseases. This method could be achieved by 
employing the use of electroactive polymers in formulating intranasal drug delivery 
system with the aid of external stimuli such as electromagnetic force to propel non-
invasively the drugs directly from the nose to CNS within shortest time in a 
sustainable manner. This could be proffered as a future advancement in intranasal 
drug delivery in the management of CNS diseases and brain disorder. 
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 CHAPTER 3 
AN IN VITRO EVALUATION OF A CARMUSTINE-LOADED NANO-CO-PLEX 
FOR POTENTIAL MAGNETIC-TARGETED NOSE-TO-BRAIN DELIVERY 
 
3.1. INTRODUCTION 
Brain cancer is a life threatening disease that occurs when there is formation of 
abnormal cells within the brain, of which glioma is the most common (Killela et al., 
2013). Despite the poor prognostic factors of malignant tumor, the quality of life of 
patients is seriously affected and may often lead to cognitive dysfunction (Omuro 
and DeAngelis, 2013). It was estimated that there would be about 23,000 new 
cases and over 15,000 deaths in 2015 in the United State alone due to brain 
cancer (Siegel et al., 2015). Several highly effective chemical and biological 
therapies have been researched to target brain tumors in order to improve its 
treatment. However, limited results have been achieved due to the difficulty of 
chemotherapeutics penetrating into the CNS due to the protective mechanism of 
the Blood Brain-Barrier (BBB). Radiotherapy and surgery are the alternative 
options that have been used both of which only provide temporary life extension 
(Hainfeld et al., 2013). The surgical technique is highly invasive and is challenged 
with excising tumor cells which may in fact affect normal brain cells. It is estimated 
that the 2-year survival rate is approximately 25% (Sullivan et al., 2014). 
 
Carmustine (BCNU) is known to be an effective chemotherapeutic for the 
treatment of brain tumors (Qian et al., 2013). It is a nitrosourea compound which is 
highly lipophilic. It hydrolyzes in vivo to produce reactive metabolites which cause 
alkylation and crosslinking of DNA and RNA. It is known to inhibit repair and 
causes formation of high molecular complexes through de-novo purine synthesis 
(Dhakane and Ubale, 2012). Targeted delivery of BCNU to the brain has been 
challenged with bioavailability issues. The systemic route of drug administration is 
fraught with a short elimination half-life resulting in frequent administration leading 
to side effects such as hepatotoxicity and pulmonary fibrosis (Qian et al., 2013). 
Several drug delivery strategies have been developed to overcome these 
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challenges and improve the treatment of brain tumors. These include the use of 
polymers in various embodiments such as nanoparticles, micelles, microcapsules, 
copolymers, bioconjugation, microspheres and implants (Fattahi et al., 2013a, 
2013b; Kim et al., 2009; Zhang et al., 2009; Xu et al., 2006; Painbeni et al., 1998). 
However, most of these approaches lack the ability to specifically target the tumor 
cells and instill adequate local concentrations of chemotherapeutic agents. 
Alternative strategies include the development of microelectromechanical systems 
(MEMS) devices (Li et al., 2005, 2004). MEMS devices function by a micro-
reservoir releasing a specific dose of chemotherapeutics at the site of the tumor 
thereby improving local concentration and targeting ability. Biodegradable 
polymeric microchips (Grayson et al., 2003) are similar to MEMS in terms of multi-
dose controlled release at the target site. However, these approaches are 
characterized by invasiveness, which is of major concern, especially during 
implantation of the devices. The most effective and well known approach is via 
localized delivery employing implants at the site of the tumor. Gliadel Wafer® (MGI 
Pharma, Bloomington, MN, U.S.A.) implants are currently approved for tumor 
resurrection, but high risk factors such as infection post implantation and brain 
abscess limit its use (McGovern et al., 2003). 
 
Researchers are constantly looking for ideal strategies to overcome the above 
mentioned challenges. Magnetic targeting using magnetic nanoparticles (Yang et 
al., 2011) and molecular targeting employing ligands (Ren et al., 2012) are the two 
most studied approaches to combat the challenges of side-effects, low deposition 
of drugs at the target site and the spreading of chemotherapeutics to healthy 
organs of the body (Yang et al., 2011). Both strategies are quite efficient but are 
still fraught with low bioavailability issues since the mode of administration is still 
via the systemic pathway and will be limited by the BBB.  
 
Intranasal drug delivery systems are more efficient in delivering therapeutic agents 
to the brain via the olfactory pathway. This method of administration has the 
advantages of circumventing the BBB, ease of administration, non-invasiveness, 
avoidance of the gastrointestinal tract and first pass metabolism, dose reduction 
and side-effect minimization (Mistri et al., 2012; Chalbot et al., 2010; Ozsoy et al., 
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2009; Afifi et al., 2005). The integration of magnetic targeting with an intranasal 
drug delivery system may be an enhanced strategy of delivering 
chemotherapeutics to the brain tumor cells. 
 
In this study we have successfully synthesized BCNU-loaded magnetized 
nanoparticles coated with a complex of Polyvinyl alcohol (PVA) conjugated to 
Polyethyleneimine (PEI) and FIuorecein isothiocyanate (FITC) referred to as a 
„Nano-co-Plex‟, intended for intranasal delivery to the brain via the olfactory 
pathway. The magnetic Nano-co-Plex (with the aid of an external magnet) would 
be projected and guided to the brain following intranasal administration. The 
choice of PVA is to facilitate and achieve good mechanical strength and chemical 
stability after conjugation. Essentially, branched PEI was selected due to the 
number of amine groups which are chemo-specific in forming amide bonds. It has 
also been widely used as a DNA and gene carrier as it possesses excellent ability 
to bind and release DNA (Zhang et al., 2014; Huth et al., 2004). FITC was 
selected due to its excellent fluorescent attributes, and it has been widely used as 
dye for cell labeling (Pinheiro et al., 2013; Xu et al., 2012; Ge et al., 2009). The 
conjugation of these compounds to form the Nano-co-Plex that has high BCNU 
loading and release capacity as well as having the attribute of high magnetization 
with a cell labeling property is a novel approach for synthesizing an intranasal 
targeted drug delivery system for the management of brain tumors. 
 
3.2. MATERIALS AND METHODS 
3.2.1. Materials 
Polyvinyl alcohol (PVA) (30kDa, 87−90% hydrolyzed), branched polyethylenimine 
(PEI) 1.8 kDa, iron (II) chloride tetrahydrate (FeCl2·4H2O), iron (III) chloride 
hexahydrate (FeCl3·6H2O), phosphate buffer solution (PBS) (pH=7.2), hydrochloric 
acid (HCl), sulphuric acid (H2SO4), N-hydroxysuccinimide (NHS), 1-ethyl-3 (3- 
dimethylaminopropyl) carbodiimide (EDC), FIuorescein isothiocyanate, 
epichlorohydrin, sodium hydrogen carbonate (NaHCO3), sodium hydroxide 
(NaOH), dialysis tubing (Mw=10,000g/mol), carmustine (BCNU), chloroform, 
acetonitrile and deuterated water (D2O). These chemicals were purchased from 
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Sigma-Aldrich Corp. (St. Louis, MO, USA). All other solvents and reagents were of 
analytical grade and were used as received. Deionized water was used in this 
experiment. 
 
3.2.2. Preparation of the Iron Oxide Nanoparticles 
Iron oxide nanoparticles were synthesized by dissolving 0.3mol of FeCl2·4H2O and 
0.6mol of FeCl3·6H2O in 60mL aqueous medium to obtain 1:2 molar ratios of Fe
2+ 
and Fe3+. This mixture was added drop wise to 200mL of NaOH (0.4 M, pH=13) 
heated up at 75°C. This was done under continuous stirring condition while the 
mixture was being purged with N2 gas to eliminate oxygen. This condition was 
maintained until dark precipitates of iron oxide nanoparticles were produced. The 
iron oxide nanoparticles so formed, were separated from the supernatant by 
centrifugation at 5,000 rpm for 30 minutes using an Eppendorf centrifuge 5804 
(Hamburg, Germany). The precipitates were washed with deionized water purged 
with N2 while under sonication (Sonics vibra cell, Newtown, CT, USA) for 30 
minutes and subjected to centrifugation once again to separate the precipitates 
from the supernatant. The precipitates, which are magnetite nanoparticles, were 
then washed several times with deionized water and air dried. 
 
3.2.3. Preparation of the Nano-co-Plex 
In order to prepare the Nano-co-Plex for drug loading, it is necessary to first 
synthesize PVA chlorohydrin derivative (PVA-CH). PVA-CH was prepared by 
dissolving 500mg of PVA in water (5mL) at 80°C.  Dilute H2SO4 (1M, 0.7mmol) 
was added to the solution after the PVA has completely dissolved followed by drop 
wise addition of 22.8mmol of epichlorohydrin. This mixture was stirred for 24 hours 
after which 5%w/v NaHCO3 was added to neutralize the mixture. Acetone was 
added to the mixture to precipitate out the chlorohydrins. The obtained PVA-CH 
was filtered, dissolved in 10mL of distilled water and then dialyzed against water 
for 2 days while changing the water every 12 hours. The product was 
subsequently freeze dried using Freezone 12 freeze drier (Labconco, Kansas City, 
USA). 
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FITC was included in order to investigate the cellular uptake and internalization 
characteristics of the Nano-co-Plex, and was conjugated by using the 1-ethyl-3 (3-
dimethylaminopropyl) carbodiimide/N-hydroxylsuccinimide (EDC/NHS) coupling 
method. NHS (115mg) and 191.7mg of EDC were added to 40mL of PBS (pH=6) 
at 25°C. After stirring for 15 minutes, FITC (16.6mg) was added to the solution 
with continued stirring. Aqueous solutions of PEI (100mg, 10mg/mL) was then 
added sequentially to this solution and stirred for 2 hours. 
 
PVA-CH (100mg) was dissolved in deionized water (10mL) at 70°C, and then an 
aliquot of FITC EDC/NHS/PEI previously prepared was added followed by addition 
of NaOH (4M, 5mL). The resulting mixture was stirred for 24 hours at 65°C. The 
synthesized magnetite nanoparticles were added and stirred for 24 hours. The 
resulting mixture was dialyzed against water for 48 hours followed by 
lyophilization. The lyophilized product was dispersed in deionized water and 
sonicated for 20 minutes. The particles were collected using a permanent magnet 
to separate them from the suspension while the supernatant was discarded. The 
particles were dried under vacuum at 40°C and are tagged Nano-co-Plex (NCP). 
This synthesis method was followed for samples prepared by changing the 
concentration percentage ratio of PVA and PEI in the formulation and are referred 
to as NCP-1, NCP-2 and NCP-3 with concentration percentage ratio of 70% PVA 
to 30% PEI, 50% PVA to 50% PEI and 30% PVA to 70% of PEI, respectively, as 
shown in Table 3.1. 
 
Table 3.1: Formulation percentage ratio of conjugated polymers used 
Samples NCP-1 NCP-2 NCP-3 
PVA Concentration (wt. %) 70 50 30 
PEI Concentration (wt. %) 30 50 70 
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3.2.4. Determination of Structural Integrity of the BCNU-loaded Nano-co-Plex 
3.2.4.1. Fourier Transform Infrared spectroscopy analysis of the BCNU-
loaded Nano-co-Plex 
Fourier Transform Infrared (FTIR) spectroscopy (Perkin-Elmer, Beaconsfield, 
BUCKS, UK) was employed to determine the structural modification of the 
nanoparticles used. FTIR spectra were obtained with samples subjected to 
pressure of 120 psi for 25 scans over a range of 4000-550cm-1. FTIR was 
performed on the individual components (PVA, PEI, FITC) that were used to 
prepare the complex and the drug-loaded nanoparticles. 
      
3.2.4.2. Nuclear Magnetic Resonance analysis of the Nano-co-Plex 
The 1H NMR was performed on PVA, PEI and the Polyplex employing NMR 
spectroscopy operating at 300MHz (Bruker Avance BioSpin, Germany). Each 
sample was dissolved in deuterated water (D2O) with concentration of 15mg/mL. 
The spectra of each of the samples were obtained and analysed. 
 
3.2.5. Thermal Stability and Quantitative Analysis of the Nano-co-Plex 
The composition of the polymer coated iron oxide particles were ascertained out 
by employing thermal gravimetric analysis (TGA) (PerkinElmer, TGA 4000, 
Llantrisant, Wales, UK). The quantity of polymer coated on the iron oxide particles 
were determined by the TGA. The TGA was configured to starting temperature of 
30oC and end temperature of 900oC under continuous flow of N2. Samples were 
heated at a rate of 10oC per min. Thermograms were generated as percentage 
weight vs. temperature and analyzed using Pyris™ software (PerkinElmer, 
Llantrisant, Wales, UK). 
 
3.2.6. Size and Stability Analysis of the BCNU-Loaded Nano-co-Plex  
Nanoparticle size and size distribution profiles were generated using a ZetaSizer 
NanoZS (Malvern Instruments, Malvern, UK) instrument equipped with non-
invasive backscatter technology set at an angle of 173°. The zeta potential of the 
synthesized nanoparticles was determined by exposing particles from each 
formulation independently to a controlled electric field and their mobility through 
Brownian motion was measured. This was achieved by a combination of Laser 
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Doppler Velocimetry and Phase Analysis Light Scattering at a maximum sample 
conductivity of 200mS/cm. 
 
3.2.7. Determination of Size and Morphology of BCNU-Loaded Nano-co-Plex 
The size and the morphology of the nanoparticles were visualized by employing a 
FEI Tecnai T12 transmission electron microscope operating at 120kV. Sample 
preparation was carried out by dispersing the particles in acetone and then 
ultrasonicated for 10 minutes using sonic vibra cell, (MO, USA). A drop of the 
dispersed sample was applied on a carbon coated copper grid placed on a filter 
paper for absorption of excess and acetone. The copper grid was allowed to air 
dry. 
 
3.2.8. Determination of Magnetization Properties of the BCNU-Loaded 
Nano-co-Plex 
Magnetic studies were performed employing a Quantum Design Superconducting 
Quantum Interference Device (SQUID) magnetometer (Quantum Design Inc., San 
Diego, CA). Approximately 30mg of samples were used per scan. The applied 
Magnetic Field (MF) ranged from -30,000Oe and 30,000Oe at room temperature. 
  
3.2.9. Analysis of the Crystalline Structural Properties of BCNU-Loaded 
Nano-co-Plex 
The XRD patterns were obtained utilizing a Rigaku 600 X-ray Diffractometer 
(RIGAKU, Inc., Tokyo, Japan) equipped with Cu-Kα radiation (λ=1.54056 Å). The 
diffractograms were obtained using the following parameters: Scan axis= Theta/2-
Theta, scan range of 0°-90°, scan step of 0.1 and scan speed of 2.0°/min. The 
voltage and current was set to 40kV and 15mA respectively. 
 
3.2.10. Establishment and Confirmation of the Interaction Profile Employing    
Computational Simulations 
All modeling simulations were performed using HyperChem™ 8.0.8 Molecular 
Modeling Software (Hypercube Inc., Gainesville, FL, USA) and ChemBio3D Ultra 
11.0 (CambridgeSoft Corporation, Cambridge, UK). The 3D structures of PVA and 
PEI were archetyped using ChemBio3D Ultra in their syndiotactic stereochemistry. 
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The structures of FITC and BCNU were constructed with natural bond angles in 
HyperChem 8.0.8. The models were primarily energy-minimized using the MM+ 
Force Field algorithm and the resulting structures were once again energy-
minimized using the AMBER 3 (Assisted Model Building and Energy Refinements) 
Force Field algorithm. The conformer having the lowest energy was used to 
develop the molecular complexes. A complex of one polymer molecule with 
another was assembled by parallel disposition and the energy-minimization was 
repeated to generate the final molecular complex models: PEI-PVA; PEI-FITC; 
and PEI-BCNU. Full geometrical optimization was conducted in vacuum employing 
the Polak–Ribiere Conjugate Gradient method until an RMS gradient of 
0.001kcal/mol was reached.  
 
3.2.11. Determination of the Loading Capacity and Efficiency of BCNU within      
the Nano-Co-Plex 
The BCNU loading was carried out in the dark by dispersing 5mg of NCP-1 in 5mL 
aqueous BCNU solution (drug concentration=0.1mg/mL). The mixture was 
sonicated for 30 min at 10 °C and then shaken in a rotary shaker (Rotavapor® RII, 
Büchi Labortechnik AG, Flawil, Switzerland) at 200rpm at 10°C for 6 hours to 
facilitate BCNU uptake.  Magnetite nanoparticles were removed from the solution 
every 30 minutes by employing a permanent magnet. The optical density of 
residual BCNU was immediately measured at 230nm by using high performance 
liquid chromatography (HPLC) (Waters, Milford, Massachusetts, USA). The HPLC 
system was equipped with a Waters symmetry300TM C18 5 µm, 4.6 x 250mm 
column, a UV-detector and a Waters binary HPLC pump. 3:7 (v/v) mixtures of 
acetonitrile and deionized water was used as the mobile phase with a flow rate of 
1.0mL/min, at wavelength of 230nm, in order to calculate the amount of BCNU 
adsorbed on the nanoparticles. Nanoparticles were redispersed in the buffer 
solution after each measurement for further BCNU adsorption. This exercise was 
repeated until there were no further changes in the concentration of BCNU 
indicating loading capacity had reached saturation point. The BCNU-loaded NCP 
(BCNU-NCP) obtained were then magnetically separated and freeze dried. This 
procedure was repeated for NCP-2 and NCP-3. 
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3.2.12. Determination of the In Vitro Drug Release Profile of BCNU released 
from the BCNU-Loaded Nano-co-Plex 
The release study was carried out by dispersing the dried BCNU-loaded NCP in 
5mL PBS pH 7.4 and incubating at 37°C in an orbital shaker incubator (YIHDER, 
Taiwan). At fixed incubation times, the BCNU-loaded nanoparticles were 
separated using a permanent magnet from the solution washed with deionized 
water. The separated nanoparticles were lyophilized employing Freezone 12 
freeze drier (Labconco, Kansas City, USA), the lyophilized product was then 
dissolved in chloroform followed by addition of mixtures of acetonitrile and 
deionized water in ratio 3:7 v/v. The chloroform from the mixtures was removed 
employing rotary evaporator (Rotavapor® RII, Büchi Labortechnik AG, Flawil, 
Switzerland). The polymers were then deposited on the side of the reaction vessel. 
The resultant solution was quickly analysed for BCNU employing HPLC. The 
released quantity of BCNU was calculated by determining the difference between 
the total amount of drug loaded and the amount obtained from HPLC result 
analysis. The entire drug release procedure was carried out for BCNU-NCP-1, 
BCNU-NCP-2 and BCNU-NCP-3. 
 
3.2.13. Cytotoxicity Analysis, Cellular Uptake and Internalization of the 
BCNU-Loaded Nano-co-Plex 
3.2.13.1. Cytotoxicity studies via 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl 
tetrazolium bromide assay on the conventional BCNU and BCNU-
loaded Nano-co-Plex 
The human glioblastoma cell line (A172) was employed in this study. The cell line 
was obtained from Cellonex, (Johannesburg, South Africa). The cells were grown 
in a 9:1 mixture of Dulbecco's modified Eagle's medium (DMEM) with 5% L-
glutamine and fetal bovine serum (FBS) (Cellonex, Johannesburg, South Africa), 
supplemented with 1% penicillin-streptomycin (Sigma-Aldrich; St. Louise, MO, 
USA) in a T-25 culture flask (Sigma-Aldrich; St. Louise, MO, USA) after which the 
cell line was expanded to large T-175 (175 cm2) culture flasks. The culture grew in 
a T-175 flask containing growth media (DMEM and 10% FBS) in an incubator (RS 
Biotech Galaxy, Irvine, UK) set at 37°C and 5% CO2, with media changed every 
48 hours. Cultured cells were dissociated from the culture flask with 0.25% trypsin 
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and then neutralized with Dulbecco's phosphate buffer saline (DPBS); the cells 
were quickly centrifuged at 1000 rpm for 5 minutes at room temperature. The cells 
were collected and then dispersed in 15mL of DMEM and 10% FBS. Cell counting 
was carried out by trypan blue dye exclusion employing a hemocytometer. The 
BCNU-loaded Nano-co-Plex was exposed to UV light for disinfection overnight 
prior to inoculation. The experimental cells were seeded at a concentration of 
1.0x104cells/well into each well of a 96-well plate, in 180µL of DMEM and 10% 
FBS medium/well. The plates were then incubated at 37°C and 5% CO2 overnight 
to allow cells adhesion to the bottom of the plates. Seven plates (A-G) were 
employed in this experiment, each plate contained similar contents and 
represented incubation times of 0, 4, 8, 16, 24, 48 and 72 hours, respectively. The 
wells in each plate were divided into 6 groups with predetermined quantities of 
BCNU-loaded Nano-co-Plex and conventional BCNU added to each well as 
depicted in Table 3.2. After incubation, each plate was removed according to the 
respective time of incubation for assay. 
 
Table 3.2: DPBS, NCP, BCNU-NCP and BCNU contents distribution in each plate 
Group Number of 
well used 
Contents added to each 
well 
BCNU quantity in 
each well (µg) 
Control  15 20µL of DPBS 0 
 
NCP 15 20µL of DPBS and 0.5mg 
of NCP (drug free Nano-
co-Plex) 
 
0 
BCNU-NCP-1 15 20µL of DPBS and 0.5mg 
of BCNU-NCP-1 
 
46 
BCNU-NCP-2 15 20µL of DPBS and 0.5mg 
of BCNU-NCP-2 
 
77 
BCNU-NCP-3 15 20µL of DPBS and 0.5mg 
of BCNU-NCP-3 
 
88 
BCNU 15 20µL of DPBS and 
0.088mg of BCNU 
88 
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The cell viability was measured by using the 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay. Each well was injected with 20μL of 
MTT solution (5mg/mL) in DPBS (pH 7.4) and further incubated for 4 hours. The 
media and the unreacted MTT were then carefully aspirated from each well 
leaving behind the formazan products. The formazan precipitate was then 
dissolved with 150mL of 100% dimethyl sulfoxide (DMSO) (Sigma Chemical Co., 
St. Louis, MO, USA) and the optical density of the solution measured with a 
microplate reader (FilterMax™ F5 Multi-Mode Microplate Reader, Molecular 
Devices, USA) at 570nm. The number of viable cells is directly proportional to the 
quantity of formazan products formed as quantified by the microplate reader. The 
results are presented as cell viability (CV) percentage (mean ± standard 
deviation); the percentage of viable cells was therefore calculated using Equation 
3.1. 
 
       
                                 
                                              
    
Equation 3.1 
 
                                 
3.2.13.2. Cellular uptake and internalization studies of the BCNU-loaded 
Nano-co-Plex 
The cellular uptake and internalization studies of BCNU-NCP were carried out 
using the human glioblastoma A172 cell line. Six 24-well plates divided into 2 
groups of three well-plates were used in this experiment. A172 cells were cultured 
as described in Section 2.13.1. Cells were seeded at a concentration of 5 x 
104cells/well in 24-well plates (Sigma-Aldrich; St. Louise, MO, USA) and incubated 
for 24 hours at 37°C and 5% CO2. After 24 hours, the well plates were then 
divided into 2 groups, group 1 consist of 3 well plates which were fixed with 0.1 
Tesla neo disc magnets (Magnetech, Capetown, South Africa) positioned under 
the well plates. Group 2 comprised of three well plates which did not have 
magnets attached to them. Preliminary studies showed that the magnet used has 
no effect on the growth of the cells (data not included). The cells in the two groups 
were incubated with BCNU-NCP-1, BCNU-NCP-2 and BCNU-NCP-3, respectively, 
at concentration of 0.5mg/mL at 37°C for a period of 1 hour. The media was 
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removed from each well and washed 5 times in DPBS in order to rid the cells of 
nanoparticles that were not internalized by the cells. The cells were then visualized 
under a Confocal Laser Scanning Microscope (CLSM, Leica Microsystems, 
Wetzlar, Germany). 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Synthesis of the BCNU-Loaded Nano-co-Plex 
In this study, we have achieved the synthesis of an anti-cancer drug-loaded 
nanoparticulate delivery system with superparamagnetic properties and cell 
labeling capability which can accommodate a high drug payload with the ability to 
respond to external MF intended for targeted delivery of drug to brain tumor 
following intranasal administration. Figure 3.1 shows the schematic of the 
synthesis of BCNU-loaded Nano-co-Plex. The magnetite was synthesized 
following the precipitated procedure of the combination of iron II and iron III salts in 
the ratio 1:2 at high pH under N2 gas to yield magnetite. PVA and PEI have been 
conjugated by utilizing the chemistry of the epoxidation reaction wherein PVA was 
reacted with epichlorohydrin in acidic medium to form a PVA chlorohydrin 
derivative (PVA-CH) by opening up the epoxide ring. Low molecular weight 
branched PEI was carefully selected for this work because of its non-toxic 
attributes to cells as opposed to the high molecular weight PEI. Conjugation of low 
molecular weight branched PEI with FITC was achieved by following NHS 
coupling chemistry. The addition of this conjugate (PEI-FITC) to PVA-CH at high 
pH formed a polymer complex (Polyplex) which in situ with the magnetite resulted 
in the coating of the magnetite nanoparticles with the Polyplex. The coated 
magnetite so obtained (Nano-co-Plex) was then loaded with BCNU to obtain the 
formulation.  
 
The mechanism of the conjugation of PVA with PEI is based on the replacement of 
the chlorine atom in the PVA-CH derivative by the amine group of the PEI after the 
opening of the epoxide ring forming a direct covalent bond between carbon and 
the nitrogen atom of the PVA-CH derivative and the amine group of the PEI. It has 
been established that branched PEI has numerous primary and secondary amine 
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groups (McBain et al., 2007). FITC can form amide bonds with PEI and can also 
form a thiourea covalent bond between the NH2 group of PEI and the 
isothiocyanate (–N=C=S) group of FITC (Pinheiro et al., 2013). It therefore means 
that PVA as well as FITC are covalently attached to the amine groups of the 
branched PEI. The mechanism of the coating of the magnetite by the Polyplex 
may have been through hydrogen bonding between the OH groups of PVA and 
the positively charged surface of the iron oxide core of the nanoparticles (Kayal 
and Ramanujan, 2010). Furthermore, the amine group on the PEI chain may bind 
tightly to the surface of the magnetite via donation of a pair of non-bonding 
electrons of N2 atom to an empty orbital of magnetite ion (Xu et al., 2012). PEI is a 
cationic polymer; its presence allows the complex to be positively charged. This 
attribute allowed BCNU, which is a negatively charged compound, to undergo 
electrostatic interaction with the complex and thereby formed a van der Waals 
bond between its molecules and the amine group of PEI. Coulomb forces may 
also contribute to the binding. The formation of hydrogen bonding is also possible 
between the N atom of BCNU and the OH group of PVA which may further 
strengthen the bonding of BCNU into the matrix. 
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Figure 3.1: Schematic of the synthesis of BCNU-loaded Nano-co-Plex. 
 
3.3.2. Assessment of the Structural Modifications of the BCNU-Loaded 
Nano-co-Plex 
3.3.2.1. Structural modification assessment via Fourier Transform Infrared 
spectroscopy 
The FTIR spectra of the synthesized magnetite, native PVA and PEI and FITC are 
shown in Figure 3.2a, b, c and d respectively. The low frequency band at 575cm-1 
indicates Fe-O symmetry stretching vibration of the synthesized magnetite (Ma et 
al., 2007). For PVA, the O-H stretching band at 3289cm-1 and C-H stretching band 
at 2910 were observed (Kayal and Ramanujan, 2010; Raju et al., 2007). The 
strong absorption peak at 1579cm-1 corresponds to the amine group of PEI (Wang 
et al., 2006). The intense absorption band observed at 2004cm-1 is the 
characteristic band for –N=C=S of FITC (N. Zhang et al., 2012).  
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FTIR spectra of BCNU, NCP and BCNU-NCP are shown in Figure 3.2e, f and g, 
respectively.  In Figure 3.2e the spectra of BCNU shows its native peaks of N-H, 
and C-Cl stretching vibration at 3350cm-1 and 621cm-1, respectively. In Figure 3.2f, 
the spectra of NCP, there is still the presence of the Fe-O stretching vibration 
(567cm-1), in addition to this, there are characteristic peaks of PVA, PEI and FITC. 
The peak around 3400cm-1 on the magnetite skeleton represents OH and it has 
shifted to 3215cm-1 in Figure 3.2f, suggesting that Polyplex was chemisorbed into 
the magnetite surface. The broad peak observed at 3216cm-1 is associated with N-
H symmetric vibration of the amine group in PEI and overlapping O-H stretching of 
the PVA molecule arising from the intermolecular hydrogen bonds. The peak at 
2811cm-1 is the C-H stretching from the PVA alkyl group while the band at  
1449cm-1 and 1094cm-1 are CH2 stretching and C-O-C stretching, respectively 
(Mansur et al., 2008). The peak at 1297cm-1 represents a C-N stretching vibration; 
this basically indicated the formation of a carbon-nitrogen bond as a result of the 
cleavage of the carbon chlorine bond from the epoxide chain and the amine group 
of PEI. This further confirmed the covalent bond between PVA and PEI molecules.  
 
The peak at 1559cm-1 represents N-H stretching vibration of an amide an 
indication of the formation of amide group (Duan et al., 2012) from the reaction of 
the carboxylic acid group of FITC amine group of the PEI thus confirming the 
presence of FITC in the complex. The disappearance of the absorption band of 
N=C=S at 2004cm-1 in Figure 3.2f and 2g suggested the formation of thiourea 
bond, which further confirmed the presence of FITC. Figure 3.2g is the absorption 
spectra of BCNU-NCP, here in addition to the peaks in Figure 3.2f, there are 
peaks at 1375cm-1 and 621cm-1 representing the N=O stretching vibration and C-
Cl stretching vibration of the BCNU compound, respectively. These peaks 
confirmed that BCNU was adsorbed within the complex and held in place by 
electrostatic forces such as hydrogen bonding and van der Waals force within the 
matrix of the polymeric coating complex. 
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Figure 3.2: FTIR spectra of a) synthesized magnetite, b) native PVA, c) native 
PEI, d) native FITC, e) BCNU, f) NCP-3 and g) BCNU-NCP-3. 
 
3.3.2.2. Structural modification assessment via Nuclear Magnetic Resonance 
analysis  
The 1H NMR was carried out on the PVA, PEI and Polyplex in order to further 
confirm the PVA- PEI conjugation. The 1H NMR results are displayed in Figure 
3.3. The methylene (CH2) and methine (CH) groups of PVA are visible at about 
1.70 and 4.03 ppm, respectively, in the 1H-NMR spectrum, as shown in Figure 
3.3a. The 1H-NMR spectrum of branched PEI (Figure 3.3b) shows characteristic 
peaks of methylene signals from 2.61-2.38 ppm. Due to samples being recorded in 
D2O, the NH2 peaks were not observed due to deuterium exchange. The 
Polyplex, which comprises both PVA and PEI, is formed by crosslinking of PEI and 
PVA. When PEI is crosslinked to PVA, the proton spectrum shows methylene 
resonance at 3.14 ppm which is indicative of -NH-CH2-CH-OH-; the new NH-CH2 
bond is visualized only in the spectrum of the Polyplex, and it is highlighted as 
shown in Figure 3.3c. The NMR spectrum further suggested the conjugation of PEI 
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to PVA. From the integration obtained from the NMR spectra, the conjugation ratio 
is estimated to be ~4:1 PEI to PVA in the Polyplex. 
 
 
Figure 3.3: 1H NMR spectra of (a) PVA, (b) PEI and (c) Polyplex. The red circle 
and arrow indicating the new NH-CH2 bond formed by the conjugation of PEI and 
PVA at peak 3.14 ppm. 
 
 
3.3.3. Morphology and Particle Size of the BCNU-Loaded Nano-co-Plex 
The TEM micrographs of the uncoated nanoparticles and the drug loaded 
nanoparticles, BCNU-NCP-1, BCNU-NCP-2 and BCNU-NCP-3, are shown in 
Figure 3.4a, b, c and d, respectively. The average size of the uncoated magnetite 
is about 30±6nm while that of drug-loaded nanoparticles average about 45±8nm. 
The increase in size may be attributed to the polymer coating; this is supported by 
the result obtained from the zetasizer and further confirmed by TGA. The size of 
the nanoparticles is very important in the formulation; the smaller the size of the 
drug loaded particles the more they can quickly migrate through the cells as they 
are being attracted by the external magnetic force applied. The morphology of the 
synthesized magnetite shows spherically and hexagonally shaped particles. The 
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drug loaded nanoparticles are also of these shapes even after coating as 
observed in Figure 3.4. It is imperative for this shape to be maintained as this is 
one of the parameters that assists the drug-loaded particles in being propelled by 
a smooth upward movement through to the cancer cells (Trewyn et al., 2008). The 
hexagonal shape may assist the nanoparticles to possess a better penetrating 
ability into the cancer cells by utilizing the angular sections as contact points for 
access.  
 
The TEM results revealed that the surface of the synthesized magnetite is smooth 
in comparison to the coated nanoparticles; this may be attributed to various 
components of the conjugated complex. The rough surface may also help to keep 
the drug molecules anchored to the polymer complex. The size of our drug-loaded 
Polyplex coated magnetite is within the range of those that have been previously 
reported in the literature (Chertok et al., 2010; Kayal and Ramanujan, 2010; 
McBain et al., 2007; Roque et al., 2009; Yang et al., 2011) but with a different 
shape. The variation in sizes observed in our nanoparticles compared to that 
found in the literature may have been due to the differences in the components of 
the coated materials, the mode of coating, synthesis, and preparation techniques 
used to mention just a few. The size obtained by us is deliberate as we require 
sizes that are moderate, i.e. not too large and not too small. The nanoparticles 
should not be too large so as to have easier penetration and movement of the 
nanoparticles through the cells to the target tumor site. Larger magnetic 
nanoparticles have high tendency of aggregating thereby resulting in poor tumor 
accumulation because they may not be able to extravasate into the interstitial 
space of the brain tumor cells (Zhang et al., 2009). Additionally, the nanoparticles 
should not be too small in order to optimize loading capacity of BCNU as well as to 
have an optimum magnetization effect; it has been reported that extremely small 
magnetic nanoparticles have poor accumulation ability at the target tumor site 
because the magnetic forces may not be able to overcome the Brownian motion 
forces (Yavuz et al., 2006). Therefore, the average particle size obtained in this 
study was uniform and consistent which offered an advantage of the drug-loaded 
magnetic coating being evenly distributed on the magnetite after loading. 
85 
 
 
Figure 3.4: TEM image of a) Uncoated magnetite, b), c) and d) BCNU-loaded 
Nano-co-Plex (BCNU-NCP-1, BCNU- NCP-2 and BCNU- NCP-3 respectively). 
The blue box in a) indicates uncoated particle while the red boxes in b), c) and d) 
indicate coated particles. 
 
3.3.4. Size Distribution and Zeta Potential Analysis of the BCNU-Loaded 
Nano-co-Plex 
The hydrodynamic sizes of the uncoated and coated magnetite obtained from the 
zetasizer are 35±6nm and 45±8nm, respectively which are slightly more than the 
size obtained from the TEM. This difference may be attributed to the absorption of 
liquid by the nanoparticles during the analysis bearing in mind that TEM analysis 
uses solid samples. The zeta potential of the synthesized magnetite was 
+10.1±1mV while that of Nano-co-Plex was +32±2mV and that of BCNU-loaded 
Nano-co-Plex was +21±2mV, as shown in Figure 3.5. The synthesized magnetite 
has the lowest zeta potential while the coated nanoparticles have the highest of 
+32±2mV. The reason for this is due to the polymeric coating which contains 
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cationic PEI which added to the overall charge of the coated magnetite. On the 
other hand, the drug loaded nanoparticles have zeta potential of +21±2mV which 
is a reduction in zeta potential from the nanoparticles without the drug, the reason 
for this is due to the fact that BCNU is an overall negatively charged molecule; 
(Hua et al., 2011), its interaction with the cationic polymeric complex resulted in 
the reduction of the positive charges on the overall charges of the formulation. The 
high zeta potential suggested that the particles are not clustering together and are 
therefore arranged relatively individually. The resultant high positive charges on 
the particles means there will be repulsion of the particles towards themselves, 
thereby reducing considerably nanoparticles agglomeration.  
 
It is important to note that despite concerns, previous studies in the literature have 
shown that a positive zeta potential of nanoparticles have no notable cytotoxic 
effect on normal cells (Merhi et al., 2012). Furthermore, tumor cells have 
negatively charged surface (Márquez et al., 2004), therefore the use of positively 
charged nanoparticles will allow enhanced binding to tumor cells and provide 
better cell uptake and internalization (Liu et al., 2013). 
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Figure 3.5: Zeta potential of a) synthesized magnetite b) Nano-co-Plex (NCP-3) 
and c) BCNU-loaded Nano-co-Plex (BCNU-NCP-3). 
 
3.3.5. Assessment of the Crystalline Structural Properties of the BCNU-
Loaded Nano-co-Plex 
Figure 3.6 shows the XRD results in 3D. The results confirmed the crystalline 
nature of both the coated and uncoated particles. The characteristic peaks 
obtained for the synthesized magnetite at 2θ are 29.4°, 34.7°, 42.5°, 52.9°, 56.4°, 
and 62.0°. The peaks obtained for NCP-1, NCP-2 and NCP-3 are similar to that of 
the magnetite. Overlapping of the spectra is observed due to similar peak values 
of the coated samples with the magnetite, the difference is however in the intensity 
of the peaks. At 2θ=29.4°, NCP-3 has the least intensity while the magnetite has 
the highest intensity; this is attributed to degree of coating of the magnetite, the 
more coating the less intensity obtained. It is interesting, however, to note that 
despite the coating of the magnetite with the polymeric complex, the coated 
nanoparticles still maintain the crystalline property of the magnetite.  
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Figure 3.6: XRD spectra of uncoated Magnetite and Nano-co-Plex (NCP-1, NCP-
2 and NCP-3). 
 
3.3.6. Assessment of the Thermal Stability and Quantitative Analysis of the 
Nano-co-Plex 
TGA was employed to evaluate the thermal stability as well as the weight loss of 
the coated magnetite nanoparticles. Figure 3.7 depicts the weight loss against 
temperature curves of uncoated and coated magnetite nanoparticles which was 
heated up to 900°C. The quantity of coatings onto the magnetite nanoparticles 
was determined by TGA. The result of the TGA firstly confirmed the presence of 
the coating as evidenced from the % weight loss of the formulation at 450°C, and 
secondly indicated the % weight of the drug-loaded coated complex and that of the 
magnetite in the formulation. Table 3.3 shows the percentage weight loss of 
BCNU-NCP-1, BCNU-NCP-2 and BCNU-NCP-3 to be 9.5%, 18.5% and 32% 
respectively. It was clear that a maximum of 32% of the drug-loaded Nano-co-Plex 
was coated on the magnetite as can be observed from the TGA curve, this 
therefore leaves approximately 68% magnetite content in the formulation 
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indicating a high magnetization capability which was consistent with the high 
saturated magnetization value obtained from the SQUID measurement. The 
complete degradation at 450°C of the complex leaves the magnetite nanoparticles 
as residue above this temperature. There is no significant weight loss in the TGA 
curve of uncoated magnetite at temperature as high as 900°C. The weight loss 
from 100 to 200°C may be attributed to the loss of water and the dehydration 
reaction of OH groups in PVA chains in the complex. 
 
Table 3.3: Percentage weight loss of the synthesized magnetite and the various 
formulations. 
Formulations Weight loss (%) 
Magnetite 0.1 
NCP-1 9.5 
NCP-2 18.5 
NCP-3 32.0 
 
 
 
Figure 3.7: TGA thermograms of a) uncoated magnetite and Nano-co-Plex b) 
NCP-1, c) NCP-2 and d) NCP-3. 
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3.3.7. Assessment of Attraction Sensitivity of the BCNU-Loaded Nano-co-
Plex to an External Magnetic Field  
The goal of this study is designing a formulation which has sufficient magnetization 
in order to enable the drug loaded polymeric coated nanoparticles to be quickly 
projected to the CNS via the olfactory pathway and subsequently be guided to the 
site of the tumor on application of external MF for targeted delivery of BCNU. It is 
therefore important for the design of the formulation to be of high magnetization 
capacity. Figure 8 shows the magnetization results which indicated saturated 
magnetization (Ms) of 87emu/g, 78emu/g, 65emu/g and 61emu/g for magnetite, 
NCP-1, NCP-2 and NCP-3, respectively. All the four samples exhibited 
superparamagnetic properties as evidenced by the absence of remanence in the 
hysteresis curve in Figure 3.8. These superparamagnetic properties are an 
indication that the sizes of the particles are in the nano range and possess single 
magnetic domain characteristics (Sánchez et al., 2004).  
 
The limited spatial extent thus achieved with the magnetic particles is responsible 
for the relatively low observed fields required to saturate these materials, which is 
an efficient approach in confining the magnetic species and to avoid long-range 
magnetic exchange interactions from producing magnetic ordering or memory 
effects. This property makes the formulation a good candidate for biomedical 
applications as the nanoparticles are not magnetic before application of external 
MF and are immediately deprived of magnetization after the external MF has been 
removed. Moreover, as demonstrated in Figure 3.8, even cycling of the MF leaves 
no remanent magnetization. The nanoparticles only exhibit magnetization in the 
presence of a MF.   
 
It can be observed from the curves that the Ms of the coated nanoparticles is lower 
than that of the synthesized magnetite, the reason for this decrease in Ms is 
attributed to the coating of the magnetite which reduced the effect of the MF on 
NCP-1, NCP-2 and NCP-3. Another reason is the overall quantity (relative mass 
amount) of magnetite in the samples, which decreases from NCP-1 to NCP-3. This 
result supported those obtained from the TGA regarding the weight loss of the 
samples when subjected to thermal analysis; the more the polymeric coating the 
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less the effect of magnetization on the nanoparticles. NCP-3, which has more 
coating as seen earlier, therefore has the lowest magnetization capability. It is 
demonstrated that all the three samples surveyed in Figure 3.8 become near-fully 
saturated and magnetized in relatively small fields. This means that the magnetic-
species impregnated substances studied here are amenable to be reproducibly 
manipulated under applied fields as low as 5000 Oe, and again fully released after 
termination of the location process. We note that a field of this magnitude amounts 
to as little as one third to one half the field intensity produced by modern 
neodymium-iron-boride permanent magnets.    
 
 
Figure 3.8: Magnetization curve of the synthesized magnetite and that of the 
Nano-co-Plex (NCP-1, NCP-2 and NCP-3) measured at 25°C showing the 
hysteresis loop. 
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3.3.8. BCNU Loading into the Nano-co-Plex  
The BCNU loading profile of NCP was studied and the loading profile is shown in 
Figure 3.9; the loading profile showed initial rapid adsorption of BCNU into the 
NCP after which the rate of adsorption was reduced and finally reached a 
saturation value of 93.54µg, 154.92µg and 176.82µg for NCP-1, NCP-2 NCP-3, 
respectively after 6 hours of loading. The loading of BCNU into the Nano-co-Plex 
is time dependent as the drug loaded increases with time for the three samples; 
saturation point is obtained after 6 hours of loading. From the result, a higher PEI 
content in the formulation resulted in higher BCNU loading. This may be attributed 
to the binding of the BCNU molecules to the PEI molecule since the PEI contains 
a high number of amine groups which are positively charged and could display 
high electrostatic interaction with the negatively charged BCNU through the amine 
group in the chains of PEI. It can be inferred that, the more the free amine groups 
available, the greater the drug binding capacity. All the formulations containing 
high PEI contents loaded more BCNU. The high and rough surface area may have 
also contributed to the binding of the drugs to the complex. From the result 
analysis, it can be deduced that for each milligram of NCP, there is approximately 
93.54µg, 154.92µg and 176.82µg of BCNU loaded into it, respectively. The highest 
loading percentage of BCNU to NCP was approximately 17.7% (w/w). 
93 
 
 
Figure 3.9: BCNU loading profile of Nano-co-Plex (NCP-1, NCP-2 and NCP-3). 
 
3.3.9. Assessment of the In Vitro Drug Release Profile of BCNU from the 
Nano-co-Plex 
BCNU is widely known to be unstable to light and it has a melting point of about 
32°C (Xu et al., 2006). This is the reason why the loading experiment has to be 
performed in the dark and at low temperature. In order to get accurate data, we 
therefore obtained the release quantity not by taking the reading from the released 
drug in the buffer solution but by determining what was left in the drug-loaded 
nanoparticles employing HPLC. The release profiles of BCNU in the three 
preparations (BCNU-NCP-1, BCNU-NCP-2 and BCNU-NCP-3) are shown in 
Figure 3.10. The release profiles showed a rapid release of BCNU in the first 10 
hours after which it decreased and then plateaued. The profiles also indicated an 
increase in release of BCNU with an increase in the quantity of drug loaded in the 
sample.  BCNU-NCP-1 which has loading capacity of 93.45µg release maximum 
of 30.2% of its drug content after 72 hours, while BCNU-NCP-2 with loading 
capacity of 154.92µg released 56.9% and BCNU-NCP-3 with loading capacity of 
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173.82µg released 78.8% of its drug content after 72 hours. The drug release 
profiles can be explained by the interactions between the drug molecules and the 
polymeric complex which were not as a result of covalent bonding but electrostatic 
forces such as van der Waals bonding which are weak bonds and can be broken 
in buffer solution at 37°C as the polymer complex holding the BCNU degrades or 
erodes. The release could also be explained by the diffusion rule which indicated 
that the higher the concentration the higher the rate drug is diffused into the 
environment. The drug release profiles were observed to follow Fick's law of 
diffusion for monolithic systems. The drug release also depends on the erosion of 
the polymeric matrix, as the polymeric complex remains in the buffer solution; the 
matrix degrades, thus releasing the drugs into the environment as the electrostatic 
force holding the drugs in the matrix are being reduced due to polymeric matrix 
erosion. This implies that the drug could be released from the polymeric matrix 
depending on the degradation and erosion rate of the Polyplex in the buffer. 
 
Figure 3.10: In vitro release profile of BCNU-loaded Nano-co-Plex (NCP-1, NCP-2 
and NCP-3). 
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3.3.10. Establishment and Confirmation of the Interaction Profile Employing 
Computational Simulations 
Aside from the various covalent bonds formed by the reactions of the polymer 
moieties during the conjugation, there are other non-bonding interactions that 
enhance the stability of the polymer complex. To further confirm the molecular 
interaction between the polymer segments that constitute the Polyplex, 
computational simulation mechanics was employed. Figure 3.11a, b and c showed 
the interaction profiles of PEI/PVA, PEI/FITC and PEI/BCNU, respectively. It was 
observed that intermolecular hydrogen bonding occurred between the hydroxyl 
group of the PVA and the amine group of the PEI in which the N in PEI is the 
hydrogen bonding donor and the O in the PVA the acceptor. Likewise, in the 
PEI/FITC interaction profile the amine group of the PEI is the donor and the 
carboxylic group in the FITC is the acceptor. The same explanation goes for the 
PEI/BCNU interaction profile. There is also evidence of van der Waals and 
electrostatic forces observed due to the ionic properties of the components of the 
Polyplex. BCNU is an overall negatively charged compound and it is capable of 
undergoing electrostatic interaction with the positively charged PEI through its nitro 
group and the amine group of PEI, this is in agreement with the result obtained 
from the FTIR. These non-bonding interactions in the form of hydrogen bonding, 
van der Waals and electrostatic forces, which is as a result of bond stretching, 
bond angle and torsional contributions, further account for the stability of the 
Polyplex formation. 
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Figure 3.11: Computational simulations of interaction profile of a) PVA and PEI, b) 
FITC and PEI and c) BCNU and PEI. The color codes for various elements are as 
follows: Carbon=cyan, Nitrogen=blue, Oxygen=red, Sulphur=yellow and 
Hydrogen=white. 
 
3.3.11. Assessment of the Cytotoxicity and Cellular Uptake of the BCNU-
Loaded Nano-co-Plex  
3.3.11.1. Cytotoxicity studies of the BCNU-loaded Nano-co-Plex 
The results of the MTT assay displaying the percentage of cell viability against 
time of incubation, which was used to measure the cytotoxicity of the BCNU-
loaded Nano-co-Plex, are displayed in Figure 3.12. The results showed that the 
NCP which is drug-free did not have any significant cytotoxicity on human 
glioblastoma cells as the cell viability percentage was ~96% after 72 hours.  
BCNU-NCP-1, BCNU-NCP-2 and BCNU-NCP-3 displayed cytotoxicity to human 
glioblastoma cells with cell viability percentage reaching 49.8%, 19.4% and 7.3%, 
respectively. This highlights the low toxicity of the Nano-co-Plex delivery system; 
cytotoxicity is attributed the BCNU. BCNU-NCP-3 showed the highest cytotoxicity 
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towards the human glioblastoma cells. The result of the conventional BCNU 
cytotoxicity at 88ug/mL showed that the cell viability percentage went as low as 
30.1% at 24 hours of incubation after which the cell viability percentage began to 
increase gradually to 33.9% after 72 hours. The increase in the viability 
percentage might be due to the instability of the BCNU which could affect its 
potency and therefore could no longer cause apoptosis nor inhibit the proliferation 
of the human glioblastoma cells. These results therefore showed the superiority of 
BCNU-NCP compared to the conventional drug. The graph revealed that for the 
period of 72 hours BCNU-NCP-3 continued to release drug into the cells in its 
potent form while the conventional drug lost its potency after 24 hours. The ability 
of BCNU-NCP-3 to continuously release BCNU may be attributed to NCP‟s 
protective and stabilizing property as BCNU is embedded in the matrix of the 
Polyplex while it erodes gradually, and thereby overcoming the BCNU 
disadvantage of short half-life and instability. These results exhibited the efficacy 
of the BCNU-loaded Nano-co-Plex. The results obtained are also in agreement 
with the release profile of BCNU-loaded Nano-co-Plex as previously discussed 
(Figure 3.10). Comparing the release profile of BCNU-NCP-1, BCNU-NCP-2 and 
BCNU-NCP-3 which achieved 30.2%, 52.9% and 78.8% release, respectively after 
72 hours, it was established that the in vitro release profile corresponded to the 
cytotoxicity levels of the drug-loaded NCP observed in the studies. 
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Figure 3.12: Cell viability of human glioblastoma A172 cell line treated with 
BCNU-NCP-1, BCNU-NCP-2, BCNU-NCP-3 and BCNU incubated at 37°C for 72 
hours. 
 
3.3.11.2. Cellular uptake and internalization of the BCNU-loaded Nano-co-
Plex 
The BCNU-loaded Nano-co-Plex consists of FITC of which its primary function is 
to label the nanoparticles in order to investigate the cellular uptake and 
internalization characteristics of the Nano-co-Plex. The results obtained after 
incubation of 0.5mg/mL of BCNU-loaded Nano-co-Plex for a period of 1 hour are 
displayed in Figure 3.13.  The results showed qualitative analysis using 
fluorescent images for the group that were incubated with and without application 
of magnets. The group that were incubated with the application of magnets 
showed more uptake as displayed by high fluorescent intensity compared to the 
group without application of magnets. BCNU-NCPs possess magnetic property 
and thus in the presence of external MF, the nanoparticles are attracted towards 
the magnet, this action increases the mobility of the nanoparticles towards the 
internalization of the particles into the cells. There is therefore indication that more 
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BCNU-NCPs internalized more in the presence of external magnet at a given time 
in comparison with those without magnets. These results were an indicative of 
more cellular uptake of the BCNU-NCP and magnetic targeting to the A170 cells.  
 
 
Figure 3.13: Fluorescent microscopy analysis of human glioblastoma A172 cell 
line treated with BCNU-NCP-1, BCNU-NCP-2 and BCNU-NCP-3 incubated at 
37°C for 2 hours without and with application of magnet. 
 
3.4. CONCLUDING REMARKS 
Magnetite nanoparticles were synthesized and successfully coated with Polyplex 
that was prepared as a nanocarrier for BCNU loading. Both the nanocarrier and 
the BCNU-loaded Nano-co-Plex possess fluorescent ability for cell labeling and 
were characterized and confirmed to possess high magnetization. The magnetic 
100 
 
studies also showed the superparamagnetic properties of the formulation which is 
an attribute of successful magnetic targeted delivery devices. The average size of 
the Nano-co-Plex was ~35nm as indicated by TEM and also confirmed by the 
zetasizer analysis. The TGA results confirmed the coating and the quantity of the 
polymer complex on the magnetite. FTIR and NMR confirmed the conjugation of 
PVA, PEI as well as FITC in the Nano-co-Plex; it also confirmed the adsorption of 
BCNU onto the Nano-co-Plex. The loading capacity of the synthesized Nano-co-
Plex was found to be efficient for BCNU. The release profiles indicated a 
sustainable release of BCNU and up to 75% of drug released after 72 hours. 
Magnetic targeting and internalization cell studies revealed enhanced uptake and 
internalization of BCNU-loaded Nano-co-Plex in HG cells in the presence of an 
external MF. Due to the size, high payload of drug, as well as high magnetization 
attribute of the formulation, it may be a suitable magnetic targeted intranasal drug 
delivery system for delivering BCNU to brain tumors. Magnetic drug targeting via 
the nasal route may therefore be a promising method of delivering drugs to the 
brain. 
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 CHAPTER 4 
DEVELOPMENT OF THE IN SITU THERMOSENSITIVE ELECTRO-
RESPONSIVE MUCOGEL FOR INCORPORATION OF THE BCNU-LOADED 
NANO-CO-PLEX  
 
4.1. INTRODUCTION 
The attribute of direct connection of nasal mucosa to the central nervous system 
(CNS) may assist delivery of therapeutic agents directly from the nasal mucosa to 
the CNS, thereby overcoming the problem of BBB, increasing the bioavailability of 
drugs to the CNS. Amongst the several intranasal dosage forms such as drops, 
sprays, gels and powders; a gel formulation has the most advantages, due to its 
ability to increase residence time of the formulation in the nasal mucosa 
(Chaturvedi et al., 2011). Gel formulations may also act as a protective 
embodiment for therapeutic agents against enzymatic degradation. To exploit the 
advantages of a gel and overcome its challenges in clinical use (Wu et al., 2007), 
a thermosensitive polymer such as Pluronic F127 (F127) was used in the 
formulation. F127 is a non-ionic, hydrophilic triblock copolymer of polyoxyethylene 
and polyoxyproylene (PEO-PPO-PEO). This copolymer exhibits thermo-reversible 
properties, remaining as a liquid at low temperature and forms a gel at 
physiological temperature. The copolymer molecules aggregate into spherical 
micelles containing a dehydrated hydrophobic PPO core and outer shell of 
hydrated swollen PEO chains. In aqueous medium, the micellar nature has been 
demonstrated to be suitable for incorporating drugs as well as for sustained 
release of bioactive agents (Akash et al., 2014).  
 
Inclusion of mucoadhesive polymers may result in effective intranasal gel 
formulations with prolonged residence time. Chitosan (CS) is a natural polymer 
that has been widely used in pharmaceutical industries and its mucoadhesive 
property has been well researched (Baltzley et al., 2014; Saladini et al., 2012; Patil 
and Sawant, 2011). Thus, CS can be employed in formulating an intranasal gel in 
conjunction with hydroxylpropyl methylcellulose (HPMC), which also possesses 
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significant mucoadhesion (Fahmy, 2012). Thus, innovative approaches for 
controlling the release of therapeutic agents from the gel in a controlled and 
predetermined quantity for a fixed period of time, by applying an external electrical 
stimulus to modulate drug-loaded release can be explored. This was achieved by 
including an electro-active polymer (EAP) into the formulation. Examples of such 
polymers are polyaniline (PANI) (Kumar et al., 2012; Soni et al., 2012; Tsai et al., 
2011), polypyrrole (PPy) (Shi et al., 2014; Stewart et al., 2014) and polythiophene 
(PT) (Imae et al., 2014). Among these EAPs, PANI has been given much attention 
due to its intrinsic electro conducting abilities and its application in numerous areas 
of technological advancement which include fields of artificial muscles (García-
Gallegos et al., 2016), rechargeable batteries (Li et al., 2012; Xiao et al., 2012), 
microwave technologies (Cheng et al., 2015; Wang et al., 2015), biosensors 
(Özcan and Aydin, 2016) and drug delivery systems (Shokry et al., 2015; Tsai et 
al., 2011). 
 
In this study, a novel biocompatible and biodegradable Thermosensitive Electro-
Responsive Mucogel (TERM) made from a combinatorial blending of CS, HPMC, 
PF127 and PANI, developed with the ability for a prolong residence time in the 
nasal mucosa. Carmustine (BCNU)-loaded Nano-co-Plex (BCNU-NCP) was then 
incorporated into the TERM to form the “Nanogel Composite”, a delivery system 
which is a liquid at room temperature but forms gel at physiological temperature 
for ease of administration via intranasal route and can be electro modulated for 
controlled release of drug upon application of an external electric field. This study 
further explores the prospect of electro-actuation of the gel in an “on-off” drug 
release kinetics by means of an electrical switching for the control of drug within 
the nasal mucosa for onward delivery to the brain. The formulation was optimized 
employing a design of experiment (DOE), with the aid of a box-behnken 
experimental design software. 
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4.2. MATERIALS AND METHODS 
4.2.1. Materials 
Pluronic F127 (Mw=12,600g/mol), medium Mw chitosan (CS) (Mw=400,000g/mol), 
polyaniline (PANI) (Mw=20,000g/mol), hydroxylpropyl methylcellulose (HPMC), 
acetic acid, polyvinyl alcohol (PVA) (30kDa, 87−90% hydrolyzed), branched 
polyethylenimine (PEI) 1.8 kDa, iron (II) chloride tetrahydrate (FeCl2·4H2O), iron 
(III) chloride hexahydrate (FeCl3·6H2O), hydrochloric acid (HCl), sulphuric acid 
(H2SO4), N-hydroxysuccinimide (NHS), 1-ethyl-3(3-dimethylaminopropyl) 
carbodiimide (EDC), fIuorescein isothiocyanate, epichlorohydrin, sodium hydrogen 
carbonate (NaHCO3), sodium hydroxide (NaOH), dialysis tubing 
(Mw=10,000g/mol) and carmustine (BCNU) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Double deionized water was obtained from a Milli-Q water 
purification system (Milli-Q, Millipore, Billerica, MA, U.S.). All other reagents used 
were of analytical grade and were employed as purchased. 
 
4.2.2. Preparation of the Thermosensitive Electro-Responsive Mucogel 
The TERM was prepared by solubilizing 20g of Pluronic F127 (F127) in 100mL of 
deionized water by stirring continuously for 1 hour. Partial solubility of the mixture 
was observed. The solution was then placed in an ice bath for another 1 hour after 
which the turbid solution was stored in a refrigerator at 4°C. A clear and 
transparent solution was observed after 24 hours of storage. CS (2g) was 
dissolved in 100mL of 1%v/v acetic acid. F127 and CS blend was prepared by 
slowly adding CS solution to the F127 solution and stored in an ice bath for 4 
hours. PANI (0.2%w/w) was then added to the mixture for a further 4 hours. HPMC 
(1%w/w) was lastly added to the final mixture. HCl (0.1mL, 0.1M) was then added 
to the mixture, resulting in a greenish-blue appearance.  The sample was then 
stored at -80ºC over night, thawed at room temperature and then kept at 4ºC for 
further application. 
 
4.2.3. Preparation of Carmustine-Loaded Nano-co-Plex 
The carmustine (BCNU)-loaded Nano-co-Plex (NCP) was prepared as described 
in Chapter 3, Sections 3.2.2, 3.2.3 and 3.2.11.  
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4.2.4. Incorporation of the Carmustine-Loaded Nano-co-Plex into the 
Thermosensitive Electro-Responsive Mucogel 
BCNU-loaded NCP (5mg) was added to 1mL of TERM and stirred for 1 hour for 
homogenization at 4ºC. The resultant blend, “Nanogel Composite” was then stored 
in a refrigerator at 4ºC for further application. 
 
4.2.5. Optimization Studies Employing a Box-Behnken Experimental     
Design for the Nanogel Composite  
A Box-Behnken Experimental Design was applied guided through a 3-factor, 3-
level quadratic design employing Minitab Statistical Software, V15 (Minitab Inc., 
State College, PA, U.S.). Three formulation independent variables were 
considered viz, the concentration of F127 (15-25%w/w), CS (0.1-0.6%
w/w) and PANI 
(0.1-0.8%w/w). The lower and upper limits of the independent variables obtained 
after the preliminary studies are presented in Table 4.1. HPMC (1%v/v) was 
constant in all the formulations. The design generated 15 formulations which are 
listed in Table 4.2. Response surface analysis was carried out on all the variables. 
Surface and contour plots were generated from the responses which were based 
on the Box-Behnken template to visualize the data in terms of the effect of the 
formulation variables on the response factors of the formulation. 
 
Table 4.1: Lower and upper limits of the variables employed for the Box- Behnken 
design. 
Polymers Lower limits (%w/w) Upper limits (%
w/w) 
F127 15 25 
CS 0.1 0.6 
PANI 0.1 0.8 
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Table 4.2: Series of formulations statistically generated by the Box–Behnken 
design. 
Formulation CS (% w/w)a F127 (% w/w)b PANI (%w/w)c 
1 0.1 20 0.8 
2 0.6 20 0.1 
3 0.6 15 0.45 
4 0.35 25 0.8 
5 0.35 20 0.45 
6 0.1 25 0.45 
7 0.35 25 0.1 
8 0.1 15 0.45 
9 0.1 20 0.1 
10 0.6 25 0.45 
11 0.35 20 0.45 
12 0.6 20 0.8 
13 0.35 15 0.1 
14 0.35 20 0.45 
15 0.35 15 0.8 
achitosan concentration, bpluronic F127 concentration, cpolyaniline concentration 
 
4.2.6. Determination of Structural Modification and Chemical Interaction of 
the Nanogel Composite 
The structural modification and chemical interaction between the polymers of the 
Nanogel Composite were carried out on the lyophilized gel formulation, as well as 
native polymers. FTIR Spectroscopy (PerkinElmer Spectrum 100, Beaconsfield, 
United Kingdom) over a range of 4000–550cm-1 was employed. The structural 
integrity was also elucidated by obtaining the XRD patterns of the Nanogel 
Composite and the native polymers employing a Rigaku 600 x-ray diffractometer 
(RIGAKU, Inc., Tokyo, Japan) equipped with Cu-Kα radiation (λ=1.54056 Å). The 
diffractograms were obtained using the parameters listed in Table 4.3. Integrated 
X-ray Diffraction software (PDXL 2.1, Rigaku, Tokyo, Japan) was used to analyze 
the results obtained. 
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Table 4.3: X-ray diffraction parameters 
Parameter Settings 
Soller (inc.) 2.5° 
Incident Height Slit (IHS) 10mm 
Divergence Slit (DS) 1.25° 
Solar Slit (SS) 13mm 
Soller (rec.) 2.5° 
Receiving Slit (RS) 13mm 
Filter None 
Monochromater None 
Voltage 40kV 
Current 15mA 
Step 0.1° 
Speed 2°/minute 
Scan axis Theta/2-Theta 
Scan range 0°-90° 
Scan mode Continuous 
 
 
4.2.7. Determination of the Mucoadhesive Behavior of the Nanogel 
Composite 
Mucoadhesion study was carried out on all the 15 Nanogel Composite 
formulations by employing 0.5%w/v solution of mucin in simulated nasal buffer 
solution. The Nanogel Composite (20mg/1.5mL) was dispersed in the buffer 
solution. The mixture was vigorously shaken and homogenized at 34°C for 2 
hours. The dispersions were then centrifuged at 5,000rpm for 10 minutes to pellet 
the Gel-Mucin Complex. The supernatant was collected and used for free mucin 
content analysis. The quantity of mucin adsorbed onto the gel was the difference 
between the total quantity of mucin added and the free mucin content in the 
supernatant. The concentration of free mucin in the solution, after 6 hours was 
determined by UV spectrophotometry at a wavelength of 201nm (IMPLEN 
Nanophotometer™, Implen GmbH, München Germany). A calibration curve was 
prepared by using a series of known concentrations (0.1–1.0 mg/mL) of mucin in 
PBS (pH 6.0) as the standard. 
 
4.2.8. Determination of Gelation Temperature of the Nanogel Composite 
Gelation temperature was measured using two methods. The first method was by 
visual inspection as described elsewhere by Majithiya and co-workers (2006). 
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Briefly, 1mL samples of each formulation was measured and placed in transparent 
5mL vials with a magnetic bar. These vials were then placed in a water bath that 
was heated from temperature of 20°C. The temperature of the water bath was 
increased at the rate of 1°C/minute while under magnetic stirring. The temperature 
was recorded when the magnetic bar stopped moving due to an increase in 
viscosity signifying the gelation temperature. The test-tube inverted approach 
(Chung et al., 2005) was also used as part of the visual method to support the 
magnetic bar method. The gelation temperature was measured at a point at which 
the formulation no longer flowed when the vial was tilted at any angle. Each 
formulation was tested 3 times. The second method was evaluation by rheological 
analysis. This was undertaken by carrying out temperature ramp experiments, 
employing a thermostatically controlled (UTC-MARS II), Modular Advanced 
Rheometer System (ThermoHaake MARS Thermo Fischer Scientific, Karlsuhe, 
Germany) fitted with a cone and plate geometry with a diameter of 3.5 cm and 
cone angle of 1° (sensor C35/1°) Ti at a temperature range of 20–40°C. 
 
4.2.9. Determination of the Electrical Conductivity of the 15 Nanogel 
Composite Formulations 
Electrical conductivity was assessed on the Nanogel Composite formulations 
employing a TDSTestTM Kit Model WD-35661-70 (Oakton instruments, Vernon 
Hills, IL, USA). The Nanogel Composite (5mL) was placed in a 50mL buffer 
solution (pH 6) and electrodes were applied onto the gel surface. The conductivity 
of the gel was recorded for all 15 formulations. This was performed in triplicate. 
 
4.2.10. In vitro Determination of the Release Profiles of the 15 Nanogel 
Composite Formulations upon Application of an Electrical Stimulation  
BCNU-NCP release was evaluated by the dialysis method (Zaki et al., 2007). The 
dialysis tubing cellulose membrane (Mw=12,000-14,000g/mol, Sigma-Aldrich, 
Steinhelm, Germany) was first immersed in a warm deionized water so as to 
remove the glycerol and sulphide from the tubing. Each formulation containing 
(5mg/mL) BCNU concentration was placed in the dialysis tubing while the two 
ends of the tubing were sealed, this was then immersed in a dissolution vessel 
containing 50mL of PBS (pH 6) dissolution medium, the temperature was kept at 
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34±1°C, with speed of rotation maintained at 50rpm. Electrical stimulation was 
carried out by applying a Potential Difference (PD) of 5V using a 
potentiostat/galvanostat (PGSTAT302N, Autolab, Utrecht, Netherlands). This was 
performed by placing a platinum electrode as the cathode and a gold electrode as 
the anode on the dialysis tube containing the Nanogel Composite in the buffer 
medium. Aliquots of 2mL were withdrawn from the release medium at time 
intervals of 1 hour. In order to maintain sink conditions, fresh PBS of 2mL was 
replaced into the released medium. Sampling was undertaken prior and after each 
application of electrical stimulation. The amount of BCNU-loaded Nano-co-Plex 
released is quantified by determining the amount of iron content in the withdrawn 
solution. Figure 4.1 illustrates the electro-simulation setup. 
 
 
Figure 4.1: A schematic diagram depicting the electro-stimulation in vitro release 
experimental setup. 
 
4.2.10.1. Quantitative analysis of the BCNU-loaded Nano-co-Plex released 
from the   Nanogel Composite 
This experiment was performed to determine the quantity of BCNU-loaded NCP 
that was released when 5V of PD was applied on the Nanogel Composite. The 
release of BCNU-loaded NCP from the Nanogel Composite was then determined 
by calculating the amount of iron contents in the released medium. This is due to 
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iron being the core of the BCNU-loaded NCP. Iron content was determined by 
using Wang and Edgar‟s method (Wang and Acosta, 2013). Briefly, a sample of 
0.5mL was taken from the aliquot withdrawn prior and after the application of 
electric stimulation. This sample was then added to 7.5mL of 6N HCl in a 50mL 
beaker for 24 hours. This procedure was to solubilize all the iron species in the 
solution. The iron present in the solution was in the form of Fe3+ (Ferric chloride) 
with a yellowish-red color due to oxidation in the presence of HCl and the exposed 
air. A UV spectroscopy (IMPLEN Nanophotometer™, Implen GmbH, München, 
Germany) was used to measure the absorbance at 450nm. A calibration curve 
was generated from standard samples by dissolving 0.1mg-1mg of iron oxide 
nanoparticles in 7.5mL of 6N HCl and 0.5mL of deionized water for 24 hours. The 
quantity of iron was determined from the calibration curve. 
 
4.2.11. Ex Vivo Evaluation of Mucoadhesive Strength of the Nanogel 
Composite 
A texture analyzer (TA) (TA.XT plus, Stable Microsystems, Surrey, UK) was 
employed to determine the mucoadhesive strength of the Nanogel Composite. 
This was performed by measuring the force required to detach nasal mucosa 
membrane from each of the formulation. Freshly excised rabbit nasal membrane 
was attached to the upper probe of the instrument. The Nanogel Composite (1mL) 
was placed below the platform inside a temperature controlled compartment 
(34±1°C). The upper probe fixed with the rabbit nasal tissue was then lowered in 
order to establish contact with the surface of the Nanogel Composite. The 
exposed nasal mucosal membrane surface area was 0.785cm2. Measurement 
settings were displayed in Table 4.4. These measurements were repeated 5 times 
for each of the formulation, (N=5). Mucoadhesive strength was calculated from the 
generated force-distance curve as the peak detachment force (Fdet) measured in 
Newton (N) and work of adhesion (Ɯadh) in Joules (J). The peak detachment force 
was taken as the maximum force needed for detaching the matrix formulation from 
the tissue while the work of adhesion was calculated as the area under the Force-
Distance curve (Adeleke et al., 2015). 
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Table 4.4: The parameter settings for the mucoadhesion analysis of the Nanogel 
Composite. 
Parameters Settings 
Pre-Test Speed 1mm/sec 
Test Speed 0.5mm/sec 
Post-Test Speed 1mm/sec 
Trigger Type Force 
Trigger Force 0.05N 
Applied Force 0.5N 
contact force 0.001N 
Contact Time 2min 
Return Distance  10mm 
 
 
4.2.12. Evaluation of the Thermal Behavior of the Optimized Nanogel 
Composite 
Differential scanning calorimetry (DSC 1 STARe system, Mettler Toledo, 
Schwerzenbach, Switzerland) was employed to analyze the thermal behavior of 
the Nanogel Composite and the native polymers. The native polymers and the 
Nanogel Composite were subjected to a heating gradient, ranging from 0-300°C at 
a rate of 5°C per minute under innert conditions. Thermal gravimetric analysis 
(TGA) (PerkinElmer, TGA 4000, Llantrisant, Wales, UK), was also employed to 
further elucidate the thermal stability of the Nanogel Composite. The TGA was 
configured at a starting temperature of 30°C and end temperature of 900°C under 
continuous flow of nitrogen. Samples were heated at a rate of 10°C/min. 
Thermograms were generated as percentage weight vs. temperature. All results 
were analyzed using Pyris™ software (PerkinElmer, Llantrisant, Wales, UK). 
 
 
4.2.13. Determination of Surface Morphology and Porosity of the Optimized 
Nanogel Composite 
4.2.13.1. Scanning Electron Microscopy 
The TERM and the optimized Nanogel Composite were lyophilized in order to 
assess the morphological characteristics of the formulation. Samples were sputter-
coated using gold compound (EPI sputter coater) (SPI ModuleTM sputter-coater 
and control unit, West Chester, PA, USA), which was mounted on an aluminum 
spud. After coating the samples for 120s, under helium gas conditions, the 
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samples were analyzed using a FEI ESEM Quanta 400F (FEITM, Hillsboro, OR, 
USA) electron microscope, employing an electron acceleration charge of 20kV, to 
produce high resolution images of the particles. 
 
4.2.13.2. Determination of the porosity profile of the Nanogel Composite 
Porositometric analysis was carried out on the lyophilized optimized Nanogel 
Composite in order to evaluate pore size and the surface area of the optimized 
formulation employing a porositometric analyzer (Micrometrics ASAP 2020, 
Norcross, GA, USA). A sample of Nanogel composite (100mg) was placed in the 
sample tube and a glass filler rod was inserted into the sample tube to reduce the 
total free space volume in the tube, thereby speeding up the degassing process. 
The nanogel then went through the degassing stage to eliminate residual moisture 
and contaminants in the sample. The second stage involved the transfer of the 
tube to the analysis port for pore size, volume and surface area measurement in 
accordance with the BET and BJH models. The measurements were carried out 
with the parameters shown in Table 4.5. 
 
Table 4.5: Porositometry parameters employed in the measurement of 
TERM/Nanogel Composite 
Parameters Target/Rate 
Evacuation rate (mm Hg/s) 50 
Temperature ramp rate (°C/min) 10 
Target temperature (°C) 40 
Hold temperature (°C) 30 
Hold time (min) 900 
Hold pressure for evacuation and heating phase (mm 
Hg/s) 
100 
 
 
Monolayer capacity of the gel was determined by using the BET linear equation 
(Equation 4.1) (Calvo et al., 1995). 
 
 
  (
  
 )    
 
 
   
 
   
  
(
 
  
) 
Equation 4.1 
Where W is the quantity of nitrogen gas absorbed at the relative pressure of P/Po 
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Wm was the monolayer capacity and C is the constant which is related to the 
difference between the molar free energy of absorption of the first layer and the 
liquefaction layer. 
Using the molecular cross-sectional value, Am, the surface area was determined 
from the monolayer capacity applying Equation 4.2 and 4.3 (Ramburrun et al., 
2015). 
 
                                                  Equation 4.2 
 
        
       
 
 
               Equation 4.3 
where As(BET) and as(BET) are the total and specific surface areas, respectively 
of the absorbent of mass, m, and L is the Avogadro constant. 
 
4.2.14.  Rheological Analysis of the Optimized Nanogel Composite 
Rheological studies of the optimized Nanogel Composite were carried out to 
measure and assess various rheological parameters of the Nanogel Composite in 
comparison to the native polymer F127. This was achieved by employing a 
thermostatically controlled (UTC-MARS II), Modular Advanced Rheometer system 
(ThermoHaake MARS Rheometer, Thermo Fischer Scientific, Karlsuhe, Germany) 
fitted with a cone and plate geometry with a diameter of 3.5cm and cone angle of 
1° (sensor C35/1°) Ti. The parameter settings used for the rheological analysis are 
provided in Table 4.6. During the temperature ramp experiment, the cone and the 
plate were covered with a solvent trap to prevent the samples from drying up 
which might be due to solvent evaporation. The frequency employed was the 
frequency at which the yield value was obtained. 
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Table 4.6: The parameter settings for the rheological analysis of Nanogel 
Composite and F127. 
Tests  Parameters 
 Shear 
Rate (s-1) 
Shear 
Stress (Pa) 
Time (s) Frequency 
(Hz) 
Temperature 
(°C) 
Shear 
Viscosity 
 
0.00-200  180  34 
Yield Stress 
 
 0.200-200 200  34 
Oscillatory  
Stress Sweep 
 
 0.200-200  0.1, 1, 10 34 
Oscillatory 
Frequency 
Sweep 
 
   50.0-0.05 34 
Creep and 
Recovery 
Test 
 
  60-180  34 
Temperature 
Ramp 
   1 20-40 
 
 
 
4.2.15. Evaluation of the Electro-activity of the Optimized Nanogel 
Composite 
Electro-activity of the Nanogel Composite was determined by carrying out cyclic 
voltammetry on the Nanogel Composite. This was achieved by the adapted 
method of Tsai and coworkers (Tsai et al., 2011). Briefly, the Nanogel Composite 
was first homogenized in PBS (pH 6.0) which was the conducting solvent for 5 
minutes, followed by 3 minutes ultrasonication (Vibra-CellTM, Sonics® Sonics & 
Material Inc., Newtown, CT, U.S.). Nitrogen gas was passed through the solution 
obtained for purging. Galavanometer (PGSTAT302N, Autolab, Utrecht, 
Netherlands), a three-electrode system with a saturate Ag/AgCl (3.0 M KCl) as the 
reference electrode, a platinum wire as the auxiliary electrode, and a 5mm glassy 
carbon electrode as the working electrode were employed for the analysis. A scan 
rate of 0.1Vs-1 was applied. 
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4.2.16. In Vitro Drug Release Analysis from the Optimized Nanogel 
Composite on the Application of an Electrical Stimulation  
In vitro drug release analysis from the optimized Nanogel Composite was 
performed as detailed in Section 4.2.10.  The quantity of BCNU in the aliquot of 
the BCNU-NCP was carried by extracting the BCNU using dichloromethane 
(DCM) as reported by Levin and coworkers (1978). This was then analyzed 
employing the Ultra Performance Liquid Chromatography (UPLC). 
 
4.2.16.1. Quantitative determination of the BCNU-loaded Nano-co-Plex 
released from the optimized Nanogel Composite 
The BCNU-loaded Nano-co-Plex released from the optimized Nanogel Composite 
was determined by calculating the amount of iron content in the released solution 
as described in Section 4.2.10.1. 
  
4.3. RESULTS AND DISCUSSION 
4.3.1. Preparation of the Thermosensitive Electro-Responsive Mucogel and 
the Nanogel Composite  
In order to prepare a suitable nasal formulation that will have the advantage of 
ease of administration, the formulation should possess the ability of being a sol at 
room temperature and transitions to a gel at nasal mucosa temperature (sol-gel-
sol phase transition). The Nanogel Composite was prepared by blending together 
F127 and CS, HPMC and PANI.  F127 represented the thermosensitive portion of 
the formulation, the CS and the HPMC represented the mucoadhesion portion of 
the formulation while PANI was the electroactive moiety of the formulation. Results 
of the preliminary studies showed that a lower limit of 15, 0.1 and 0.1%w/w for 
F127, CS and PANI respectively and upper limits of 25, 0.6, and 0.8%w/w for F127, 
CS and PANI respectively were limits outside of which no meaningful formulation 
can be achieved. Addition of 1%w/w HPMC was constant throughout the 
preliminary tests. HPMC was employed to increase viscosity, adjust the gelation 
temperature and most importantly prevent leakage of incorporated therapeutic 
agent.  
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It was observed that the gelation temperature increased with the addition of CS 
and decreased when HPMC was added. The reason for the increase in gelation 
temperature with the addition of CS may be due to the acetic acid used in 
solubilizing the CS, which tends to weaken the H-bonds between the tightly 
packed configurations of the F127 gel thus disorientating the well-packed micelle 
arrangement (Zaki et al., 2007). The decrease in gelation temperature on addition 
of HPMC may be due to an increase of the viscosity of the solution provided by the 
addition of the HPMC. It was observed that the gelation temperature of all the 
resulting formulations during the preliminary tests were between 20°C and 35°C, 
since the temperature of nasal mucosa is between 32°C and 35°C (Basu and 
Bandyopadhyay, 2010), any gelling temperature between 26°C to 34°C will be 
suitable.  
 
4.3.2. Evaluation of Box–Behnken experimental design optimization 
The lower and upper limits were applied using the Box–Behnken experimental 
design to generate the 15 formulations. These formulation variables were 
evaluated for their responses to mucoadhesion, conductivity and drug release 
upon application of electric stimulation. The responses from the 15 formulations 
are shown in Table 4.7. The application of this design was based on developing an 
optimized Nanogel Composite that has the ability to release desired amount of 
drug upon application of a specific voltage to the formulation in an „„on–off‟‟ 
pulsatile drug release pattern with the aim of acquiring quality statistically scientific 
significance. 
 
Response surface analysis results generated by the Minitab Statistical Software 
revealed the correlation of the data with the response elements of the formulation.  
The residual and surface plots were generated from the response data. Residual 
plots were used to evaluate the differences in the fitted and the observed 
responses, and how best the outcome fits the regression. From Figure 4.2, it can 
be observed that the residual plot indicated a near perfect regression. The surface 
plots explicate the relationship existing between one response and two factors 
while keeping the third factor constant. Figure 4.3 shows the surface plots of the 3 
responses. The average release per cycle versus concentration of PANI and CS 
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showed the corresponding values of PANI and CS concentration for the maximum 
release per cycle achieved. Further, the maximum value of conductivity and 
mucoadhesion responses were displayed in the plots with the corresponding 
values of the variables. The optimal formulation for the three responses was 
derived by employing desirability function. The formulation was optimized for 
maximum mucoadhesion and 10% average drug release per cycle. Figure 4.4 
shows the result of the optimization by the desirability function, in relation to the 
quantity of the independent variables required to obtain the optimized formulation. 
The optimized formulation was achieved by using 0.36, 16.8 and 0.40%w/w of CS, 
F127 and PANI respectively while keeping the concentration of HPMC at 1%w/w. 
 
Table 4.7: Formulations and their corresponding responses 
Variables Responses 
Formulation 
Number 
CS (%) F127 (%) PANI (%) Conductivity 
(mS/cm) 
SD≤0.1012 
Mucin 
adsorbed 
(mg) 
SD≤0.03 
Average 
release per 
cycle (%), 
SD≤3.50 
1 0.1 20 0.8 1.7921 0.05 13.67 
2 0.6 20 0.1 0.0611 0.39 4.55 
3 0.6 15 0.45 1.2386 0.31 10.03 
4 0.35 25 0.8 1.1097 0.11 12.43 
5 0.35 20 0.45 1.8699 0.18 8.11 
6 0.1 25 0.45 0.4581 0.06 6.05 
7 0.35 25 0.1 0.0314 0.2 4.78 
8 0.1 15 0.45 2.4997 0.08 9.18 
9 0.1 20 0.1 0.1533 0.09 4.56 
10 0.6 25 0.45 0.8806 0.29 5.21 
11 0.35 20 0.45 1.8698 0.18 8.04 
12 0.6 20 0.8 1.2156 0.24 11.24 
13 0.35 15 0.1 0.276 0.21 4.76 
14 0.35 20 0.45 1.8679 0.18 8.09 
15 0.35 15 0.8 2.1283 0.12 15.82 
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Figure 4.2: Residual plots of (a) average release per cycle, (b) conductivity and 
(c) mucoadhesion. 
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Figure 4.3: Response surface plots showing the effects of F127, CS and PANI 
on (a) electro-responsive drug release, (b) conductivity and (c) mucoadhesion. 
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Figure 4.4: Response Optimization output plot by desirability function with the 
values of independent variables and predicted values of the responses of Nanogel 
Composite. 
 
4.3.3. Assessment of the Mucoadhesive Behavior of the Nanogel Composite 
The results of the mucoadhesive behavior of the Nanogel Composite are 
displayed in Figure 4.5. The nasal formulation is considered to be effective if it can 
have a long resident time in the nasal cavity. The nasal mucosa has a clearing 
mechanism that does not permit therapeutic compounds to reside for long in the 
mucosa; they are easily cleared away by the mucociliary clearance which is a 
natural defensive mechanism. It is therefore pertinent to formulate therapeutic 
agent that can adhere considerably tight to the mucosal wall to keep the 
administered formulation in the mucosa. From the experiment, the amount of 
mucin adsorbed by each formulation is indicative of the mucoadhesive capacity of 
the formulation. The results showed the amount of mucin adsorbed by the gel in 
each of the formulation. The amount of mucin adsorbed is therefore directly 
proportional to the degree of mucoadhesion of the formulation. The results 
obtained indicated that formulation 2 has the highest percentage amount of 
adsorbed mucin value (0.39mg), signifying the degree of mucoadhesion being the 
highest in this formulation compared to the other formulations in the design. This 
formulation, however, is observed to contain the highest concentration of CS and a 
low concentration of PANI. Furthermore, formulation 1 has the lowest adsorbed 
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amount of mucin (0.05mg) which also indicated lowest degree of mucoadhesion. 
This formulation contained low concentration of CS and high concentration of 
PANI in comparison to the other formulations. This outcome showed clearly that 
CS exhibits the mucoadhesion property and it is the moiety that is responsible for 
the mucoadhesive nature of the gel, while PANI did not contribute to the 
mucoadhesion. Furthermore, the results indicated that the greater the 
concentration of PANI in the formulation, the less the degree of mucoadhesion. It 
can be deduced from the results that, the higher the concentration of CS, the 
higher the degree of mucoadhesion. The results obtained also demonstrated that 
CS, which is a cationic polymer, has the ability to bind through electrostatic 
interaction with the mucus and the charged mucosal surface (Kondiah et al., 
2013). CS is solely responsible for the ionic interaction forming strong electrostatic 
bonds with the mucus of the nasal cavity thereby prolonging the residence time of 
the formulation in the nasal cavity. 
 
 
Figure 4.5: Percentage of mucin adsorbed by the 15 formulations. 
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4.3.4. Assessment of the Gelation Temperature 
The gelation temperatures of all the 15 formulations are shown in Table 4.8. The 
mechanism of gelation can be explained by the change in the number of micelles 
formed with change in temperature. As the temperature increases, so does the 
number of formed micelles thereby leading to a tightly packed micelle formations 
and entanglements, the solution thus becomes immobile which results in gel 
formation (Majithiya et al., 2006). Furthermore, gelation may be brought about by 
the conformational alterations in the orientation of the CH3- groups in the PPO side 
chains, which is the micellar core, coupled with dehydration of the micelles 
(Cabana et al., 1997). Furthermore, from Table 4.8, the gelation temperature was 
observed to increase as the quantity of CS in the formulation increases, this is due 
to the hydrophilic properties of CS which interfered with the hydrophobic 
interaction of F127 (Chung et al., 2005). Formulation 3 has the highest gelation 
temperature which stands at 32°C while formulation 6 has the lowest gelation 
temperature of 21.5°C.  The gelation temperature values obtained from the 
rheological experiment are very close to those observed with visual inspection 
methods as shown in Table 4.8.  
 
Table 4.8: Gelation temperature of the 15 formulations 
 Gelation temperature (ºC) 
Formulation number Rheological 
determination (N=3) 
Visual inspection (N=3) 
1 22.5±0.11 24±0.82 
2 28±0.05 30.3±0.47 
3 32±0.08 31.7±0.94 
4 25±0.1 26.3±0.47 
5 27.5±0.05 29.3±0.47 
6 21.5±0.1 22±0.82 
7 22±0.06 23±1.41 
8 23.5±0.12 24.3±0.94 
9 20±0.1 21.7±0.94 
10 24±0.05 24±0.82 
11 27±0.1 28.7±0.94 
12 29.5±0.06 31.3±1.25 
13 23±0.1 24.3±0.47 
14 27.5±0.12 28±0.82 
15 26±0.5 28.3±1.25 
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4.3.5. Electro-Responsiveness of the Nanogel Composite via Electric 
Conductivity Assessment  
The electrical conductivity of the 15 Nanogel Composite formulations was 
investigated in order to evaluate their electro-responsive behavior when electric 
current is passed through them. Figure 4.6 shows the results of the conductivity 
test; the formulation with the most electrical conductivity is formulation 12 with a 
value of 27.8±1.8mS/cm. This formulation contained the highest concentration of 
PANI. Formulation 9 was found to have the lowest conductivity value; this 
formulation contained the lowest concentration of PANI of all the formulations. 
These results signify that PANI is responsible for the conductivity of the Nanogel 
Composite. The emeraldine base of PANI is highly conductive when doped with 
HCl, thus enhancing the conductivity of the formulation. The conductivity property 
of the Nanogel Composite is directly proportional to the ability to respond to 
electrical stimulation. It is therefore pertinent to infer that the higher the 
concentration of PANI in the Nanogel Composite, the higher the conductivity and 
subsequently the higher the response when electric stimulation is applied to it. The 
electrical stimulation is the key to the release of drug from the Nanogel Composite. 
Therefore, in order to modulate the release of drug incorporated in the Nanogel 
Composite, the electrical properties of the Nanogel Composite must be given 
adequate attention. 
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Figure 4.6: Electrical conductivity of the 15 formulations of the Nanogel 
Composite 
 
4.3.6. In Vitro Assessment of Release Behavior of the 15 Nanogel Composite 
Formulations on Application of Electrical Stimulation 
The purpose of developing an electro-responsive system is to ensure that it 
releases therapeutic agent that is incorporated into it on application of electrical 
stimulation. The in vitro drug release carried out was to assess the electro-
actuated release of BCNU-NCP from the Nanogel Composite upon application of 
electric stimulation.  The preliminary studies revealed that a potential of 5V is 
adequate to invoke release of BCNU-NCP from the Nanogel Composite. The 
release studies were carried out using 5V potential difference for all the 
formulations. All the formulations released BCNU-NCP upon application of 
electrical stimulation. Figure 4.7 shows the release profile of BCNU-NCP for all the 
15 formulations. Formulations 15, 1, 4 and 12 demonstrated average release 
percentage of 15.82%, 13.67%, 11.89% and 11.24% respectively. These 
formulations contained the highest concentration of PANI relative to the 
concentration of the other native polymers in each of the formulation. This 
confirms that PANI is the moiety that is responsible for the release of BCNU-NCP 
from the Nanogel Composite, with the release being proportional to the 
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concentration of PANI in the formulations. The mechanism of release may be 
explained by the electrical conducting characteristics of PANI. During the 
application of electrical stimulation, hydrolysis of water occured which tend to 
protonate the NH group of the PANI. The PANI molecules are thereby excited 
within the nanogel matrix and thus transport the PANI molecules towards the 
cathode. This action may therefore lead to disruption of the H-bonding holding the 
matrix together as a result of this; the micellar structure of the nanogel begins to 
dismantle and the nanogel begins to erode, subsequently resulting in the release 
of the BCNU-loaded NCP in the matrix system of the gel. It may therefore be 
inferred that the release of BCNU-loaded NCP was due to the matrix erosion when 
electrical stimulation was applied. It is envisaged that disintegration of the Nanogel 
Composite occurred by surface erosion during the migration of the PANI moiety 
towards the cathode. The release was found to follow zero-order kinetics. 
Furthermore, the release profile demonstrated a pulsatile “on-off” switchable 
release upon electro-actuation as seen in Figure 4.7.  
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Figure 4.7: BCNU-NCP release profiles in simulated nasal fluid (pH 6.0) for 
Formulations 1-15. 
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4.3.7. Ex vivo Mucoadhesion Analysis 
The mucoadhesive strengths of the 15 formulations were measured by ex vivo 
analysis. The average maximum detachment force in Newton and work of 
adhesion in mJ were determined from the peak and Area under the curve (AUC), 
respectively, of the Force-Distance profiles as presented in Figure 4.8 and Figure 
4.9. Formulation 2 demonstrated the highest value of 0.622±0.013N while 
formulation 1 displayed the lowest value of 0.076±0.007N. Likewise, the work of 
adhesion for formulation 2 was the highest with value of 0.2855±0.00997mJ, while 
formulation 1 demonstrated the lowest with value of 0.02488±0.00521mJ as 
illustrated in Figure 4.9. The major factor which is responsible for these 
observations can be attributed to the concentration of CS present in the 
formulation. Formulations with high concentration of CS are more mucoadhesive 
than those containing low CS concentration. The NH3
+ group of CS of the 
formulation has the ability to crosslink with the carboxylic group of mucin in the 
mucus of the nasal mucosa to form a polymer network and thereby strengthening 
the bonds holding them together. These results are in agreement with the 
chemical analysis performed using the reaction of mucin with the formulation as 
explained in Section 4.3.3. 
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Figure 4.8: Tensile detachment measurement displaying Maximum force of 
adhesion of the Nanogel Composite formulations from rabbit nasal mucosal 
tissue wetted with simulated nasal buffer at pH 6.0 (SD≤ 0.015; N=5). 
 
 
Figure 4.9: The total work of adhesion for removing Nanogel 
Composite from rabbit nasal mucosal tissue wetted with simulated 
nasal buffer at pH 6.0 (SD≤ 0.00997; N=5). 
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4.3.8. Assessment of the Structural Modification of the Optimized Nanogel 
Composite 
4.3.8.1. Assessment of the structural modification employing Fourier 
Transmission Infrared spectroscopy 
The structural integrity of TERM and Nanogel Composite were assessed 
employing FTIR. Figure 4.10 depicts the FTIR spectra of the native polymers that 
were employed in formulating the Nanogel Composite. The native polymers 
displayed their unique characteristics absorption peaks at various bands; these 
are summarized in Table 4.9. 
 
 
 
Figure 4.10: FTIR spectra of a) HPMC, b) PANI, c) CS and d) F127. 
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Table 4.9: FTIR spectra of HPMC, PANI, CS and F127 showing their major 
characteristic native bands. 
Samples  IR bands 
(cm-1) 
Description References 
HPMC  3442 O-H stretching vibrations (Sahoo et al., 
2012) 
  2900 C-H stretching vibrations  
  1635 Cyclic rings stretching 
vibrations 
 
  1453 Asymmetric bending 
vibrations of methoxy 
group 
 
  1373 Cyclic anhydride  
  1050 C-O-C stretching 
vibrations 
 
 
PANI  1589 N=Q=N ring stretching 
vibrations 
(Trchová et al., 
1999) 
  1379 N-B-N ring stretching 
vibrations 
 
  1297 C-N stretching vibrations  
  1153,1103, 
825 
 
C-H bending vibrations   
CS  3400–3500 amino group (Sionkowska 
et al., 2004) 
  3288 O-H stretching vibrations  
  2890 CH3 stretching vibrations  
  1651 C=O stretching 
vibrations 
 
  1587 NH bending vibrations  
  1373 NH- bending vibrations 
 
 
F127  2877 Aliphatic C-H stretching 
vibrations 
(Karolewicz et 
al., 2014) 
  1466 Aliphatic C-H bending 
vibrations 
 
  1341 O-H bending vibration  
  1097 C-O stretching vibrations  
 
Q and B represent abbreviations for quinoid and benzenoid moieties in PANI 
polymers respectively. 
 
Figure 4.11 displays the FTIR spectra of F127, the TERM, and Nanogel 
Composite. F127 exhibits 2 distinct strong bands at 2877cm-1 which corresponds 
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to aliphatic C-H stretching, and strong peak at 1097cm-1 which corresponds to the 
C-O stretching vibrations as depicted in Figure 4.11a. These two distinct strong 
bands are also present in TERM and Nanogel Composite. Figure 4.11b shows the 
spectrum of TERM, in addition to the peaks observed in F127, there are other 
additional peaks at 3323cm-1, 3182cm-1, 3959cm-1, and 2626 cm-1. These peaks 
represent the absorption band of other excipients that were present in the 
formulation. This confirms the difference in physicochemical features of TERM in 
comparison to that of the F127 and Nanogel Composite. The spectrum of Nanogel 
Composite is very similar to that of TERM; however, it is worth noting that there is 
a distinct difference in the intensity of C-H band observed at 2880cm-1 amongst 
the three spectra. The highest intensity of the peak was observed for F127 
followed by TERM and then the Nanogel Composite as highlighted in Figure 4.11. 
This phenomenon can be explained in terms of the H-bond interaction of F127 
with CS, PANI and HPMC in the blend; the C-H bond is synonymous to the 
polyoxypropylene block of F127, the more functional groups capable of forming H-
bonding with it the less the intensity of the peak generated. In this case CS and 
HPMC, they can form H-bonding including van der Waals bonds with F127. 
Furthermore, the broad band observed at 3323cm-1 is evidence of H-bonding that 
is formed due to the interaction of the F127 with the other excipients in the 
formulation. Infrared spectroscopy is known to be a highly effective method for 
investigating H-bonding interactions in polymer blend systems (Chu et al., 2013). It 
is pertinent to therefore note that there is no chemical conjugation or covalent 
bonding within the components that made up the Nanogel Composite. The stability 
of the gel is solely dependent on the interactions of the functional groups of the 
polymers to form non-ionic bod such as H-bonding, electrostatic interaction and 
van der Waals forces. 
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Figure 4.11: FTIR spectra of a) F127, b) TERM and c) Nanogel Composite 
 
4.3.8.2. Assessment of structural integrity by XRD spectroscopy 
To further validate the structural integrity of Nanogel Composite, XRD analysis 
was performed to investigate the crystallinity of the formulation. Figure 4.12 shows 
the XRD of the Nanogel Composite, CS, PANI and HPMC. F127 spectrum 
displayed a high degree of crystallinity as evidenced by the intensity of the peaks 
at 2θ=19.5° and 23.6°. The intensity of these peaks is, however, being reduced 
drastically in the spectrum of the Nanogel Composite with shifts in the 2θ position 
to 17.9° and 22.1°. This shift in 2θ position can be explained by the polymer-
polymer interactions of the excipients due to the polymer blending. The CS, PANI 
and HPMC exhibit semi-crystalline features as evidenced by their broad peaks at 
9.8° and 19.17° for CS, 20.2° for PANI and 18.7° for HPMC. Their semi-
crystallinity may be responsible for the low intensity and shift in the 2θ value 
observed in the spectrum of the Nanogel Composite.   
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Figure 4.12: XRD spectra of the Nanogel Composite (black), F127 (red), CS 
(green), PANI (blue) and HPMC (purple). 
 
4.3.9. Evaluation of the Thermal Stability of the Optimized Nanogel 
Composite 
Thermogravimetric analysis (TGA) was performed in order to investigate the 
thermal stability of the formulation and to compare the thermogram obtained with 
that of the native polymers that constitute the Nanogel Composite. Figure 4.13 
shows the thermograms of the Nanogel Composite, F127, CS, HPMC and PANI. It 
can be seen that the Nanogel Composite begins to decompose at temperature of 
220°C, F127 at 240°C, CS at 280°C, HPMC at 320°C while PANI demonstrated 
significant decomposition at 380°C. The decomposition curve of the Nanogel 
Composite demonstrated gradual decomposition up to 40%, following complete 
decomposion at 390°C; whereas, F127 was seen to decompose from 240°C to 
360°C. The variation in decomposition of Nanogel Composite and the native 
polymers, signifies the unique thermal property of the Nanogel Composite. To 
further explicate the thermal behavior of Nanogel Composite, DSC evaluation was 
carried out; Figure 4.14 shows the DSC thermogram of Nanogel Composite, F127, 
CS, PANI and HPMC. The melting point of the Nanogel Composite reflected at 
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60°C. F127 exhibits a melting point at 56°C, highlighting the slightly enhanced 
thermal stability of the Nanogel Composite compared to its native polymer. This 
observation correlates with the result obtained from the TGA analysis. The 
endothermic curve of F127 is sharper and steeper than that of the Nanogel 
Composite; this may be attributed to the retardation of heat flow due to the 
presence of the other polymers in the composite. 
 
 
Figure 4.13: TGA thermograms of a) Nanogel Composite, b) F127, c) CS, d) 
HPMC and f) PANI. 
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Figure 4.14: DSC thermogram of Nanogel Composite (black), F127 (red), CS 
(green), PANI (blue) and HPMC (purple). 
 
4.3.10. Assessment of the Surface Morphology and Porosity of the Nanogel 
Composite 
The samples of TERM, Nanogel Composite before and after application of 
electrical stimulus were lyophilized and the lyophilized samples were viewed under 
SEM and compared with the native polymers that constitute the Nanogel 
Composite in order to evaluate their surface morphology. Figure 4.15 illustrates 
the SEM images obtained from the native polymers. Figure 4.15a, b, c and d 
depict the surface morphology of F127, CS, HPMC and PANI respectively. Figure 
4.16a depicts the surface morphology of the TERM while Figure 4.16b shows the 
cross sectional view of TERM. There are pores in the morphological structure of 
TERM as it is also made clear by the cross sectional view. The formation of these 
pores allows the incorporated nanoparticles to be embedded into the gel matrix. 
Figure 4.16c shows the surface morphology of the Nanogel Composite before 
application of electrical stimulation, the image shows little or no visible pores as it 
was envisaged that most of the pores may have been filled with the nanoparticles. 
Figure 4.16d depicts the morphology of the Nanogel Composite after application of 
electrical stimulation and 5 released cycles. Numerous pores observed was due to 
the release of the nanoparticles occupying the sample, upon electro-actuation, 
140 
 
were released creating large and numerous pores in the matrix of the residual 
Nanogel Composite.  
 
This observation is supported by the results obtained from the porositometric 
analysis as shown in Figure 4.17. Figure 4.17 shows the isotherm linear plots of 
TERM, the Nanogel Composite before and after application of electrical 
stimulation for 6 released cycles. For the plots, a type IV isotherm with type H1 
hysteresis loop was observed. Brunauer–Emmett–Teller (BET) and Barrett-
Joyner-Halenda (BJH) adsorption and desorption profiles were employed to 
characterize the pore size by using the technique of relative adsorption of N2 gas. 
This was used to evaluate the pore size, pore volume and surface area for the 
TERM and the Nanogel Composite before and after application of electrical 
stimulation in order to correlate the outcome of the porosity to the results obtained 
for both the SEM and electro-modulation drug release cycle.  
 
The analysis of the porosity based on the BET and BJH characteristics observed 
is shown in Table 4.10. The Table shows evidence of the TERM having a pore 
size and volume greater than that of the Nanogel Composite before electro-
actuation, however, Nanogel Composite after electro-actuation exhibited higher 
pore size, volume and surface area values than the TERM and Nanogel 
Composite before electro-actuation. These results supported the observations of 
the SEM analysis. This is a good attribute that makes TERM a good candidate for 
nanoparticle loading and subsequent release of the incorporated nanoparticles 
when electrical stimulation is applied.  
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Figure 4.15: SEM images of native a) F127, b) CS, c) HPMC and d) PANI. 
Magnification=740x. 
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Figure 4.16: SEM images of a) TERM b) cross section view of TERM, c) Nanogel 
Composite before application of electrical stimulation and d) Nanogel Composite 
after application of electrical stimulation and 5 released cycle. Magnification=740x. 
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Figure 4.17: Isotherm linear plots of a) TERM, b) Nanogel Composite before 
application of electrical stimulation and c) Nanogel Composite after application 
of electrical stimulation. (N2 adsorption in red and desorption in burgundy color). 
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Table 4.10: Results of the porosity analysis of the TERM and the Nanogel 
Composite 
Parameter  TERM Nanogel 
Composite 
before 
electrical 
stimulation 
Nanogel 
Composite 
after 
electrical 
stimulation 
Surface Area    
Single point surface area (m²/g) 2.5204 1.8090 13.5209 
BET Surface Area (m²/g) 4.5176 0.8913 19.1719 
t-Plot External Surface Area (m²/g) 6.6994 1.177 26.2364 
BJH Adsorption cumulative surface 
area of 
pores between 17.000 Å and 
3000.000 Å 
diameter (m²/g) 
3.489 1.9413 14.013 
BJH Desorption cumulative surface 
area of 
pores between 17.000 Å and 
3000.000 Å 
diameter (m²/g) 
 
4.2747  5.5164 
Pore Volume    
Single point adsorption total pore 
volume of pores less than 798.210 Å 
diameter at P/Po=0.975135248 
(cm³/g) 
0.004702 0.001379 0.022153 
BJH Adsorption cumulative volume 
of pores between 17.000 Å and 
3000.000 Å diameter (cm³/g) 
0.005369 0.001394 0.051699 
BJH Desorption cumulative volume 
of pores between 17.000 Å and 
3000.000 Å diameter (cm³/g) 
 
0.005386 0.001342 0.049943 
Pore Size    
Adsorption average pore width (4V/A 
by BET) (Å) 
41.6362 19.2247 46.2190 
BJH Adsorption average pore 
diameter (4V/A) (Å) 
61.549 9.894 147.579 
BJH Desorption average pore 
diameter (4V/A) (Å) 
50.396 8.509 362.138 
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4.3.11. Assessment of Gelation Temperature of the Optimized Nanogel 
Composite 
The gelation temperature is the temperature at which there is a transition of liquid 
phase to solid phase (sol-to-gel phase transition). Visual inspection showed that 
the magnetic stirrer stopped rotating at temperature of 28±1°C for the magnetic 
bar method while 29±1°C was observed for the test-tube inverted method. Figure 
4.18a and Figure 4.18b illustrate the visual inspection before gelation and after 
gelation with the test tube inverted method. 
 
 
Figure 4.18: Test tube inverted method for the determination of gelation 
temperature, a) before gelation at room temperature and b) immediately after 
gelation at 29±1°C. 
 
 
4.3.12. Assessment of Rheological Properties of the Nanogel Composite 
The rheological behavior of polymers used in devising drug delivery systems can 
have a great influence on both in vitro and in vivo behaviours of the systems. 
Factors such as polymer characteristics, temperature, concentration pH, 
modification combinations, ions and additives may affect the rheological properties 
of the drug delivery devices. It is therefore pertinent to carry out the rheological 
investigation on the Nanogel Composite. The results of the rheological evaluation 
are depicted in Figure 4.19-Figure 4.24. 
 
4.3.12.1. Shear viscosity 
The basic viscosity of the optimized Nanogel Composite against the native 
polymer F127 shows that for both, the viscosity was observed to decrease as the 
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shear rate increased, this phenomenon is said to follow the non-Newtonian flow 
pattern (Ngwuluka et al., 2013). The Nanogel Composite and the F127 both 
displayed shear thinning characteristics classifying them as pseudoplastic 
however, from Figure 4.19; it is revealed that the shear viscosity of Nanogel 
Composite is more than that of F127 at every shear rate, observed at the same 
concentrations. As the shear rate increases, the viscosity decreases; the loss of 
viscosity may be due to the tightly bounded micelles of the polymers tendency to 
begin to loosen up and thereby dismantling the crosslinking of the entangled 
micelle arrangements of the PEO-PPO-PEO in the structure of the polymer. 
 
 
Figure 4.19: Rheogram of viscosity as a function of shear rate of Nanogel 
Composite and F127. 
 
4.3.12.2. Yield stress 
The yield stress of a compound is the point at which the substance begins to flow 
freely due to deformation of its intrinsic structure. It is apparent that below the yield 
stress point the compound has the characteristics of a solid substance and above 
this point the liquid characteristics of the substance is exhibited. It is important 
therefore to measure the yield stress of the optimized Nanogel Composite and 
F127 in order to determine the yield values which provide the insight on their yield 
which is a direct influence on the type and strength of the matrix formed in 
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comparison to the native polymer. Figure 4.20 shows the stress yield rheogram of 
both the Nanogel Composite and F127 which represents the plot of shear (γ) 
versus shear stress (τ). The apparent yield values for TERM and F127 were 
113.0Pa and 31.13Pa respectively. These values were calculated employing 
RheoWin software PC version 3. The yield value of Nanogel Composite is clearly 
greater than that of F127, this may be due to the increase in internal strength of 
the Nanogel Composite as the addition of the excipients such as CS, PANI and 
especially HPMC may have increased the interaction and cohesiveness of the 
molecular structure of the Nanogel Composite over F127 at the experimental 
temperature of 34°C and thereby increasing the mechanical strength and 
enhancing the physicomechanical characteristics of the Nanogel Composite over 
F127. 
 
 
Figure 4.20: Rheogram of Yield stress of Nanogel Composite and F127. 
 
4.3.12.3. Oscillation stress sweep 
The viscoelastic region of the optimized Nanogel Composite and F127 was 
determined by using oscillation stress sweep method. The viscoelastic property is 
a measure of the mechanical strength of the polymers which have a direct 
consequence on the manner the polymer behaves during electrical actuation and 
subsequently drug release kinetics. This measurement is frequency dependent; 
148 
 
frequencies of 0.1, 1 and 10 Hz were used. The elastic modulus also known as 
storage modulus G‟ represents the elasticity of a material while loss modulus G′′ 
represents the viscosity of a material. Intra and intermolecular crosslinking within a 
polymer network may be related to the elastic modulus properties of the polymer 
(Moura et al., 2007). In this case, the PEO‟s chains in the micellar layer enable the 
formation of a tighter structure in the Nanogel Composite than the F127, which is 
an indication of a display of a higher elastic modulus G‟ with a corresponding 
increase in its mechanical strength. Figure 4.21 shows the oscillation stress sweep 
of both TERM and F127 depicting the elastic modulus G‟ as a function of shear 
stress at a frequency of 0.1 Hz. The G‟ value observed in TERM compared to 
F127 may be explained by the induced transformation of intramolecular interaction 
further contributed by the HPMC to form the complex. 
 
 
Figure 4.21: Rheogram of oscillation stress sweep of Nanogel Composite and 
F127. 
 
4.3.12.4. Frequency sweep 
Structural elucidation of a material in an entangled, crosslinking or three 
dimensional network states such as gel, paste or liquid may be determined by 
employing the oscillation frequency sweep rheological method. Figure 4.22 shows 
the rheogram of the optimized Nanogel Composite against the native polymer 
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F127, depicting elastic and loss moduli (G‟ and G”) against the angular frequency 
(ω). Both the elastic and loss moduli were observed to increase with increase in 
angular frequency (ω). In case of the Nanogel Composite, the loss modulus is 
higher than the elastic modulus at a very short angular frequency, after which the 
elastic modulus became higher after the crossover point. This phenomenon was 
observed at very short angular frequency. The implication of this is that the 
Nanogel Composite behaved as an elastic material for the most part of the test 
and therefore exhibited a solid-like characteristic. On the contrary from Figure 
4.22, F127 exhibited a higher loss modulus than the elastic modulus until the 
angular frequency was about 150 rad/s, when crossover took place. This indicated 
that for most part of the test F127 behaved like a viscous liquid and therefore 
exhibited liquid-like characteristics. We can therefore conclude that the Nanogel 
Composite possesses enhanced structural ability compared to F127 and may 
therefore be suitable for an electrical-pulsatile controlled drug release device. 
 
 
 
Figure 4.22: Frequency sweep rheogram of Nanogel Composite and F127. 
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4.3.12.5. Creep recovery test 
The creep recovery test was used to further assess the elasticity of the polymers 
on application and removal of the applied stress. After deformation, materials may 
retract or spring back to its original position or shape. The results of this test may 
help in evaluating the subsequent behavior of materials on release of stress. The 
ability of the material to spring back after the removal of the stress is an indication 
of the elasticity of the material. Figure 4.23 shows the creep recovery test of both 
the optimized Nanogel Composite and F127, where J (1/Pa) is plotted against time 
(s). Both the Nanogel Composite and F127 showed elastic deformation and 
possess the ability to recover when the stress was removed. However, the 
recovery time for the Nanogel Composite is shorter than that of F127 on 
application of the same load and from the graph, it can be deduced that the 
Nanogel Composite has more ability to recoil and restore back to its original 
position than F127. This also supports the higher elasticity of the Nanogel 
Composite over the F127.  
 
Figure 4.23: Rheogram of creep recovery test for the Nanogel Composite and 
F127. 
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4.3.12.6. Temperature ramp analysis 
The temperature ramp is used to evaluate the change in the properties of a 
material on temperature variance. This method can be used to determine the 
gelation temperature of materials by observing the temperature at which there is a 
drastic change or movement in the sol-gel properties of the materials. Figure 4.24 
shows the temperature ramp rheograms of the optimized Nanogel Composite and 
F127 where viscosity is plotted against temperature. The experiment was carried 
out at a temperature range of 20 to 40±1ºC. The Nanogel Composite is seen to 
have a gelling temperature of 27.5±0.5ºC while F127 has a gelling temperature of 
21±0.5ºC. The gelling temperature was graphically determined as the temperature 
at which the curve of the apparent viscosity against temperature starts to plateau. 
Furthermore, the gelling temperature can equally be determined by plotting G‟ and 
G” against temperature. The temperature at the crossover point is taken as the 
gelling temperature as illustrated in Figure 4.25. the crossover point where the 
curve of G‟ crosses the curve of G” is that point where there is a significant phase 
transition from sol-to-gel state. 
 
 
Figure 4.24: Rheogram of temperature ramp of Nanogel Composite and F127. 
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Figure 4.25: Rheogram showing G‟G” plot against temperature for a) F127 and 
b) Nanogel Composite 
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4.3.13. Assessment of the Electro-active Properties of the Nanogel 
Composite Employing Cyclic Voltammetric Analysis 
In order to assess an electro-responsive formulation, it is important to determine if 
the formulation has an element of redox properties. Cyclic voltammetry (CV) is 
used to assess the oxidation-reduction reactions of the formulation; this enables 
analysis of the movement and exchange of ions in the media. The results of the 
measurements for the Nanogel Composite are illustrated in Figure 4.26 where 
Figure 4.26a depicts the voltammogram of PANI and Figure 4.26b the 
voltammogram of Nanogel Composite. It can be observed from the two 
voltammograms that there is similarity between them. However, the important 
parameter to look for in a cyclic voltammetric analysis is the peak potentials, the 
PANI exhibits two oxidation peak potentials at 1.10V and 1.45V while it exhibits 3 
reduction peak potentials at 0.5V, 0.7V and -0.83V. For the Nanogel Composite, 
the peaks observed are similar with a slight shift in oxidation and reduction peaks 
to 1.42V, 0.85V; reduction peaks are 0.5, 0.7, and -0.83V. The significant 
difference was actually in the output current generated. The output current for 
PANI Voltammogram is 1.5mA and 0.6mA for oxidation and reduction, 
respectively. While that of Nanogel Composite is 0.6mA and -0.4mA for oxidation 
and reduction respectively.  
 
PANI is known to exist in three forms, the emeraldine, pernigrinline and 
leucoemeraldine (Weerakoon et al., 2012). Figure 4.27 shows the three forms of 
PANI and their transition and reversible states. The first peak may be 
corresponded to the inter conversion between pernigraniline and emeraldine, the 
second peak may be associated with formation of benzoquinone and 
hydroquinone which may be due to the breakdown of the polymer chain during 
electrolysis (Kannusamy and Sivalingam, 2013) while the third reduction peak 
observed may be due to the PANI emeraldine salt being electronically reduced to 
PANI leucoemeraldine base. The whole redox activity is, however, reversible in 
both PANI and Nanogel Composite. 
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Figure 4.26: Voltammogram of a) PANI and b) Nanogel Composite 
 
 
 
 
Figure 4.27: The three forms of PANI showing their transition and reversible 
states 
 
4.3.14.  Assessment of the In Vitro Drug Release Analysis of the Optimized 
Nanogel Composite on Application of Electrical Stimulation 
It is necessary to evaluate the release capability of Nanogel Composite on 
application of electrical stimulation. Preliminary studies revealed that the Nanogel 
Composite did not release significant quantity of BCNU-NCP if electrical 
stimulation was not applied, but upon application of electrical stimulation 
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substantial drug is released as demonstrated in Figure 4.28. Various studies have 
shown that mucoadhesive polymers retard drug-release in a gel formulation (Ravi 
et al., 2015; Zaki et al., 2007). The addition of CS therefore slows down the drug 
release. Furthermore, the addition of HPMC has the ability to retard the drug 
release substantially when blended with F127 (Desai and Blanchard, 1998), this is 
a major and important reason for including this polymer into the formulation as the 
release of drug without electrical stimulation is not desired. The combination of the 
retardation ability of both CS and HPMC is responsible for the insignificant release 
of drugs without the application of electrical stimulation. The in vitro release of 
BCNU-NCP from the optimized formulation is illustrated in Figure 4.28. The 
formulation was optimized to release 10% of BCNU-NCP loaded in the Nanogel 
Composite on electrical stimulation, applying 5V of potential. The results obtained 
from the release studies showed that the average release percentage of BCNU-
NCP upon application of 5V electrical stimulation for 1 minute per cycle is 10.24%. 
This value is very close to the desired percentage release of 10% for the optimized 
formulation.  
 
BCNU concentration from the released BCNU-NCP was further analysed, the 
release profile obtained was similar to that of the BCNU-NCP release profile. 
Figure 4.29 shows the release profile of the BCNU from the NCP over 6 hours. 
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Figure 4.28: BCNU-NCP release profile in simulated nasal fluid (pH 6.0). 
 
 
 
 
Figure 4.29: In vitro BCNU release profile from the BCNU-NCP for a period of 6 
hours 
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4.4. CONCLUDING REMARKS 
A novel biocompatible and biodegradable thermosensitve electro-conductive 
mucoadhesive gel was prepared by blending Pluronic F127, CS, HPMC and PANI. 
BCNU-loaded Nano-co-Plex was incorporated into the polymer matrix to form a 
Nanogel Composite. The Nanogel Composite was optimized using the Box–
Behnken experimental design. The lower and upper limits was used to generated 
15 Nanogel Composite formulations in which conductivity, mucoadhesion and 
electro-actuation drug release were the responses undertaken to generate the 
optimal formulation. This formulation was characterized using FTIR, XRD, TGA, 
DSC, SEM, rheological, cyclic voltammetric and porositometric analyses to assess 
the physicochemical properties of the formulation. A thermally-stable gel with 
suitable rheological and mucoadhesion properties was formulated. Results 
revealed a Nanogel Composite that possesses porous matrix and was found to 
have the ability to undergo redox reaction which allows response to ES. The 
formulation was prepared to form an in situ gel at a temperature of 27.5±0.5°C. 
The release profile of the formulation when ES was applied demonstrated a 
desired 10.28% release of nanoparticles per release cycle. This formulation may 
therefore be a suitable candidate for use as an intranasal drug delivery system 
that can be modulated to deliver therapeutic agents to the brain via electro-
actuation in an “on-off” drug release kinetics by means of an external ES for a 
controlled nose-to-brain delivery. 
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 CHAPTER 5 
EX VIVO EVALUATION OF THE IN SITU NANOGEL COMPOSITE 
 
5.1. INTRODUCTION 
Several therapeutic agents introduced into the nasal mucosa migrate into the 
systemic circulation rather than traversing directly to the brain (Fortuna et al., 
2014; Lewis et al., 2012). This is due to the blood rich vessels in the nasal mucosa 
causing the therapeutic agents to face the challenge of the BBB (Tabatabaei et al., 
2015). There is evidence of nose-to-brain drug delivery most of which has been 
reviewed in Chapter 2 of this thesis. However, the probability of the therapeutic 
agents administered via the intranasal route reaching the systemic circulation is 
higher than the drug getting to the olfactory bulb for nose-to-brain delivery. This is 
due to slow movement of the therapeutic agents as the drug migrates and 
transverses across the nasal epithelial mucosa to the olfactory region (Grassin-
Delyle et al., 2012). Those that get to the brain do so by migrating through the 
nasal epithelial tissue to the olfactory region and subsequently to the CSF and 
brain.  
 
The mechanism of transport depends solely on therapeutic agent‟s 
physicochemical characteristics, passive diffusion and gravity (Lin et al., 2005). 
This poses a major challenge to nose-to-brain drug delivery as bioavailability of 
drug is substantially reduced. However, an effective nose-to-brain formulation 
should be able to migrate to the olfactory region as quickly as possible in order to 
increase bioavailability of drug in the brain as any delay causes the therapeutic 
agents to be absorbed through the systemic pathway and may significantly reduce 
bioavailability due to drugs recirculating back to face the challenges of the BBB. 
An enhanced transportation of the therapeutic agents to the brain through the 
olfactory pathway will be an advantage.  
 
BCNU-NCP are magnetic nanoparticles which are paramagnetic and therefore 
respond to Magnetic Field (MF). It is therefore important to evaluate the 
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permeability of BCNU-NCP through the nasal tissues with or without MF to 
observe the effect of a MF on the permeation and transportation of the 
nanoparticles across the nasal epithelial tissue. This chapter is based on the ex 
vivo evaluation of the Nanogel Composite by studying the mechanism by which 
the Nanogel Composite releases therapeutic agents on application of Electric 
Stimulation (ES) and how the released BCNU-NCP permeate through the nasal 
tissues of rabbit. Furthermore, the effect of a MF on the permeation was examined 
to compare the permeability of BCNU-NCP in the presence and absence of 
external MF. The nasal tissue of rabbit was employed for this assessment. Several 
researchers have used the nasal tissue of rabbits to evaluate the permeability of 
active compounds across the nasal epithelia membrane (Ohtake et al., 2003; 
Maitani et al., 1992). 
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Pluronic® F127 (Mw=12,600g/mol), medium molecular weight chitosan (CS) 
(Mw=400,000g/mol), polyaniline (PANI) (Mw=20,000g/mol), sodium hydroxide, 
hydroxylpropyl methylcellulose (HPMC), acetic acid, these chemicals were 
purchased from Sigma-Aldrich, (Steinhelm, Germany). Double deionized water 
was obtained from a Milli-Q water purification system (Milli-Q, Millipore, Billerica, 
MA, U.S.). All other reagents used were of analytical grade and were employed as 
purchased. 
 
5.2.2. Preparation of the Nanogel Composite 
The preparation of the Nanogel Composite was carried out as described in 
Chapter 4, Sections 4.2.2, 4.2.3, and 4.2.4. 
 
5.2.3. Ex Vivo Evaluation of the Nanogel Composite 
5.2.3.1.  Preparation of the rabbit nasal tissue for permeation studies 
These studies were performed according to method adapted from Kubo et al. 
(1994). Ringer solution was prepared by mixing 154mM of sodium chloride, 
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5.64mM of potassium chloride, 2.16mM of calcium chloride, 11.10mM of dextrose 
and 2.38mM of sodium bicarbonate in 1000mL of deionized water and the pH 
adjusted to 6.0. The nasal mucosa tissues used in these experiments were 
obtained from a New Zealand White rabbit. Prior approval was obtained from the 
University of the Witwatersrand Animal Ethics Committee. The rabbit was 
euthanized with an appropriate dose of sodium pentobarbitone. The nasal septum 
was carefully removed from the bone block and immersed and adequately rinsed 
in an ice-cold Ringer‟s solution previously prepared. Two pieces of the nasal 
mucosa were stripped with care using forceps and surgical scissors from the nasal 
mucosa ready for the permeation studies. 
 
5.2.4. Ex Vivo Evaluation of Mucoadhesive Strength of the Nanogel 
Composite 
A Texture Analyzer (TA) (TA.XT plus, Stable Microsystems, Surrey, UK) was 
employed to determine the mucoadhesive strength of the formulations. This was 
undertaken by measuring the force required to detach nasal mucosa membrane 
from each of the formulations. Freshly excised rabbit nasal membrane was 
attached to the upper probe of the instrument; a 1mL of Nanogel Composite was 
placed below the platform inside a temperature controlled compartment. The 
temperature was regulated to 34±1°C. The upper probe containing the membrane 
was then lowered at a speed of 10mm/min to touch the surface of the gel. A force 
of 0.1N was applied for 2 minutes to ascertain intimate contact with the gel. The 
exposed nasal mucosa membrane surface area was 0.785cm2. 
 
5.2.5. Determination of the Permeation Capability of the BCNU-Loaded 
Nano-co-Plex across Rabbit Nasal Tissue  
One of the important aspects of this work is to investigate how rapidly the 
nanoparticles released from the gel migrate from the nasal mucosa through the 
nasal epithelial tissue, to the olfactory region for subsequent delivery to the brain. 
Thus ex vivo permeation studies would give a better assessment of the 
permeation of the formulation through nasal tissue. Furthermore, the use of 
electric and magnetic fields would be assessed to see the effect of these 
parameters on the release and subsequent transportation of drug across the nasal 
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epithelial tissue. The permeation studies were performed by employing the 
experimental setup illustrated in Figure 5.1. The diffusion cells used were a side-
by-side type. This apparatus consists of donor and receptor half-cells of 12mL 
volume capacity. The choice of this apparatus was due to the use of a bar magnet 
that was positioned at the receiver compartment in order to evaluate the effect of 
MF on the permeation of the nanoparticles. The apparatus was equipped with a 
stirrer on each compartment and the system was connected to a thermostat 
controlled water jacket maintaining a temperature of 34±1°C. The apparatus was 
then mounted on an agitator to aid mixing. The tissue thickness was measured 
using a micrometer; the tissue was then mounted on a glass disc with round hole 
of 5mm diameter with the mucosal surface facing the donor compartment and the 
serosal side facing the receptor compartment. This was then placed in between 
the donor and the receptor compartments of the diffusion cell apparatus which 
contained pre-warmed PBS (pH 6) at 34±1°C to mimic nasal mucosa physiological 
conditions. The nasal mucosa was equilibrated in the PBS solution for 1 hour to 
achieve electrophysiological steady state.  
 
The optimized formulation containing (5mg/mL) drug concentration was 
transferred onto the mounted nasal tissue. The whole system was maintained at 
34±1°C. The formulation solidified immediately after being transferred into the 
donor compartment containing the nasal tissue. ES of PD (5V) was applied at time 
points of 0.5, 1, 2, 4, 6, 8, 16, 20 and 24 hours, applied using a 
potentiostat/galvanostat (PGSTAT302N, Autolab, Utrecht, Netherlands). A 
permanent magnet of 0.4 Tesla was placed at 1cm from the receiver compartment 
after each electrical application. Aliquot samples (1mL) were withdrawn and 
replaced with the same quantity of fresh pre-warmed PBS. Sampling was carried 
out prior and after each ES. The amount of BCNU-NCP permeated was quantified 
by determining the amount of iron contents in the withdrawn solution as iron 
formed the core of the BCNU-NCP. All experiments were repeated 3 times. The 
whole procedure was repeated with ES but no application of the permanent 
magnet and without both electrical and magnetic stimulation. This was done in 
order to evaluate the effect of ES as well as MF on the permeation characteristics 
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of the formulation. Table 5.1 summarizes the assessment procedures that were 
employed for the permeation studies.  
 
 
Figure 5.1: Schematic diagram of side-by-side diffusion cell. 
 
 
Table 5.1: Assessment procedures used in the permeation studies 
Test Formulation Application of 
Electro-stimulation 
Application of 
Magnetic Field 
1 Nanogel Composite None No 
2 Nanogel Composite Yes No 
3 Nanogel Composite Yes Yes 
 
5.2.5.1.  Quantitative analysis of the BCNU-loaded Nano-co-Plex permeated 
through the rabbit nasal epithelial tissue from the Nanogel 
Composite 
BCNU-loaded Nano-co-Plex permeated through the nasal epithelia tissue of rabbit 
was determined by following the procedure described in Chapter 4, Section 
4.2.10.1. 
 
5.2.5.2.  Evaluation of BCNU-loaded Nano-co-Plex permeability 
The BCNU-NCP permeability was calculated by ascertaining the cumulative 
diffusion of BCNU-NCP per unit area of the nasal tissue. The steady state flux (Js) 
was calculated from the slope of the linear section of the line obtained after 
plotting the amount of drug permeating nasal epithelium per unit area (mg/cm2) 
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against time (h) as shown in Equation 5.1 and the permeation coefficient P 
calculated using Equation 5.2. 
 
   
  
  
 
Equation 5.1 
 
  
  
  
 
Equation 5.2 
Where Js is the flux (mg/cm2/h), Qs is the amount of drug (mg), A is the area 
(cm2), T is the time interval (h), P permeability coefficient (cm/h) and Cd is the 
initial concentration (mg/mL) of the sample in the donor compartment. 
Enhancement ratios (ER) of BCNU-NCP permeation through rabbit nasal mucosa 
were calculated based on P values, according to        Equation 5.3 
 
   
                                 
                                    
     
       Equation 5.3 
 
Where P(Nanogel Composite with ES and MF) is the permeability coefficient of 
BCNU-NCP when there is application of electric and magnetic fields, and 
P(Nanogel Composite without ES and MF) is the permeability coefficient when 
there is no application of electric and magnetic fields. 
 
5.2.5.3.  Evaluation of the effect of magnetic field on cytotoxicity of the 
BCNU-loaded Nano-co-Plex on human glioblastoma A170 cells 
The effect of MF on cytotoxicity of BCNU-NCP was evaluated by employing the 
human glioblastoma cell line (A170) and following the method used in Chapter 3, 
Section 3.2.13.1 with slight modification. Briefly, two sets of seven plates (A-G) 
and (H-N) were employed in this experiment, each plate contained similar contents 
and represented incubation times of 0, 4, 8, 16, 24, 48 and 72 hours, respectively 
for the two sets. The well in each first set of plates was divided into 4 groups (1-4) 
which were Control, NCP, BCNU-NCP and BCNU group respectively. The second 
set of seven plates contains only 1 group (group 5), which is group BCNU-NCP 
(with the application of MF). Predetermined quantities of BCNU-NCP and 
conventional BCNU were added to each well as depicted in Table 5.2. The plates 
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were incubated for the time of incubation they represented. The second set of 
plates (H-N) was fixed with 0.1 Tesla neo disc magnets (Magnetech, Capetown, 
South Africa) positioned under the well plates.   After incubation, each plate was 
removed according to the respective time of incubation for assay. The contents 
distributions in each plate are displayed in Table 5.2. The cell viability was 
measured as described in Chapter 3, Section 3.2.13.1. 
 
Table 5.2: Distribution of DPBS, NCP, BCNU-NCP and BCNU contents in 
individual plate. 
Group Number of 
well used 
Contents added to 
each well 
BCNU quantity in 
each well (µg) 
Control  15 20 µL of DPBS 0 
 
NCP 15 20 µL of DPBS and 
0.5mg of NCP (drug 
free Nano-co-Plex) 
 
0 
BCNU 15 20 µL of DPBS and 
0.088mg of BCNU 
88 
    
BCNU-NCP 15 20 µL of DPBS and 
0.5mg of BCNU-NCP-3 
 
88 
BCNU-NCP (with 
application of a 
Magnetic Field) 
15 20 µL of DPBS and 
0.5mg of BCNU-NCP-3 
 
88 
 
5.3. RESULTS AND DISCUSSION 
5.3.1. Ex Vivo Evaluation of Mucoadhesive Strength of the Optimized 
Nanogel Composite 
The attachment or adherence of a polymeric material to a mucosal membrane, 
such as nasal mucosa, can be referred to as mucoadhesion. A nasal drug delivery 
formulation should ideally possess good mucoadhesive characteristics in order to 
be retained within the nasal cavity for a prolonged period of time to exert the 
desired delivery of drug to the brain. The process of mucoadhesion between a 
polymeric system and a mucosal surface is facilitated by ionic bonding, covalent 
bonding, hydrogen bonding, electrostatic forces, such as van der Waals forces, 
hydrophobic interactions and chain interlocking (Zaman et al., 2015). The degree 
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of interaction between the formulation and the mucosal surface is also dependent 
on the viscosity of the mucus on the surface of the mucosal membrane, the 
degree of chain entanglement within the formulation and the water contents. CS 
and HPMC have been carefully selected to prepare the Nanogel Composite due to 
their mucoadhesive properties. The mucoadhesion is the average maximum 
detachment force (MDF) and was determined from the peak of the Force-Distance 
profiles generated by textural profiling for the Nanogel Composite. The optimized 
formulation exhibited a MDF of 0.53±0.07N and work of adhesion of 
0.27±0.056mJ. These results suggest that the Nanogel Composite possessed 
desirable adhesive properties and this could be attributed to the ability of the 
selected polymers to form H-bonds with the mucosal membrane upon hydration 
with nasal solution on the surface of the mucosa, which resulted in gelling of the 
formulation. 
 
5.3.2. Calibration Curve of Iron 
A calibration curve for iron was constructed in PBS (pH 6; 34°C), using a known 
series of concentrations (0.1mg/mL-1mg/mL) of iron, the observed absorbance 
plotted against the known concentration of iron using a UV-Vis at 450nm is 
displayed in the calibration curve of iron depicted in Figure 5.2. 
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Figure 5.2: Calibration curve of iron 
 
5.3.3. Assessment of the Permeation of the BCNU-Loaded Nano-co-Plex 
across the Rabbit Nasal Tissue  
The permeation of the BCNU-NCP is based firstly on the release of the BCNU-
NCP from the Nanogel Composite followed by BCNU-NCP transportation across 
the nasal epithelial tissue to the receiver compartment through the nasal epithelial 
tissue. Figure 5.3 shows the plot of the cumulative BCNU-NCP permeation against 
time for the permeation studies. Figure 5.3 shows the cumulative permeation 
curve of BCNU-NCP released and permeated with application of ES and MF, ES 
only, and without application of both ES and MF, respectively. The results showed 
that the sample with the application of ES and MF displayed the highest quantity of 
BCNU-NCP permeation across the nasal epithelial tissue, followed by the sample 
with application of ES but no MF, and the least is the sample with no application of 
ES.  
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Figure 5.3: Permeation curve showing the cumulative amount of BCNU-NCP 
Permeated across the nasal epithelial tissue of rabbit at 34±1°C in a diffusion 
cell. Data are expressed as mean ± SD (N=3). 
 
The flux, which determines the amount of molecules that permeated through nasal 
epithelial tissue and the permeability coefficient, which is a measure of the 
distance traveled by the drug molecules per unit time (Adeleke et al., 2015), were 
calculated and displayed in Table 5.3. The results revealed that the BCNU-NCP 
flux and permeability coefficient for the sample with the application of MF were 
1.4177x10-2±1.7245x10-3 and 5.6709x10-3, respectively. These results displayed 
extensive synergistic and efficient permeation due to the application of the MF. 
The BCNU-NCP are magnetic nanoparticles and they have the ability to respond 
to MF; they are therefore quickly transported across the nasal epithelia tissue due 
to the high magnetization properties of the nanoparticles. This thereby enhanced 
the permeation of the nanoparticles and thus increases bioavailability of BCNU-
NCP at the receptor compartment. For the sample with only application of ES 
where there was no application of MF, the curve displayed an increase in 
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permeation as the time increased; in this case, the BCNU-NCP flux and 
permeability coefficient were 1.4177x10-2±1.7245x10-3 and 5.6709x10-3, 
respectively. The BCNU-NCP was released on electro-actuation but the 
nanoparticles were transported across the nasal epithelium tissue unaided and 
thus the mode of transportation was by passive diffusion following the 
concentration gradient across the nasal epithelium tissue. The BCNU-NCP flux 
and permeability coefficient for the sample without the application ES were 
2.7654x10-3±7.0929x10-4 and 1.1062x10-3, respectively. This sample displayed the 
lowest values and this can be explained by the fact that there was no application 
of ES to trigger the release of the BCNU-loaded NCP, the little amount of BCNU-
loaded NCP released and permeated might have been attributed to those 
nanoparticles that adhered onto the surface of the Nanogel Composite that 
eventually migrated into the diffusion medium. This further confirmed that 
nanoparticles release is also based on electro-actuation of the Nanogel 
Composite. 
 
The enhancement ratio was calculated and the results are displayed in Table 5.3. 
The results revealed that the enhancement ratio when comparing the sample 
without both the application of ES and MF to when there is application of ES only, 
was approximately 5-fold in terms of permeability and approximately 86-fold for the 
sample with the application of MF. Furthermore, the enhancement ratio when 
comparing formulation with the application electric field only to that of application 
of both ES and MF was approximately 5-fold across the nasal epithelial tissue. It is 
therefore evident from these results that MF application greatly enhances the 
permeability of BCNU-NCP across the nasal epithelial tissue and will indeed 
permit rapid transport of nanoparticles across the nasal epithelial tissue to the 
olfactory region of the nasal mucosa for onward delivery to the CNS in order to 
circumvent the BBB and enhance bioavailability of therapeutics in the brain. 
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Table 5.3: Flux, Permeability coefficient and Enhancement ratio for permeation of 
BCNU-NCP through the nasal tissue of New Zealand white rabbit.  
Formulation Flux, Js 
(mg.cm-2.h-1) 
Permeability 
Coefficient, 
P 
Enhancement 
ratio* 
Enhancement 
ratio** 
Nanogel Composite 
(No application of 
ES and MF) 
 
2.7654x10-3 
±7.0929x10-4 
1.1062x10-3 - - 
Nanogel Composite 
(with application of 
ES and MF) 
 
1.4177x10-2 
±1.7245x10-3 
5.6709x10-3 5.13 - 
Nanogel Composite 
(with application of 
both ES and MF) 
7.3681x10-2 
±1.6912x10-3 
2.9472x10-2 85.63 5.20 
*The enhancement ratio is based on the permeation of Nanogel Composite 
without the application of Electro-actuation and a magnetic field. 
 
**The enhancement ratio is based on the permeation of Nanogel Composite 
without application of a magnetic field. 
 
5.3.4. Assessment of the Magnetic Field Influence on the Cytotoxicity of 
BCNU-Loaded Nano-co-Plex on Human Glioblastoma A170 Cells 
The effect of the MF on the cytotoxicity of BCNU-NCP was evaluated by 
employing human glioblastomer A170 cell lines. The results revealed that BCNU-
NCP with application of magnet demonstrated greater toxicity towards 
glioblastomer A170 cells than when there was no application of magnet as shown 
in Figure 5.4. These results demonstrated remarkably the effect of the magnet in 
enhancing the internalization of the nanoparticles by attracting them towards the 
A170 cells. 
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Figure 5.4:   effect on toxicity of human glioblastoma A172 cell line showing the 
control treatment, treated with NCP, BCNU, BCNU-NCP and BCNU-NCP (with 
magnetic field) incubated at 37°C for 72 hours. 
 
5.4. CONCLUDING REMARKS 
The ex vivo investigation further demonstrated the efficacy of the nanoparticles 
being released from the Nanogel Composite when ES is applied. The released 
nanoparticles were found to permeate across the rabbit nasal epithelial tissue as 
revealed by the results. Furthermore, the permeation of the nanoparticles was 
found to be enhanced by the application of a MF as seen from the permeation 
coefficient values. This study therefore proves that this novel delivery system is 
practicable with significant potential and the study can therefore be taken further to 
an in vivo investigation in a suitable animal model which will be further discussed 
in detail int the next Chapter. 
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 CHAPTER 6 
IN VIVO EVALUATION OF THE OPTIMIZED NANOGEL COMPOSITE 
 
6.1. INTRODUCTION  
The drug release behavior of the Nanogel Composite has been extensively 
determined in vitro. However, in vitro evaluations of a novel drug delivery system 
may provide valid information regarding the drug release properties; they cannot 
completely simulate in vivo conditions. Therefore, in vivo studies still need to be 
conducted to obtain significant pharmacokinetic data. The use of an in vivo model 
offers greater pharmacokinetic and pharmacodynamic accuracy as well as a more 
realistic clinical extrapolation.  The use of rabbits in neuroscience may be a 
suitable option for comparing experimental modelling of human brain diseases as 
the larger animal allows for multiple sampling in the same animal and relatively 
accurate results compared to smaller laboratory animals such Sprague Dawley 
Rats (Traystman, 2003). The entrance into the nasal cavity of the rabbit is larger in 
comparison to that of the rat and may therefore enable ease of administration of 
the formulation (Bojsen-Moller and Fahrenkrug, 1971). In addition, euthanasia of 
rabbits to obtain CSF at each time interval may not be necessary due to the larger 
rabbit model having a larger CSF volume.  
 
The use of electrodes and magnetic headband would also be more appropriate in 
rabbit model than smaller animal model. Furthermore, the use of electrodes in 
intranasal drug delivery to the brain has been successfully carried out by Lerner 
and co-workers  (2004) using New Zealand White Rabbit. Electrotherapy has been 
carried out by Vaiman and co-wrokers (2004) for the treatment of nasal valve 
collapse. Additionally, Wan-Ching Ho (2015) employed ES on the nose to treat 
nasal polyps and allergic rhinitis. The acquisition of in vivo data from the 
formulation is essential to corroborate the feasibility of the novel delivery system in 
human patients. The in vivo studies were therefore carried out employing New 
Zealand white rabbits to evaluate the release behaviour of the Carmustine-loaded 
Nano-co-Plex (BCNU-NCP) from the Nanogel Composite upon the application of 
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ES on the nose of the rabbit and to assess the effect of an external MF on the 
released BCNU-NCP transportation across the nasal epithelial tissue towards the 
olfactory pathway for onward nose-to-brain delivery of the BCNU-NCP. 
Furthermore, the release of BCNU was determined by calculating the quantity of 
BCNU released in CSF, brain and the blood of the rabbit after intranasal 
administration and to establish the influence of ES in releasing the BCNU-NCP in 
an “on-off” pulsatile fashion. It is essential to also conduct a thorough toxicity study 
through histopathological evaluation on the nasal epithelial tissues exposed to the 
formulation and the placebo in comparison to the control. 
 
6.2. MATERIALS AND METHODS 
6.2.1. Materials 
New Zealand White rabbits (2-2.5 kg) were acquired from the Central Animal 
Service (CAS), University of the Witwatersrand (Wits), Galantmine (Gal) and 
carmustine (BCNU) were purchased from Sigma-Aldrich (Steinhelm, Germany). 
The UPLC chromatographic separations were performed with a SunFireTM C18 
column (3.5μm, 4.6x75mm) (Waters, Milford, MA, USA) auto sampler and 515 oval 
pumps. Double de-ionized water was used (Milli- Q, Millipore, Johannesburg, 
South Africa). UPLC solvents were of UPLC grades and all other reagents used 
are of analytical grades and of the highest purity. All drugs and their respective 
dosages as administered to the rabbits are provided in Table 6.1. Ketamine, 
Xylazine, Buprenorphine, Carprofen, Isoflurane, Oxygen, Procaine and Sodium 
pentobarbitone were provided by the CAS (Wits). 
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Table 6.1: Details of drugs, anesthetics, analgesics and other medicinal or 
experimental substances used, including the doses and routes of administration 
Drug/Substance Route Dose Frequency 
Nanogel Composite IN 0.5mg/kg once 
Carmustine IV 1mg/kg once 
Ketamine IM 50mg/kg once 
Xylazine IM 5mg/kg once 
Buprenorphine IM 0.05mg/kg When necessary 
Carpofen IM 4mg/kg When necessary 
Isoflurane Inhalation 2% once 
Oxygen Inhalation 12% once 
Procaine Topical 0.5% When necessary 
Sodium pentobarbitone IP 100mg/kg once 
IN=Intranasal, IV=Intravenous, IM=Intramuscular and IP=Intraperitoneal 
 
 
6.2.2. Animal Ethics Clearance 
Animal ethics clearance for these in vivo studies was obtained from the Animal 
Ethics Screening Committee (AESC) of the University of the Witwatersrand. Ethics 
Clearance Number 2015/05/C (Appendix D). 
 
6.2.3. Preparation and Sterilization of Nanogel Composite  
Preparation of Nanogel Drug Composite (Nanogel Composite) was carried out as 
described in Chapter 4, Sections Chapter 4, Sections 4.2.2, 4.2.3, and 4.2.4. The 
Nanogel Composite was sterilized by exposing the formulation to UV light 
overnight in an aseptic and sterile environment. 
 
6.2.4. In Vivo Experimental Studies 
In vivo studies to evaluate the release of BCNU loaded Nano-co-Plex from the 
Nanogel Drug Composite on application of ES and Magnetic MF and further 
evaluation of the BCNU release kinetics from the Nano-co-Plex were carried out. 
 
6.2.4.1. Pilot studies for determining the workability and suitability of the 
application of electric stimulation and magnetic field. 
The purpose of this pilot study was to demonstrate the workability and suitability of 
the Nanogel Composite using New Zealand white rabbits. It was to also examine 
the mode of administration and the effects of the application of the external electric 
and magnetic stimuli on the rabbit model. The three rabbits approved for the Pilot 
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study arrived at CAS. The rabbits were weighed on arrival and on the day of the 
procedure. The weight was recorded according to Table 6.2. The animals were 
monitored and fed with rabbit food and water. The rabbits were closely monitored 
and found to be generally healthy. 
 
Table 6.2: Weight of the three rabbits on day of arrival and a day prior to 
procedure. 
Rabbits 1 2 3 
Weight on arrival (kg) 
 
2.30 2.40 2.15 
Weight on procedure day 
(kg) 
2.30 2.50 2.19 
 
6.2.4.1.1. Preparation of the dosage forms of the Nanogel Composite and the 
conventional BCNU  
The sterilized optimized formulation (Nanogel Composite) was prepared and 
sterilized as described in Section 6.2.3. In order to compare Nanogel Composite to 
the conventional drug currently on the market so as to evaluate the superiority of 
the Nanogel Composite in terms of their drug release kinetics, the BCNU 
intravenous injection (IV) from the market was prepared by aseptically weighing 
accurately 5mg of BCNU and then dissolved it in 5mL of sterile 10% ethanol 
solution to make a concentration of 1mg/mL.    
 
6.2.4.1.2. Experimental procedures for the pilot study 
The rabbits were sedated before dosing by injecting ketamine (50mg/kg) and 
xylazine (5mg/kg) into the marginal vein of the rabbit‟s ear. Nanogel Composite 
(200μL, 0.5mg/kg) was intranasally administered into the nasal cavity of the rabbit 
using a 1mL syringe with rubber needle attached, to instil 100μL into each nostril.  
ES of 5V potential difference was applied for a period of 1 minute using electrodes 
from a potentiostat/galvanostat (PGSTAT302N, Autolab, Utrecht, Netherlands) on 
the nose of the rabbits after dosing as shown in Figure 6.1a. A magnetic headband 
equipped with 0.4 Tesla magnetic strength, (Magnetech, Capetown, South Africa) 
was placed on the rabbit‟s head as shown in Figure 6.1b. The rabbit was then left 
to recover from the sedation with careful observation. The rabbits were returned 
180 
 
back to the cage after full recovery. Fluid sampling was carried out prior and after 
ES at predetermined time interval. Blood samples (2mL) were collected through 
the marginal vein of the left ear following the procedure highlighted in Section 
6.2.4.2.4 as depicted in Figure 6.5f, followed by CSF (125μL) withdrawal by 
cisternal puncture through the foramen magnum as detailed in Section 6.2.4.2.5 
as shown in Figure 6.5g. Each rabbit in each group was subjected to 2 sampling 
timelines.  Sampling time points were 0, 0.5, 1, 2, 4, 6, 8, 16, 20 and 24 hours. The 
rabbits were then humanely euthanized after the second sampling timeline and the 
brain removed and placed in 10% phosphate buffered formalin for drug 
concentration studies.  
 
 
Figure 6.1: Digital images of a) application of electric stimulus on the nose and 
b) Magnetic Headband fitted on the head of the rabbit. 
 
6.2.4.1.3. Pilot studies design 
The three rabbits were distributed into three groups, one rabbit per group. The 
time point was randomly chosen for this pilot study. 
Group 1: This group was the experimental group. The experimental procedure 
detailed in Section 6.2.4.1.2 was followed. Fluid sampling was carried out at 1 
hour and 6 hours for the purpose of the pilot study.  
Group 2: This group was the control group to examine the effect of electrical and 
magnetic stimulations. There was no application of both ES and MF. Fluid 
sampling was carried out at 2 hours and 8 hours for the purpose of this pilot study.  
Group 3: This group was intended to be used to obtain pharmacokinetic and 
pharmacodynamics data for comparison purposes and in vivo proof of concept. 
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A dose of 1mL of BCNU prepared as stipulated in Section 6.2.4.1.1 was 
intravenously injected into the rabbit through the marginal ear vein. Fluid Sampling 
was carried out at 1 hour after dosing.  
 
6.2.4.2. In vivo experimental design and procedure for the studies 
6.2.4.2.1. Habituation of the experimental animals (New Zealand White 
Rabbits) 
The rabbits were purchased and transported from certified suppliers. Appropriate 
pre-transportation handling, loading, journeying and unloading at the Central 
Animal services (CAS), University of the Witwatersrand, were accomplished 
according to CAS standard operating procedures (SOPs). On arrival at CAS the 
rabbits were habituated, weighed and assessed for any signs of disease, injury or 
distress and then socialized accordingly before the experimental procedures were 
conducted (Zhang et al., 2015). Animals were housed at room temperature with a 
12-hour light/dark cycle (light from 6am to 6pm), and were fed a standard rabbit 
diet with water available ad libitum as shown in Figure 6.2.  
 
 
Figure 6.2: A digital image depicting the conditions under which the rabbits 
were housed in a vivarium according to ARVO Resolution guidelines. 
 
6.2.4.2.2. Experimental design 
A total of 105 New Zealand White Rabbits were approved for these studies 
inclusive of the pilot studies.  The rabbits were randomly assigned to 4 groups of 
25 rabbits per group. Each group is subdivided into 5 groups per 2 time points. 
The experimental design and the assignment of the rabbits into the groups 
including the outline summary of the in vivo studies are illustrated in Figure 6.3. 
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Group 1 (Placebo): Drug free Nanogel Composite was administered to the 25 
rabbits in this group. There was application of magnetic headband equipped with 
0.4 Tesla magnet and ES application using electrodes with a potential difference 
of 5V on the nose of the rabbit. This group was used for comparison purposes 
against the experimental groups to evaluate pharmacokinetic and 
pharmacodynamics data. 
 
Group 2 (Positive control): Nanogel Composite was administered to all the 
rabbits in this group but there was no application of electrodes on the nose and no 
application of a magnetic headband. This group was used as control to observe 
the effect of ES and MF on drug release and onward movement of nanoparticles 
to the brain through the nasal cavity.  
 
Group 3 (Experimental group): Nanogel Composite was administered to all the 
rabbits in this group. There was application of electrodes on the nose and 
application of a magnetic headband. This group was used to obtain 
pharmacokinetic and pharmacodynamics data for comparison purposes and in 
vivo proof of concept. 
 
Group 4 (Negative control): BCNU was intravenously administered to all the 
rabbits in this group. There was no application of electrodes on the nose and no 
application of a magnetic headband. This group was used to compare the 
pharmacokinetic and pharmacodynamics properties of the current drug on the 
market, as well as administration method with that of the nasal Nanogel 
Composite formulations. BiCNU is the market leader product and was used for 
comparison purposes. 
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Figure 6.3: Schematic diagrams showing the outline summary of the in vivo 
animal studies. 
 
6.2.4.2.3. Blood sample collection 
The rabbits were anesthetized prior to blood sample withdrawal. Blood samples 
(2mL) were withdrawn directly from the marginal ear vein of the rabbits. Each 
rabbit in this study were subjected to only 2 sampling timepoints. Sampling time 
points were 0, 0.5, 1, 2, 4, 6, 8, 16, 20 and 24 hours. The withdrawn blood 
samples were immediately placed in heparinized tubes to prevent clotting. The 
blood samples were centrifuged at 5000rpm and the supernatant was transferred 
into 2mL Eppendorf tubes and stored in the -80 °C freezer for further analysis. 
 
6.2.4.2.4. Cerebrospinal fluid sample collection 
The rabbit was anaesthetized prior to the procedure. The back of the neck of the 
rabbit was shaved in order to have access to the occipital protuberance and the 
cranial margins areas of the rabbit. A 23-gauge needle was inserted approximately 
midway between these two points in order to have access to the cisterna magna 
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through the foramen magnum. The needle was slowly inserted and directed 
towards the nose of the rabbit, the needle penetrated the dura and the 
subarachnoid membranes with a slight “pop” felt confirming the puncturing of the 
cisterna magna. Appearance of CSF at the hub of the needle confirmed correct 
placement of the needle, the CSF drip from the needle and a 1mL syringe was 
used to slowly aspirate 125µL of CSF. The needle was gently removed and a mild 
pressure was applied at the needle exit point for about 15 seconds. The CSF was 
quickly transferred into an Eppendorf tube and stored in -80°C freezer. This 
procedure is illustrated in Figure 6.4. The reason for staggering the sampling 
points as well as using the 5 rabbits in all the sub-groups was due to the inability of 
rabbits to provide more than 2 sampling time points per day. The CSF sampling 
time point was therefore limited to 2 per rabbit and was well spread so as to give 
the rabbits enough recovery time. 
 
 
Figure 6.4: Digital images of the procedure for withdrawing CSF from the rabbit 
showing a) shaving of the back of the neck of rabbit, b) shaved area, c) insertion 
of needle directed towards the nose of the rabbit and d) the withdrawal of CSF 
with the aid of 1mL syringe). 
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6.2.4.2.5. Brain tissue collection 
The rabbits were humanely euthanized, and the brains were removed.  The 
extraction of BCNU from the brain tissue was performed by a modified method 
used by Ved and Kim (2011). Briefly, the brain tissue was homogenized employing 
a VDI-12 homogenizer at 20,000rpm for 15 minutes, 1mL of 1.25%(v/v) absolute 
ethanol in diethyl ether was added to 100mg of the brain sample and further 
homogenized for 2 minutes. The resultant tissue homogenate was then 
centrifuged at 5000rpm for 20 minutes. The supernatant was measured for BCNU 
contents, using the extraction methods provided in Section 6.2.5.2 followed by 
UPLC analysis. 
 
6.2.4.2.6. Experimental procedure for the in vivo studies 
The optimized Nanogel Composite delivery system was compared to the 
conventional drug currently in the market to evaluate the superiority of the new 
systems in terms of their drug release kinetics. Furthermore, a placebo (drug-free) 
system was administered to compare results. The experimental procedure for 
each group is elaborated below.  
 
Group 1 (Placebo) 
There were 25 rabbits in this group which were subdivided into 5 groups per 2 time 
points. Rabbits were sedated before dosing by injecting ketamine (50mg/kg) and 
xylazine (5mg/kg), into the marginal vein of the rabbit‟s ear. Nanogel Composite 
(200μL, 0.5mg/kg) without BCNU-NCP was intranasally administered into the 
nasal cavity of the rabbit using a 1mL syringe with rubber needle attached to it to 
instil 100μL into each nostril. ES of 5V potential difference was applied for 1 
minute using electrodes from a potentiostat/galvanostat (PGSTAT302N, Autolab, 
Utrecht, Netherlands) on the nose of the rabbits after dosing as shown in Figure 
6.1a. A magnetic headband equipped with 0.4 Tesla magnetic strength was placed 
on the rabbit‟s head as shown previously in Figure 6.1b. Fluid Sampling was 
carried out prior and after ES at predetermined time. Blood samples (2mL) were 
collected through the marginal vein of the left ear following the procedure 
highlighted in Section 6.2.4.2.4 as depicted in Figure 6.5f, followed by CSF 
(125μL) withdrawal by cisternal puncture through the foramen magnum as detailed 
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in Section 6.2.4.2.5. and shown in Figure 6.5g. Sampling time points were 0, 0.5, 
1, 2, 4, 6, 8,16, 20 and 24 hours. The rabbits were then humanely euthanized after 
the second sampling timeline and the brain removed and placed in 10% 
phosphate buffered formalin for drug concentration studies.  
 
Group 2 (Positive control) 
The same procedure detailed for group 1 above was applied to this group with the 
exception of the dosing formulation. Nanogel Composite (200μL, 0.5mg/kg) was 
intranasally administered, with no application of electrical and magnetic 
stimulation. 
 
Group 3 (Experimental group) 
The same procedure detailed for group 1 was applied to this group. The Nanogel 
Composite (200μL, 0.5mg/kg) was intranasally administered. 
   
Group 4 (Negative control) 
In this group, 1mL of BCNU prepared as stipulated in Section 6.2.4.1.1 was 
intravenously injected very slowly into the rabbits through the marginal ear. There 
was no application of electric and magnetic stimulation. All standard procedures as 
in group 1 were followed. 
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Figure 6.5: Photographic evidence of (a) Housing of the rabbits (b) preparation for 
surgery with anesthetization (c) intravenous dosing (d) intranasal dosing e) 
application of ES (f) blood withdrawal (g) CSF withdrawal (h) administration of 
oxygen after dosing and sampling (i) rabbit recovering from sedation. 
 
6.2.5. Quantitative Chromatographic Determination of BCNU in Plasma, CSF 
and the Brain Tissue of Rabbit 
Detection and quantification of BCNU in the plasma, CSF and brain samples was 
carried out on a Waters AcuityTM Ultra Performance Liquid Chromatography 
(UPLC) (Waters Corporation, Milford, Massachusetts, USA). This was made up of 
a binary solvent manager, a sample manager and fitted with a photodiode array 
detector (PAD) synchronously controlled using the Waters Empower 2 software. A 
SunFireTM C18 column (3.5μm, 4.6X75mm) (Waters, Milford, MA, USA) auto 
sampler and 515 oval pumps was used to detect and separate BCNU. 
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6.2.5.1. Development of a method for sample analysis employing Ultra 
Performance Liquid Chromatography 
UPLC was technique utilized to determine the concentrations of the drugs in the 
biological fluid retrieved at different time points through the identification of peaks. 
A method for the detection and determination of BCNU was investigated involving 
the selection of appropriate mobile phases, flow rate, wavelength and injection 
volume. The mobile phase employed was a mixture of Acetonitrile (ACN) and 
water. An isocratic method with the ratio of 70:30 (ACN:Water) proved to be the 
most suitable. Table 6.3 shows the parameters employed while galantamine was 
chosen as the internal standard for the quantification analysis. Mobile phases were 
prepared and filtered through 0.22µm Millipore filters and placed in the machine 
with the appropriate solvent flow lines placed in the two mobile phases. The initial 
step to UPLC analysis is priming the machine which includes washing of the 
pumps and lines. Two types of washing occurred, a weak wash (90%v/v double de-
ionised water and 10%v/v ACN) and a strong wash (90%
v/v ACN and 10%
v/v 
double de-ionized water). Once the priming process was completed, the column 
was equilibrated to the selected separation method.  
 
Table 6.3: UPLC parameters employed for the determination of BCNU 
concentration 
Parameters  Conditions 
Mobile phase ACN and Water (70:30) isocratic 
gradient 
Flow rate 0.5mL/min 
Injection volume 2µL 
Wavelength 230nm 
Column temperature 40ºC 
Sample temperature 25ºC 
 
 
6.2.5.2. Extraction of BCNU from rabbit plasma and CSF for UPLC analysis 
An effective liquid-liquid extraction method was developed and applied to BCNU in 
the rabbit plasma. The frozen experimental plasma samples were thawed at room 
temperature and allowed to environmentally equilibrate. The samples were then 
centrifuged at 5000rpm for 15 minutes. Centrifugation was repeated twice in order 
to release any drug present in the tissues. The supernatant was isolated and 
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0.2mL of the supernatants was transferred into Eppendorff tubes. The IS in 10% 
ethanol Gal; (100μL, 0.2mg/mL) was added to each tube, and the tubes were 
vortexed for 30s. A liquid-liquid phase extraction methodology was employed in 
extracting the drugs from the studied rabbit plasma. To each of the tube, 0.3mL of 
1.25%(v/v) absolute ethanol in diethyl ether was added. The tubes were vortexed 
for 30s and then centrifuged at 5000rpm for 20 minutes. The supernatant (ethanol-
diethyl ether layer) was then transferred to clean vials and was air dried at room 
temperature leaving dry residues containing the drugs in the vials. The residues 
were then reconstituted with 0.5mL of the UPLC mobile phase (Acetonitrile/Water 
in ratio 70:30). The solution was filtered through a 0.22µm Cameo Acetate 
membrane filter (Millipore Co., Bedford, MA, USA) into Waters® Certified UPLC 
vial for analysis. The same procedure was performed for the CSF samples and the 
supernatant samples collected from the brain, as carried out in Section 6.2.4.2.5 of 
this chapter. Measurements were conducted on all the samples from each time 
point (N=5). 
 
6.2.5.3. Validation of liquid-liquid extraction procedure 
The precision and accuracy of the extraction process was determined by repeating 
the extraction procedure performed in Chapter 6, Section 6.2.5.2 on 3 consecutive 
days to allow for the determination of inter-day precision and accuracy (N=3 for 
each day) and intra-day variability consisting of multiple injections of samples 
during a 24-hour period (N=3). Accuracy was estimated using the mean 
percentage error, based upon differences between actual and predicted 
concentrations. The precision, expressed as a percentage, was evaluated by 
calculating the intra- and inter-day variability coefficients of variation (Boon et al., 
2006). The extraction process was further validated by the use of the IS (Gal), the 
peak area of the Gal should always be similar in every sample as a constant 
quantity is always utilized. The extraction yield percentage was calculated by 
comparing the peak areas obtained from the extracted BCNU in the plasma 
(AUCplasma) to the peak areas obtained from BCNU extraction from standard 
solutions (AUCstandard) of the same concentration using Equation 6.1. 
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Equation 6.1 
 
6.2.5.4. Preparation of calibration curve 
Stock solutions of BCNU were prepared by dissolving 20mg of BCNU in 100mL of 
10% ethanol. Dilutions were made from fresh stock prepared the same day and 
kept at low temperature because of degradation. Spiking solutions with 
concentrations spanning between 0.02 and 0.1mg/mL were prepared from stock 
solution of BCNU prepared at concentration of 0.2mg/mL by diluting the stock 
solution with deionized water. Gal was selected during preliminary study as the 
suitable Internal Standard (IS). A stock solution of Gal was prepared at 
concentration of 0.2mg/mL. In order to prepare standard solutions for generating a 
standard curve for BCNU in the plasma, BCNU spiking solutions (0.1mL) and the 
IS (0.1mL) were added to Eppendorf tubes, each of which contained 0.2mL of 
blank rabbit plasma thawed previously and then centrifuged (Optima® LE-80K, 
Beckman, USA) at 5,000rpm for 15 minutes. A liquid-liquid phase extraction 
methodology was employed in extracting both BCNU and Gal added from the 
blank rabbit plasma to prepare a calibration curve. To each calibration standard, 
0.3mL of 1.25%(v/v) absolute ethanol in diethyl ether was added. The tubes were 
vortexed for 30s and then centrifuged at 5000rpm for 20 minutes. The supernatant 
(ethyl alcohol-diethyl ether layer) was then transferred to a clean vial and was air 
dried at room temperature, leaving dry residues containing the drug samples in the 
vials. The residues were then reconstituted with the UPLC mobile phase 
(Acetonitrile/Water). The solution was filtered through a 0.22µm Cameo Acetate 
membrane filter (Millipore Co., Bedford, MA, USA) into Waters® Certified UPLC 
vial for analysis. The same procedure was performed for the CSF samples. The 
ratio of the area under the curve (AUC) for the peaks between BCNU and the IS 
was plotted against the concentration of the standard solutions to generate the 
calibration curve. A linear curve was constructed from five calibration standards. 
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6.2.5.5. Determination of BCNU-NCP in the brain tissue employing Field 
Emission Electron Probe Micro Analyzer (FE EPMA) 
The presence of BCNU-NCP in the brain was confirmed by evaluating the 
presence of iron oxide nanoparticles in the brain through the detection of iron 
content in the brain sample employing Field Emission Electron Probe Micro 
Analyzer (FE EPMA). Samples of the brain obtained from the euthanized rabbit 
were homogenized for 15 minutes, the homogenate was vacuum dried at 40°C. 
Sample of the dried brain was placed on aluminum stubs with the aid of a carbon 
tape. The sample was sputter-coated with gold-palladium and then loaded into the 
FE EPMA for analysis. 
 
6.2.5.6. Histopathological Evaluation of the Nasal Mucosa of the Rabbits 
Samples of the nasal tissues of the rabbits were randomly taken from each group 
and sent to IDEXX laboratory for histopathological examination and analysis. The 
nasal mucosa of the rabbits was excised and quickly transferred into neutral 
buffered formalin. The nasal tissues were decalcified for 12 hours in rapid decal 
solution (sulphuric and hydrochloric acid) to allow for cutting and section while 
maintaining anatomical integrity of the nasal turbinate and mucosa. The formalin 
fixed tissue samples were then blocked and processed overnight in the automatic 
tissue processor as per standard operating procedure. The produced wax blocks 
were then sectioned on a microtome to produce 5-6μm sections which were then 
stained in an automated Haemotoxylin and Eosin (H&E) stainer (IdexxSA-APSOP-
205).  
 
6.3. RESULTS AND DISCUSSION 
6.3.1. Pilot Study to Assess the Effect of Electric Stimulation, Magnetic 
Headband and Fluid Sampling on the Rabbits 
The pilot study was designed to observe the effects of the ES and the MF 
application on the safety and wellbeing of the rabbits during the experimental 
period as well as to perfect the experimental procedure. The sampling frequency 
was also of concern especially the collection of CSF from the rabbit. The outcome 
of the pilot study for Group 1 was successful. This is the group that demonstrated 
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the full application of the drug delivery system. The intranasal dosing, the 
magnetic headband and the application of the ES were all carried out successfully 
without any difficulty. The fluid sample collections went easily and without any 
hindrance. Sample collections were carried out successfully at 2 timepoints (1 and 
6 hours). Group 2 was also successful as there was no problem during 
anaesthetization, dosing and fluid collection procedures. This group serves as 
control in demonstrating the effect of the magnetic headband and the electric 
stimulus applied. Sample collections were carried out successfully at 2 timelines (2 
and 8 hours). The rabbit in group 3 died after IV administration of the conventional 
BCNU. The cause of death was not clear. The cause of death may however be 
attributed to different issues and complications as a result of the administration of 
the IV injection, or it may be due to one or more of the numerous side effects of 
BCNU.  
 
BCNU is an antineoplastic cancer chemotherapeutic which works by blocking the 
growth of cancer cells. Some of the side effects of BCNU are nausea, vomiting, 
diarrhoea, gastrointestinal upset, nephrotoxicity, oral ulcers, alopecia and bone 
marrow suppression. The rate at which the IV was administered may also be a 
contributing factor according to the literature (Joshi et al., 2007), IV dosing of 
BCNU in rabbit should be administered at a very slow rate. The concentration of 
the dosage as well as the quantity may also be a contributing factor. However, 
comparing the concentration and the quantity of the dose administered in this case 
to that obtained from the literature (Joshi et al., 2007; Liu et al., 1983), possibility 
of overdose may be rule out as the right dosage was administered. The solution 
proffered to this problem was to administer the IV at a very slow rate. Group 3 was 
then repeated with an additional rabbit approved by the AESC for the purpose. 
This time, IV injection was slowly administered to the rabbit. Rabbits were closely 
monitored before and after the procedure. Blood and CSF were collected twice at 
different time points from the rabbit. The pilot study was carried out successfully 
with the novel drug delivery system, without any discomfort to the rabbits during 
dosing, application of both electric and magnetic stimulation, as well as sample 
collection procedures. The pilot study provided a useful experience and 
familiarization of procedures which were applied in the main study. 
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6.3.2. Drug Extraction, UPLC Method Validation and Assay Procedure 
Figure 6.6a and Figure 6.6b shows high resolution chromatographic peaks of the 
analyte (BCNU) and the internal standard (Gal) as obtained by the UPLC-PDA. 
The analysis revealed two separated and defined peaks (wavelength 230nm) at 
the respective retention times of 1.90 and 15.28 minutes for Gal and BCNU, 
respectively, as depicted in Figure 6.6c.  
 
 
Figure 6.6: Typical chromatogram displaying a) the spiking plasma separation of 
the Gal, b) BCNU and c) the separation of both Gal and BCNU after plasma 
extraction. 
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Figure 6.7 shows the chromatographic peaks of BCNU and Gal at 230nm after 
CSF extraction, with their respective retention times of 1.20 and 16.49 minutes. 
These retention times are very similar to those obtained from the plasma analysis. 
Figure 6.6 and Figure 6.7 further revealed that there was no change in the 
retention time when the analyte and the IS were spiked in plasma and CSF 
individually and when they were spiked in plasma and CSF together. This 
observation proved the UPLC method adopted to be a suitable and appropriate 
method for analysing the drug in the samples. The mean recovery percentage of 
BCNU from the plasma and CSF samples during the liquid-liquid phase extraction 
implemented was calculated by comparing the peak areas of both low and high 
extraction calibration standards to those of aqueous standards. Validation of the 
extraction method indicated that the mean coefficient of variation in the intra-day 
and inter-day precision and accuracy was determined to be 0.46% and 0.38%, 
respectively. The results of the extraction procedure of the spiked blank plasma 
and CSF samples revealed a mean recovery (N=5) range of 91.2-95.7% 
(SD≤3.48), these results were found to be satisfactory. The generated calibration 
curve for BCNU is displayed in Figure 6.8. 
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Figure 6.7: Typical chromatogram depicting a) the spiking CSF separation of the 
Gal, b) BCNU and c) the separation of both Gal and BCNU after CSF extraction. 
 
 
196 
 
 
Figure 6.8:  Calibration curve of BCNU at 230nm. 
 
 
6.3.3. Concentration of BCNU in the blood, CSF and brain tissue of the 
rabbit model 
The concentration of BCNU in plasma, CSF and brain were computed using the 
calibration curve generated from the area under the curve of BCNU/Gal 
(AUCBCNU/Gal) with reference to the calibration curve. Figure 6.9 shows the Mean 
BCNU concentration-time profile in plasma simultaneously compared after IV 
injection, IN administration with and without application of ES and MF. The curve 
displayed a high concentration of BCNU in the plasma for IV administration 
compared to IN administration with or without the application of ES and MF. The 
Cmax for BCNU after 30 minutes of IV and IN administration (with and without 
application of ES and MF) are 0.5843, 0.0789 and 0.0199µg/mL, respectively. The 
plasma concentration of BCNU was slowly diminishing until around 6 hours when 
the concentration became nil. The plasma concentration of BCNU for IN 
administration of Nanogel Composite with application of ES shows a steady low 
and high display of concentration peaks, this is due to the electro-actuation which 
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brought about release of BCNU-NCP which increases BCNU concentration in the 
plasma and reduces to minimum when there is no application of ES, this occurs in 
an “on-off” pulsatile fashion. However, with IN administration of BCNU-NCP, the 
plasma concentrations of BCNU were more than 10 times lower than following IV. 
The plasma concentration of IN administration of Nanogel Composite without the 
application of ES shows the lowest plasma concentration, there is insignificant 
release of BCNU-NCP; this is due to non-application of ES to release the BCNU-
NCP. 
 
 
Figure 6.9: Mean BCNU concentration-time profile in plasma after IV injection of 
the conventional BCNU, IN administration of Nanogel Composite without 
application of ES/MFand IN administration of Nanogel Composite with the 
application of ES/MF (SD≤ 0.053; N=5 at each time point). 
 
The BCNU concentration-time profile in CSF after IV injection, IN administration 
(with and without ES and MF application) is displayed in Figure 6.10. It can be 
observed that the concentration of BCNU in CSF is the highest for IN 
administration with the application of both ES and MF. A steady state profile can 
be observed for this administration with an “on-off” pulsatile switching. The 
average release of BCNU in the CSF per electro-actuation was observed to be 
0.2819µg/mL. The BCNU-NCP was released upon electro-actuation. The released 
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BCNU-NCP was rapidly transported to the CSF with the aid of the MF through the 
olfactory pathway to increase the BCNU concentration at each pulsatile release of 
the nanoparticles from the Nanogel Composite brought about by the ES. The IV 
and the IN without ES and MF application have the lowest concentration. For the 
IV, the BCNU has to pass to the CSF through the systemic pathway, this pathway 
is challenged by Blood CSF Barrier (BCB), which tends to block the drug from 
passing into the CSF and thereby drastically reducing bioavailability in the CSF, 
however some of the drugs were able to cross to the CSF as seen in the profile 
curve. For the profile of IN without the application of ES and MF, there was 
insignificant concentration of BCNU in comparison to when there is application of 
ES. This may be explained by the fact that BCNU-NCP is not being significantly 
released due to non-application of ES. Figure 6.11 shows the percentage of BCNU 
released in the CSF for IN when there is application of ES and MF. The profile 
illustrated the concentration of BCNU in the CSF for over a 24-hour period.  
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Figure 6.10: Mean BCNU concentration–time profile in CSF after IV injection of 
conventional BCNU, IN administration of Nanogel Composite without application 
of ES and IN administration of Nanogel Composite with the application of ES 
and MF at 1mg/kg dose in rabbits. (SD≤ 0.051; N=5 at each time point). 
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Figure 6.11: Percentage of BCNU released in CSF following IN 
administration. (SD≤ 0.051; N=5 at each time point). 
 
The BCNU concentration-time profile in brain tissue after IV injection, IN 
administration (with and without ES and MF application) is shown in Figure 6.12. 
Here, the concentration of BCNU for IN administration  with the application of ES 
and MF displayed the highest concentration in the brain; this mechanism is similar 
to that explained in the CSF profile. The average concentration of BCNU in the 
brain per electro-actuation was 0.1968µg/g. It can be seen from the concentration-
time profile that the Cmax of 0.00776µg/mL BCNU for IV was attained in less than 2 
min after IV and gradually diminishes to nil. The concentration of BCNU for IN 
administration of Nanogel Composite with application of ES and MF was 
approximately constant through the duration of 24 hours. This is advantageous 
because the BCNU was available in the brain with increased bioavailability. The 
brain concentration of BCNU for the IN without application ES is the lowest and it 
is insignificant in comparison to when there is application of ES and MF. 
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Figure 6.12: Mean BCNU concentration–time profile in Brain after IV injection of 
the conventional BCNU, IN administration of Nanogel Composite without 
application of ES and IN administration Nanogel Composite with the application 
of ES and MF at 1mg/kg dose in rabbits. (SD≤ 0.05; N=5 at each time point). 
 
One of the important reasons for these in vivo studies is to identify the superiority 
of the novel Nanogel Composite over the conventional BCNU available on the 
market, to prove that IN administration of Nanogel Composite with the application 
of ES and MF, may aid in increasing bioavailability of BCNU in the brain and CNS 
through an “on-off" pulsatile controlled release of therapeutics for a direct nose-to-
brain drug delivery. In order to prove this concept, comparison of BCNU 
concentration in plasma, CSF and brain tissue was further examined and analyzed 
when the mode of administration is IV, IN with or without ES and MF. Figure 6.13 
shows the BCNU concentration in Plasma, CSF and brain tissue after IV injection 
for a period of 24 hours. From the results, it can be observed that the 
concentration of BCNU is the highest in the plasma with a concentration 
approximately 9-fold more compared to that of CSF and brain. The implication of 
this is that less drug is getting into the the CSF and brain; this may be due to the 
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BBB which prevents drugs from penetrating the brain, thereby providing low 
bioavailability of BCNU in the brain, thereby providing low bioavailability of BCNU 
in the brain.  However, IN administration of Nanogel Composite with application of 
ES and MF demonstrated a high concentration of BCNU in the CSF and the brain 
as shown in Figure 6.14. The BCNU concentration in the CSF, brain and plasma 
are 0.2571µg/mL, 0.199µg/g and 0.0078µg/mL after 30 minutes, respectively, and 
0.2395µg/mL, 0.1979µg/g and 0.0072µg/mL after 24 hours respectively.  
 
Figure 6.15 depicts the BCNU concentration in the plasma, CSF and brain tissue 
after lN administration without the application ES and MF. The results are 
0.0078µg/mL, 0.0087µg/mL and 0.0076µg/g in plasma, CSF and brain, 
respectively. These values are considered to be low in comparison to the values 
obtained when ES and MF were applied, this can be explained by taking into 
consideration the ability of Nanogel Composite to release BCNU-NCP only if there 
is application of ES and in this case there was none. Therefore, the insignificant 
quantity of BCNU-NCP released was due to the BCNU-NCP that were leached out 
from the surface of the Nanogel Composite. This observation also confirms the 
effectiveness of the electro-actuation in releasing the BCNU-NCP from the 
Nanogel Composite on application of ES.  
 
The aim of this novel drug delivery system is to enhance drug bioavailability to the 
brain; our device shows that BCNU reaches the brain in much higher quantity and 
displayed efficient bioavailability compared to the conventional BCNU. 
Furthermore, there is a steady concentration of BCNU in the CSF and brain at an 
appropriate level throughout the duration of 24 hours. Figure 6.16 further clarifies 
the superiority of the novel delivery system as it illustrates the BCNU concentration 
in CSF and the brain following IV administration of the conventional BCNU and IN 
administration of Nanogel Composite with the application of ES and MF. The 
results demonstrated that the novel drug delivery system has the ability to keep 
the concentration of BCNU constant through the 24-hour duration as compared to 
the conventional drug which diminishes with time. The average BCNU 
concentration in the CSF provided by the novel drug delivery is approximately 6 
times more than that provided by the conventional drug. Furthermore, there is a 
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constant bioavailability for the period of 24 hours. This is a tremendous advantage 
over the conventional drug. 
 
 
Figure 6.13: BCNU concentration in the Plasma, CSF and Brain tissue after IV 
injection of conventional BCNU. 
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Figure 6.14: BCNU concentration in the Plasma, CSF and Brain tissue after IN 
administration of Nanogel Composite with application of ES and MF. 
 
 
 
Figure 6.15: BCNU concentration in the plasma, CSF and brain tissue after 
IN administration of Nanogel Composite without application of ES and MF. 
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Figure 6.16: Comparison of the concentration of BCNU in CSF and 
brain following IV of conventional BCNU and IN administration of 
Nanogel Composite with application of ES and MF. 
 
6.3.4. Assessment of BCNU-NCP in the Brain Tissue Employing Field 
Emission Electron Probe Micro Analyzer (FE EPMA) 
The determination of the presence of BCNU-NCP in the brain tissue after IN 
administration of Nanogel Composite and application of ES and MF was 
performed by qualitative analysis of iron content in the brain tissue. Figure 6.17 
shows the spectrum obtained from the FE EPMA, the spectra display peaks that 
belong to Fe at 0.6 and 6.4keV. This result is a confirmation of that Fe which is the 
core component of BCNU-NCP is present in the brain of the rabbit following IN 
administration Nanogel Composite. It can therefore be inferred that BCNU-NCP 
was delivered to the brain via the olfactory pathway. The Fe peaks are highlighted 
in the spectra. 
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Figure 6.17: FE EPMA spectra of brain tissue of rabbit after IN administration of 
Nanogel Composite for Fe detection. 
 
6.3.5. Histopathological Evaluation of the Nasal Epithelia of the Rabbit  
Histopathological findings for the placebo, control and experimental group were 
carried out and the findings were compared to samples taken from normal healthy 
rabbit that was not dosed and was not exposed to ES and MF, to investigate the 
effect of Nanogel Composite on the nasal epithelial tissues and to evaluate the 
effect of application of ES and MF on the rabbit model. The microscopic digital 
image of the normal nasal epithelial tissue is shown in Figure 6.18a. The 
microscopic analysis of the placebo nasal tissue shows that the nasal turbinate 
and mucosal linings appear within normal limits. No sign of deformation, 
inflammation or necrosis was observed as shown in Figure 6.18b. For the control 
group, the microscopic analysis of the nasal tissue indicated that the nasal cavity 
contained multifocal, intraluminal amorphous, highly eosinophilic material 
surrounded by moderate degenerate heterophils and hemorrhage. The 
surrounding nasal epithelium was necrotic and replaced by macrophages and 
heterophilic infiltration. Moderate edema and hemorrhage was noted in the 
submucosa. Mild secondary lymphoid follicle development was also noted 
multifocally in the nasal submucosa as shown in Figure 6.18c. 
 
The microscopic digital image of the experimental group demonstrated multifocal 
areas of moderate mucosal inflammation which was characterized by loss of the 
nasal epithelium and replacement by inflammation which consisted of 
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macrophages and heterophils. The adjacent lumen contained a few red blood cells 
and amorphous eosinophilic material. Other portions showed moderate 
submucosal heterophilic infiltration along with moderate edema and hyperemia 
with the development of a few secondary lymphoid follicles. An eosinophilic, 
roughly oblong object was also noted in the nasal cavity surrounded by 
degenerate heterophils as displayed in Figure 6.18d. 
 
Examination of the nasal tissue showed an eosinophilic intraluminal material, 
which was found in both the control and the experimental groups. This observation 
may, however, represent the Nanogel Composite. Necropurulent rhinitis was also 
observed with moderate lesions noted in the control and experimental groups. 
This observation may be as a result of irritation of the rabbit to the test substance. 
No lesions were observed in the placebo group which is an indication that the 
application of ES does not have any effect on the histopathology of the rabbit‟s 
nasal epithelial tissue. Mild and minimal lesions were present in rabbits belonging 
to the experimental group. It can therefore be concluded that, Nanogel Composite 
administered intranasally with the application of both ES and MF, has no serious 
detrimental effect on the nasal epithelial tissues of the rabbits. 
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Figure 6.18: Histological evaluation of nasal epithelia tissue samples from rabbits 
showing light digital microscopic images of the H&E stained slides of a) normal 
nasal epithelia tissue, b) placebo sample, c) control group sample and d) 
experimental group sample. Magnification is x10. 
 
6.4. CONCLUDING REMARKS 
The novel drug delivery system formulated has been proven to be more superior 
than the conventional drug which was administered intravenously. The in vivo 
studies demonstrated greater concentration of BCNU in CSF and the brain of the 
rabbit delivered via the olfactory route for the novel drug delivery system 
compared to the conventional drug. The novel drug delivery system was found to 
be 6 times more efficient in delivering therapeutics to the brain and CSF, thereby 
circumventing the BBB and permitting high bioavailability of drug to the brain. The 
ES was found to control the release of drug in a pulsatile “on-off” manner and the 
MF in the form of a magnetic headband on the rabbit head was able to attract the 
nanoparticles to the brain by quickly transporting them across the olfactory region 
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to the brain and CSF following the release brought about by the ES. The delivery 
system was found to be easily administered, the application of 5V ES, and the 
application of 0.4 Tesla were found to be safe to the animal.  The applications of 
electrodes on the nose of rabbit as well as the magnetic headband on the rabbits 
were successful without posing any discomfort to the rabbits. The microscopic 
examination of the nasal epithelial tissue following euthanization of the rabbits 
revealed that there were minimal and mild lesions on the nasal epithelial tissue. 
These findings indicated that the Nanogel Composite is biocompatible and suitable 
as a nasal formulation. It can therefore be concluded that the novel drug delivery 
system is non-toxic to the rabbits. 
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 CHAPTER 7 
RECOMMENDATIONS AND FUTURE OUTLOOK 
 
7.1. RECOMMENDATIONS 
Brain diseases are highly difficult to treat due to the Blood-Brain Barrier (BBB). 
The current therapeutic interventions employed in managing these ailments are 
challenged with low bioavailability in the brain. Brain tumors for example, are 
currently treated with an invasive method which involves surgery and implants, in 
addition to IV injection. A novel Nano-co-Plex was synthesized, loaded with 
carmustine (BCNU); an effective brain tumor therapeutic, characterized employing 
techniques such as FTIR, XRD, NMR, TGA, SQUID, TEM and Zetasizer analysis. 
The Nano-co-Plex was found to be paramagnetic and responded adequately to 
MF. These nanoparticles have high drug loading capacity and the in vitro drug 
release profile was found to be appropriate.  
 
The BCNU-loaded Nano-co-Plex synthesized was incorporated into a novel 
thermosensitive electro-responsive mucogel for potential stimuli controlled nose-
to-brain drug delivery. This formulation (Nanogel Composite) was optimized 
employing a Box-Behnken Experimental Design and characterized for its 
rheological properties, its in situ gelling behavior, electroactiveness, 
mucoadhesiveness, porosity, surface morphology and in vitro release of the Nano-
co-Plex upon application of electric stimulation in a controllable “on-off” pulsatile 
release. The BCNU-Nano-co-Plex was found to be highly toxic to tumor cells 
compared to the conventional drug, as demonstrated by the outcome of the cell 
work carried out using human glioblastoma A170 cell lines, and was non-toxic to 
normal brain cells demonstrated by evaluating PC 12 neuronal cell lines. 
Internalization of the BCNU-Nano-co-Plex was found to be enhanced by the 
application of MF.  
 
The ex vivo test revealed an enhanced permeation of Nano-co-Plex through the 
nasal epithelial tissue of New Zealand white rabbit model when there was 
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application of a magnetic stimulus. Similarly, the in vivo studies were performed by 
employing New Zealand white rabbits as an appropriate model for evaluating the 
Nanogel formulation. The in vivo studies delineated that intranasal administration 
of Nanogel Composite with the application of electric stimulus brought about by 
using electrodes on the rabbit‟s nose released BCNU-loaded Nano-co-Plex in a 
pulsatile release fashion followed by quick transport of the BCNU-loaded Nano-co-
Plex released in the nasal mucosa directly to the brain of the rabbit with the aid of 
a magnetic headband placed on the rabbit. This action resulted in high 
concentration of BCNU in the brain and CSF of the rabbit thereby improving 
bioavailability of drug in the brain with notably lower concentrations in the plasma. 
In vivo comparison of this system with the IV administration of the conventional 
BCNU indicated a very low concentration BCNU in the brain and CSF and a high 
concentration in the plasma. These results clearly demonstrated that this novel 
delivery system is superior to the conventional drug administered via IV. 
Furthermore, this delivery system is non-invasive and may therefore be a 
promising replacement of the highly invasive implant currently employed in the 
treatment of brain tumors. 
 
This research involves the synthesis of drug-loaded nanoparticles with the 
nanoparticles incorporated into a novel in situ thermosensitive elecro-responsive 
mucoadhesive gel. Both the drug-loaded nanoparticles and the gel were 
extensively characterized followed by in vitro, ex vivo and in vivo studies. The 
Nano-co-Plex synthesized has the capability and capacity to load other drugs 
which may be used for the management of other brain diseases. For example, 
Galantamine can be loaded into the Nano-co-Plex. The Nano-co-Plex is a 
positively charged entity; the positively charged amine group can form ionic 
interaction with the OH and the CH3-O- of the galantamine. There is also the 
possibility of H-bonding of Gal with the Nano-co-Plex as shown in the Figure 7.1 
which may form stable interactions for loading of Gal into the Nano-co-Plex.  
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Figure 7.1: Molecular structure of Galantamine 
 
Furthermore, the in vivo study was carried out as a proof of concept, to observe 
the effect of electric and magnetic stimuli on the release and transportation of the 
nanoparticles into the brain via a direct nose-to-brain pathway. This study can be 
advanced by inducing tumor growth in the animal model and the novel delivery 
system applied in order to further explicate the efficacy of the delivery system. 
 
7.2. FUTURE OUTLOOK 
The in vivo studies proved the workability of the Nanogel Composite starting from 
its intranasal administration to its in situ gelling capability in the nasal mucosa, the 
release of the drug loaded magnetic nanoparticles by electric stimulation and the 
quick transportation of the drug-loaded nanoparticles across the nasal epithelial 
tissue with the aid of a magnetic stimulus for direct nose-to-brain drug delivery. 
This in vivo study was carried out by employing the application of electrodes to 
discharge 5V of ES on the nose of the rabbit and a magnetic headband to deliver 
0.4 Tesla of magnetic stimulus to attract the drug-loaded nanoparticles to the 
brain. In future the electrodes and the magnetic headband may be replaced by an 
eye glasses where the nose pads of the glasses may represent the electrodes and 
the top bar of the glasses may represent the magnet which may be fabricated to 
have a microchip that can be modulated from a cellular device, to actuate the 
214 
 
release of drug in a controllable manner while the magnet will target and transport 
the released drug to the brain. This may be a future technological advancement of 
this novel drug delivery system. 
 
7.2.1. Hypothesis: Lactoferrin-Galantamine Proteo-Alkaloid Conjugate for 
The Management of Alzheimer’s Disease 
As part of the future outlook of this project, a Lactoferrin-Galantamine Proteo-
Alkaloid Conjugate for the management of Alzheimer‟s Disease was hypothesized. 
 
7.2.1.1. Introduction 
Alzheimer's disease (AD) is the most common cause of dementia which affect 
mostly elderly people, and it is connected to the loss of cholinergic neurons in 
parts of the brain (Arendt et al., 2015). AD is one of the most severe 
neurodegenerative disorders. Approximately 13% of people who are 65 years and 
above are affected by this disorder in the United States alone (Tsai and 
Madabhushi, 2014) and is the sixth leading cause of death for people with ages 65 
years and above (Alzheimer‟s Association, 2012). It is projected that by 2050, 
there will be almost one million new cases per year. Furthermore, it is expected 
that there will be remarkable increase in the number of people with AD who are 85 
years and above across all racial and ethnic groups. AD is characterized by loss of 
memory in the patient wherein the patient finds it difficult to remember things that 
are learnt recently coupled with failure of acquiring new information (Arnáiz and 
Almkvist, 2003; Bäckman et al., 2004). The symptoms noticeable at the early 
stage include difficulties in reasoning, effective planning, attentiveness, as well as 
conceptual thinking. Episodic, semantic and implicit memories are less affected 
than new facts and memories (Carlesimo and Oscar-Berman, 1992). 
Progressively, the patient is unable to perform most common activities of daily 
living such as speech, reading and writing.  
 
The cause of AD is associated with genetic heritability (Wilson et al., 2011) as well 
as cholinergic (Babic, 1999), amyloid and tau hypotheses. However, it is widely 
believed that advanced age is the major risk factor of AD. The genetic factor is 
brought about by gene mutations on chromosome 21 in the β-amyloid precursor 
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protein (APP) which are responsible for early-onset of AD in family that has history 
of the disease (Hardy and Allsop, 1991; Munoz and Feldman, 2000). The 
Cholinergic hypothesis proposed that AD is caused as a result of reduction in the 
synthesis of neurotransmitter acetylcholine (Contestabile, 2011). Protein 
misfolding disease is a characteristic of AD caused by the accumulation of 
deformed beta amyloid (Aβ) which results in senile plaques and also the 
accumulation of hyper phosphorylated tau proteins in the brain resulting into 
formation of neurofibrillary tangles. The aggregation and accumulation of these 
plaques and tangles in the brain have become the most prominent culprits of AD 
(Ittner et al., 2010; O‟Brien and Wong, 2011; DeSai et al., 2014).  
 
Iron is extremely reactive and in high concentration can lead to neuronal death 
(Raven et al., 2013). Iron is known to be so important in the mammalian cells for 
metabolism and oxygen transport (Oshiro et al., 2011), in excess may cause 
tremendous damage to the cells by generating free radicals and thereby causing 
oxidative stress which in turn triggers destructive effects that result in AD and 
other neurodegenerative disorders in general (Huang et al., 2014). Ex vivo and in 
vivo studies have shown and established an increase in brain iron in AD patients 
(Lovell et al., 1998; Castellani et al., 1999; Duce et al., 2010; Raven et al., 2013; 
Huang et al., 2014). The presence of elevated oxidative stress due to oxidation of 
iron has been confirmed in the brain of AD patients (Smith et al., 1997). More 
recently, Raven et al. (Raven et al., 2013) established that increased iron resulted 
in tissue breakdown associated with AD. They used an MRI technique to measure 
the amount of brain iron in 31 AD patients and 68 healthy subjects as control. 
They compared the results from the hippocampus and thalamus parts of the brain; 
their findings suggested strongly that iron accumulation is a possible cause of AD. 
From the evidences of various researches, it is therefore pertinent to infer that 
deposition and accumulation of iron in the brain is a center point of all the neuro-
pathological operations which is not limited to amyloid plaques, tau 
phosphorylation as well as oxidative stress in AD. There is adequate evidence to 
pin down interaction of Aβ and transition metal especially neocortical iron as the 
culprit in initiating and causing the toxicity observed in AD (Ghribi et al., 2006; 
Bonda et al., 2012; Mufamadi et al., 2012; Ayton et al., 2013; Chitra et al., 2013).  
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7.2.1.2. The hypothesis 
Several therapeutics have been researched, proposed and prepared for the 
treatment of AD, many of which have reached clinical trials and found to be 
ineffective due to some of the reasons enumerated above and are possibly 
discontinued because of their failure. Galantamine (Gal) is one of the therapeutic 
that has a success story and approval to be used for the treatment of AD. Even 
then it has not been found to be effective in treating the disease, which may be 
due to other factors such as accumulation of iron in the brain and free radical 
generation that accompanies the ailment. Combination of Gal and an iron chelator 
may be a promising strategy for dealing with this situation in order to obtain a more 
potent approach to the treatment of AD. In this study we propose the combination 
of free radical generation and the metal chelator approach to synthesize a single 
dosage form to manage effectively AD through “Proteo-Alkaloid” conjugate of 
Lactoferrin (Lf) and Gal. This is proposed to serve as “Neuroprotective-
Neurotherapeutic” agent. We therefore propose Gal and Lf conjugate as a novel 
treatment for AD. This approach will act as both a neuroprotective as well as 
neurotherapeutic intervention. 
 
7.2.1.3. Evaluation of the hypothesis 
The successful management and treatment of AD has remained elusive despite 
much research that have been carried out and those that are still ongoing. 
Researchers are constantly looking for effective therapy to deal with and manage 
this neurodegenerative disorder. Quite a number of drugs with different 
mechanisms of action and targets are available and many are still under 
development for the management of AD. The strategies involved in making these 
drugs are based on firstly the amyloid hypothesis which delved into the reduction 
of Aβ production, its clearance and aggregate blocking (Kumar et al., 2011). Due 
to the connection of Aβ to AD, extensive clinical trials have been carried out with 
drugs designed to target this peptide in a way to absolutely prevent the production 
of Aβ plaques. These drugs are still inefficient in preventing the cognitive decline in 
AD patients (Ayton et al., 2013). Nonsteroidal anti-inflammatory drugs (NSAIDs) 
such as diclofenac (Scharf et al., 1999), rofecoxib (Aisen et al., 2003) and 
indomethacin (Bernardi et al., 2012) have been suggested to reduce the risk of 
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developing AD; however the efficacy of these drugs have not been proven and in 
fact all of the therapeutics developed based on amyloid-β approaches that 
reached Phase III clinical trials were unsuccessful (Karran et al., 2011).  
 
The second strategy is based on the cholinergic hypothesis which involves the use 
of choline esterase inhibitors capable of reducing the hydrolysis of acetylcholine. 
Therapeutic agents such as, Gal, rivastigmine and donepezil are examples of 
drugs developed based on the cholinergic approach (approved for the 
management of mild to moderate AD). The clinical profiles of these therapeutic 
compounds are somewhat successful. The use of these drugs for treating AD 
patients improves their cognitive functions and generally gives symptomatic relief 
to the patients, however the efficacy of these compounds is still very low because 
only about 35% of the patients respond positively to the treatments with these 
drugs (Giacobini, 2000). These compounds are also associated with serious side 
effects such as diarrhea, vomiting and nausea (Maelicke et al., 2010) which places 
them in an inconvenient state.  
 
Our strategy focuses on lowering brain metal ions and targeting their interaction 
with Aβ peptide. Metal ions mediate generation of free radicals and thereby result 
in oxidative damage of the brain. Employing the administration of metallo-complex 
therapy is a new and promising therapy for AD. Fang Du et al. (2014) showed in 
their study that hepcidin considerably minimized brain iron in rats overloaded with 
iron. Desferioxamine is a chelator approved by the FDA for iron overload; this 
chelator has been known to offer some benefits in the treatment of AD. 
Deferiprone is another chelator that binds iron and aluminum ions, this was 
approved only in Europe. The use of chelators is however limited due to their 
inability to effectively cross the BBB and their being neurotoxic due to lack of 
elimination process of the metal-chelator complex from the brain (Liu et al., 2005). 
 
7.2.1.4. Galantamine and Alzheimer’s intervention 
Galantamine hydrobromide is an alkaloid obtained from various plants such as 
Galanthus caucasicus, Galanthus woronowii, Narcissus, and Lycoris species. It is 
a neuroactive therapeutic agent approved by both the European Medicines 
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Agency (EMA) and USA Food and Drug Administration (FDA). Its primary function 
is to inhibit the activities of the enzyme, acetylcholinesterase; this enzyme 
hydrolyses the neurotransmitter acetylcholine followed by the cessation of synaptic 
transmission. The use of Gal prevents this reaction and thereby allows the survival 
of acetylcholine for normal neurotransmission function in AD patients. Recently, 
Traykova et al. in their in vitro experiment found that Gal compound is a scavenger 
of reactive oxygen species (ROS) (Traykova et al., 2014). Additionally, Gal may 
also form a complex with nicotinic acetylcholine receptors by binding onto it, and 
thereby improving phagocytosis of microglial amyloid-beta peptides (Fong Yen et 
al., 2015). However, its clinical function is limited by its low bioavailability in the 
brain due to the BBB. Furthermore, it is associated with numerous side effects 
when administered systemically (Mufamadi et al., 2013). Owning to its ability of 
scavenging free radicals, Gal may help to treat oxidative stress due to free radicals 
generated within the brain of AD patients and hence may act as a 
neurotherapeutic agent.  
 
7.2.1.5. Lactoferrin and metal chelation 
Lactoferrin is a glycoprotein that has a strong binding affinity for iron. This cationic 
iron-binding globular glycoprotein is a member of the transferrin family. It has a 
molecular mass of approximately 80 kDa and consists of 892 amino acids (van der 
Strate et al., 2001; Baker and Baker, 2005). It was first discovered in human 
milk (Montreuil et al., 1960) and it is also known to exist in body fluids such as 
saliva, tears, vaginal fluids, semen, bile, gastrointestinal fluids, urine, nasal and 
bronchial secretions (García-Montoya et al., 2012). Lf is made up of two 
homologous domains which are called N- and C-lobes; the two globular lobes are 
folded and connected by a short α-helix. N-lobe is made up of N1 and N2 sub-
domain, likewise C-lobe is made up of C1 and C2 sub-domain with one iron site 
and one glycosylation site at each lobe (Baker and Baker, 2012). The N-lobe 
consists of amino acid residues 1–333 while the C-lobe consists of amino acid 
residues 345–692 (Carmona et al., 2014). The main function of Lf is transportation 
of iron to the cells as well as regulation of free iron in the blood and external 
secretions. Lf also serves as a vital component of the biological functions including 
an immunoregulatory role (Latorre et al., 2012), anti-inflammatory role (Yeom et 
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al., 2011) and most importantly the exertion of its antimicrobial functions against 
viral, fungal and bacterial pathogens (Sinha et al., 2013). Lf is also known to have 
an anticarcinogenic function (Ma et al., 2013) and it is a targeting molecule for 
improving brain delivery of therapeutic agents (Huang et al., 2008). The iron 
binding capability is what we are focusing on in this hypothesis as this can be 
exploited in the clearance of excess iron in the brain of AD patients. 
 
7.2.1.6. Lactoferrin-Galantamine Proteo-Alkaloid conjugate 
The current treatments for AD aside from not being very effective and their 
association with various side effects, is that they only give symptomatic relief of 
the disease and not total cure of the dementia. Therefore, a combination of two of 
these strategies in the form of a single dosage form may however be a promising 
and more effective way of treating AD. Lf has been conjugated with various 
compounds in other to increase its functionality. Nojima et al. conjugated Lf with 
branched polyethylene glycol (PEG) using N-hydroxysuccinimide coupling method 
in order to improve its half-life (Nojima et al., 2009). Additionally, Lf has been 
conjugated to pegylated nanoparticles to form Lf nanoparticles employing 
thiolation reaction (Hu et al., 2011, 2009). Furthermore, superparamagnetic iron 
oxide nanoparticles (SPION) have been conjugated to Lf by using NHS/EDC 
coupling chemistry to form Lf-SPION nanoparticles (Xie et al., 2011).  
 
In this study, we propose to conjugate Lf to Gal by “Proteo-Alkaloid” conjugation 
method through the self-assembly functionality of Lf. It is proposed that Lf may 
encapsulate the Gal molecules within its physical structure holding the Gal 
molecules inside its cavity while the Lf molecules self-assemble to form a 
protective shell around the Gal molecule. Hydrogen bonding as well as van der 
Waals forces are predicted to contribute to the stability of the complex formation. 
The demonstration of this concept is illustrated in Figure 1. This technique may be 
applied in developing a dosage form. Lf in itself is known to be a ligand for brain 
targeting; this attribute will therefore aid the penetration of the therapeutic agent 
into the brain. When the conjugate is delivered into the AD patient‟s brain, the 
release of the Gal will only happen when there is interaction of the conjugate with 
Fe3+ wherein the conjugate will open up and release the Gal molecules 
220 
 
encapsulated within the Lf molecule and at the same time Fe3+ is attracted to the 
Lf and be absorbed into it.  
 
The mechanism of conjugation and release is shown in Figure 7.2, where the 
conjugate was prepared by self-assembly of Lf and upon sensing accumulation of 
Fe3+ liberates the encapsulated Gal. The release can be explained by the fact that 
Lf changes conformational structure whenever it interacts with Fe3+. Lf deprived of 
Fe3+ is known as apo-lactoferrin while those that are saturated with iron are known 
as holo-lactoferrin. The transition from apo-lactoferrin to holo-lactoferrin which 
happens when Lf is in contact with Fe3+ results into conformational change 
accompanied with protease resistance (Takayama, 2011; Jameson et al., 1998). 
Therefore, when the conjugate is in a Fe3+ environment, the conjugate will change 
its structural conformation and thereby cause the encapsulation to open up. It is 
envisaged that this process will allow Gal to be released while Fe3+ are been 
absorbed into the Lf as it has a very strong affinity for Fe3+. The implication of this 
process will result in Gal being released to stop the activities of the free radicals 
produced through iron-initiated oxidative stress and the Lf mops up the excess iron 
in the brain of the AD patient. This is a dual action intervention that offers both 
neurotherapeutic and neuroprotective advantage. Lf, due to its ability to capture 
excess iron in the brain, may help in mediating the production of free radical that 
might result into the generation of oxidative stress which may eventually lead into 
the death of neuronal cells. Furthermore, any free radical generated will be 
scavenged by the action of the Gal. The process of the generation of free radical 
by iron in the brain, the outcome of oxidative stress and the point at which Lf-Gal 
can mediate the process is shown in the schematic diagram in Figure 7.3. This 
hypothesized technique may be a promising future strategy for managing AD. 
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Figure 7.2: Schematic diagram of the mechanism of release of Galantamine and 
absorption of iron by Lf-Gal conjugate. 
 
 
 
Figure 7.3: Schematic diagram demonstrating the potential neuroprotective-
neurotherapeutic interventional mechanism of the lactoferrin-galantamine 
conjugate. 
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7.2.2. Concluding Remarks 
This hypothesis demonstrated the theoretical analysis of the conjugation of 
Galantamine, an effective anti-cholinergic agent, and Lactoferrin, a protein with 
strong binding affinity for iron. The combination of these two compounds as one 
dosage form, with their iron and free radical scavenging ability, wherein, Lf has the 
ability to mop up excess iron in the brain and Gal acts as an antioxidant may be an 
advancement in the management of AD. This hypothesis may come to life by 
going further in carrying out the experiment in the laboratory to determine the 
potential of the conjugation as well as the in vitro, ex vivo and in vivo stability 
testing of the proteo-alkaloid so developed. It may, however, be suggested that the 
conjugate be embedded in a polymer matrix or be attached to nanoparticles that 
possess the ability to serve as a vehicle to propagate and consequently deliver the 
conjugate into the brain via a direct nose-to-brain pathway. This approach may 
present a formidable dual neuroprotection and neurotherapeutic interventional 
approach and may lead to be a novel advancement in the treatment of AD. 
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Witwatersrand, Johannesburg, South Africa, September 10, 2013, 
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Preparation and Characterization of a Dual Responsive Polymeric gel for Intranasal Drug 
Delivery.                                                                                                                                                     
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Witwatersrand, Johannesburg, 7 York Road, Parktown, 2193, South Africa. 
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Neurosciences, Department of Neurology, University of the Witwatersrand, Johannesburg, 7 York 
Road, Parktown, 2193, South Africa. 
 
A biodegradable and biocompatible electro-magneto responsive polymeric gel composite was 
prepared and characterized. The gel was synthesized by blending a Chitosan based polymer, with 
Polyaniline (PANI) a conductive polymer with high dielectric properties in the presence of metal 
oxide nanoparticles thus formed a crosslinked Interpenetrating Polymer Networks (IPN). This 
composite which is referred to as a „Metalogel‟ with the ability to respond to an external electric 
stimulus was characterized for both its magnetic properties as well as its electrical conductivity. 
The magnetic property of the gel was based on the super paramagnetic nature of the said 
nanoparticles embedded in the matrix of the composite which provided the ability to respond to an 
externally applied magnetic field. The electric property of the gel was attributed to the electroactive 
capability of polymer combination which showed a response aptitude to an externally applied 
electric field. This composite was characterized using Scanning Electron Microscopy to examine 
the morphology of the gel composite, a homogenous blended composite with well dispersed 
nanoparticles embedded in the matrix was observed. The magnetic property was characterized by 
Vibrating Sample Magnetometer, which demonstrated a hysteresis loop of the composite. An 
increase in the concentration of nanoparticles showed a corresponding increase in the 
magnetization of the gel. Measurement of the electrical conductivity of the Metalogel showed an 
increase in conductivity with increase in the concentration of polymer combination in the composite. 
This dual responsive polymeric gel may be a good candidate for biomedical applications in the area 
of intranasal drug delivery.                                                                                                                                                                                                                                                                                                          
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delivery to the brain 
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Targeted delivery of carmustine (an efficient brain tumor therapeutic) has been challenged with 
bioavailability issues, thus the most known effective delivery approach is by localized delivery with 
implants at the site of the tumor which is a highly invasive method of drug delivery. Nasal drug 
delivery has been considered as an alternative route of administering drug to the brain as it is non-
invasive, bypasses the BBB and improves convenience and compliance. Magnetic drug targeting 
via the nasal route may be a promising method of delivering carmustine to the brain. In this work 
magnetic ferrous-based nanoconstructs with superparamagnetic capability was synthesized 
successfully and loaded with carmustine for magnetically targeted delivery of carmustine to the 
brain following intranasal administration. This was achieved by first synthesizing the ferrous-based 
nanoconstructs using co-precipitation, after which the nanoconstructs were coated with a 
carmustine-loaded polymeric derivative complex. Thermogravimetric analysis was used to estimate 
the quantity of polymeric complex coat bound to the nanoconstructs. The magnetic behavior was 
confirmed by Vibrating Sample Magnetometery. The structure of the carmustine loaded ferrous 
based nanoconstructs was confirmed by Fourier Transform Infrared Spectroscopy and X-ray 
Diffractometery. The morphology and size of the nanoconstructs were determined by the 
Transmission Electron Microscopy and the Zetasize analysis. Results revealed spherically shaped 
“core-shell” nanoparticles coated with polymeric complex of size ranging between 30-70nm with a 
zeta potential value of +27mV. These ferrous-based nanoconstructs may be ideal as a magnetic 
drug targeting device for other chemotherapeutic agents that require delivery to the brain via the 
nasal mucosa. 
Key words: carmustine, ferrous-based, nanoconstructs, polymeric, core-shell, chemotherapeutic, 
BBB 
232 
 
8.2.1.3. International Society of Biomedical Polymers and Polymeric 
Biomaterials, Orlando, Florida USA, 8th-10th July, 2015, (Poster 
presentation). 
 
 
 
 
233 
 
8.2.1.4. International Society of Biomedical Polymers and Polymeric 
Biomaterials, Orlando, Florida USA, 8th-10th July, 2015, (Podium 
presentatation). 
 
 
 
 
234 
 
8.2.1.5. Faculty of Health Sciences Research Day, University of the 
Witwatersrand, Johannesburg, South Africa, September 8-9, 2015. 
(Podium Presentation).  
Preparation of a Gadolinium based Nanoparticles Coated with Polyethylene imine- 
Galantamine-Lactoferrin Complex for Intranasal Drug Delivery in Treating Alzheimer's 
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Road, Parktown, 2193, South Africa. 
 
Alzheimer's disease (AD) is the most common cause of dementia which affects mostly elderly 
people. The cause of AD is known to be due to the accumulation of deformed beta amyloid and 
hyperphosphorylated tau proteins in the brain which resulted into formation of senile plagues and 
neurofibrillary tangles. Furthermore, iron has been identified as the main cause of neuronal death 
in AD by generating free radicals and thereby causing oxidative stress which in turn triggers 
destructive effects that result into AD. Galantamine is one of the therapeutic agents that have been 
successfully used in treatment of AD. However, it is saddled with numerous side effects and is 
unable to address accumulation of iron in the brain. Combination of galantamine and iron chelator 
may be a promising strategy for dealing with these challenges. In this study, Galantamine was 
conjugated to lactoferin a natural iron chelator to form a dual intranasal drug delivery system. This 
process was achieved by synthesizing gadolinium oxide nanoparticles and then coated them with 
polyethyleneimine (PEI). Galantamine-lactoferin conjugate was then incorporated into the PEI 
coated gadolinium nanoparticles for magnetically targeted intranasal delivery of galantamine and 
lactoferin into the brain. FTIR, TGA, XRD, SQUID and TEM were employed to characterize the 
formulation. FTIR and XRD results confirmed the conjugate of galantamine to lactoferin and their 
incorporation into the PEI coated nanoparticles. SQUID results indicated superparamagnetic 
properties of the nanoparticles, TEM result showed spherically shaped nanoparticles with average 
size of 20nm. A dual therapeutic intervention in a single vehicle that can address the symptomatic 
issue via the cholinergic approach as well as clearance of iron in the brain of AD patients was 
prepared. This may be advancement in magnetically targeted intranasal drug delivery in managing 
AD. 
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Purpose: The aim of this work was to synthesize polyvinyl alcohol/polyethyleneimine/fIuorecein 
isothiocyanate (Polyplex) complex coated Magnetite (Nano-co-Plex) with superparamagnetic 
capability and cell labeling attributes loaded with carmustine (BCNU) for potential magnetically 
targeted delivery of BCNU to the brain following intranasal administration for brain tumor 
management. 
Method: This was achieved by co-precipitation reaction of Fe
2+
 and Fe
3+
 at high pH under N2, 
epoxidation of PVA and EDC/NHS coupling reaction of FITC with PEI. Drug loading was carried out 
in the dark. The release study was carried out by dispersing the dried BCNU-Nano-co-Plex in PBS 
pH 7.4 at 37°C. The formulation was characterized employing Fourier Transform Infrared 
Spectroscopy (FTIR), Thermogravimetric Analysis (TGA), Transmission Electron Microscope 
(TEM), Zetasizer, Superconducting quantum interference device (SQUID) and X-ray Diffraction 
(XRD) techniques. 
Results: FTIR spectra confirmed the synthesis of BCNU-loaded Polyplex coated Magnetite. The 
morphology, size and stability of the formulation showed hexagonally shaped particles with 
average size of 45nm with zeta potential of +21mV and poly dispersity index (PDI) of 0.22. XRD 
results further confirmed the crystalline nature of the formulation. The thermal analysis indicated 
that 1/3 of the total weight of the formulation constituted the drug-loaded polymeric coating. The 
magnetic studies showed superparamagnetic attribute of the formulation with high magnetization 
value. The loading capacity of the synthesized Nano-co-Plex was efficient for BCNU. The release 
profiles indicated a sustainable release of BCNU, with up to 75% of drug released after 72 hours. 
Conclusions: BCNU-loaded Nano-co-Plex was synthesized successfully. 
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Alzheimer’s disease  
Olufemi D Akilo
1
, Yahya E Choonara
1
, Lisa C du Toit
1
, Pradeep Kumar
1
, Girish Modi
2
 and Viness 
Pillay
1
 
 
1
Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and 
Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, 7 York Road, Parktown, 2193, South Africa.  
 
2
Division of Neurosciences, Department of Neurology, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, 7 York Road, Parktown, 2193, South Africa.  
 
Alzheimer's disease (AD) is the most common cause of dementia which affects mostly elderly 
people. The cause of AD is known to be due to the accumulation of deformed beta amyloid and 
hyperphosphorylated tau proteins in the brain which resulted into formation of senile plagues and 
neurofibrillary tangles. Galantamine is one of the therapeutic agents that have been successfully 
used in treatment of AD. However, it is saddled with numerous side effects and it is challenged by 
the blood-brain barrier (BBB). In this study Gadolinium oxide nanoparticles were synthesized and 
then coated with galantamine loaded Polyethylene glycol (PEG) intended for intranasal 
administration for direct nose-to-brain delivery for the management of AD. The synthesized coated 
nanoparticles were characterized using Fourier Transform Infrared Spectroscopy (FTIR), 
Thermogravimetric Analysis (TGA), Transmission Electron Microscope (TEM), Zetasizer, Quantum 
Design Superconducting Quantum Interference Device (SQUID) magnetometery, and X-ray 
Diffraction (XRD) techniques. FTIR results confirmed the synthesis of the Gadolinium oxide coated 
with the galantamine-loaded PEG. The XRD result revealed the crystallinity of the particles. TGA 
results confirmed the coating and also indicated the amount of PEG coating on the gadolinium 
oxide. The TEM micrographs showed a spherically shaped morphology of both the coated and the 
uncoated gadolinium oxide with average size of 15 to 25nm. The galantamine-loaded nanocarriers 
are superparamagnetic as indicated by the SQUID results. Gadolinium oxide coated with 
galantamine-loaded PEG was successfully synthesized. This formulation has potential in delivering 
galantamine directly into the brain following intranasal administration.  
Keywords: Galantamine, Gadolinium oxide, Alzheimer‟s disease, intranasal  
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